Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like all*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000077	AbbVie	03/31/2023	00074081702	(adalimumab) HUMIRA 10MG/0.1ML PFS 2-PACK	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074006702	(adalimumab) HUMIRA 1X80MG,0.8ML, 1X40MG,0.4ML PFS2PK PED CROHN'S STARTER PACK	Brand	FDA	01/03/2023	769.18	10383.96	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074061602	(adalimumab) HUMIRA 20MG/0.2ML PFS 2-PACK	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074433902	(adalimumab) HUMIRA 40MG/0.8 ML (2 PENS)	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074379902	(adalimumab) HUMIRA 40MG/0.8ML (2 SYRINGES)	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074254003	(adalimumab) HUMIRA 80MG, 0.8ML PFS 3-PACK PED CROHN'S STARTER PACK	Brand	FDA	01/03/2023	1538.37	20767.94	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074012403	(adalimumab) HUMIRA CROHN'S 80MG/0.8ML, 3 PENS STARTER PACK	Brand	FDA	01/03/2023	1538.37	20767.94	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074055402	(adalimumab) HUMIRA PEN, 40MG/0.4ML, 2 PENS	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074012402	(adalimumab) HUMIRA PEN, 80MG/0.8ML, 2 PENS	Brand	FDA	01/03/2023	1025.58	13845.27	11/11/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074024302	(adalimumab) HUMIRA PFS, 40MG/0.4ML, 2 SYRINGES	Brand	FDA	01/03/2023	512.79	6922.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074153903	(adalimumab) HUMIRA PSORIASIS; 1X80MG, 2X40MG (3PENS) STARTER PACK	Brand	FDA	01/03/2023	1025.58	13845.27	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074433906	(adalimumab) HUMIRA, CROHN'S, 40MG/0.8 ML (6 PENS) STARTER PACK	Brand	FDA	01/03/2023	1538.37	20767.94	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074433907	(adalimumab) HUMIRA, PSORIASIS, 40MG/0.8ML (4 PENS) STARTER PACK	Brand	FDA	01/03/2023	1025.58	13845.27	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074003828	(elagolix sodium) ORILISSA 150MG TABS, 4X7 PACK	Brand	FDA	01/03/2023	52.33	1098.99	09/01/2036	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074003956	(elagolix sodium) ORILISSA 200MG TABS, 4X14 PACK	Brand	FDA	01/03/2023	52.33	1098.99	03/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	06/30/2023	00074101756	(ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM) ORIAHNN CAPSULES 300MG/1MG/0.5MG; 4x14	Brand	FDA	04/03/2023	52.33	1098.99	07/23/2039	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074244003	(leuprolide acetate) LUPRON DEPOT PED, 15 MG PDS KIT	Brand	FDA	01/03/2023	187.13	3929.75	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074377903	(leuprolide acetate) LUPRON DEPOT PED, 3MONTH, 11.25MG	Brand	FDA	01/03/2023	509.71	10703.92	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074969403	(leuprolide acetate) LUPRON DEPOT PED, 3MONTH, 30MG	Brand	FDA	01/03/2023	561.40	11789.30	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074210803	(leuprolide acetate) LUPRON DEPOT PED, 7.5 MG PDS KIT	Brand	FDA	01/03/2023	93.59	1965.30	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074366303	(leuprolide acetate) LUPRON DEPOT, GYN,3 MONTH 11.25 MG PDS KIT	Brand	FDA	01/03/2023	233.38	4901.02	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074364103	(leuprolide acetate) LUPRON DEPOT, GYN,3.75 MG PDS KIT	Brand	FDA	01/03/2023	77.79	1633.66	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074334603	(leuprolide acetate) LUPRON DEPOT, URO,3 MONTH 22.5 MG PDS KIT	Brand	FDA	01/03/2023	278.11	5840.26	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074368303	(leuprolide acetate) LUPRON DEPOT, URO,4 MONTH 30 MG PDS KIT	Brand	FDA	01/03/2023	370.81	7787.03	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074364203	(leuprolide acetate) LUPRON DEPOT, URO,7.5 MG PDS KIT	Brand	FDA	01/03/2023	92.70	1946.76	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074228203	(leuprolide acetate) LUPRON DEPOT-PED 11.25 MG PDS KIT	Brand	FDA	01/03/2023	169.90	3567.96	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074347303	(leuprolide acetate) LUPRON, URO,45MG 6MTH	Brand	FDA	01/03/2023	556.22	11680.71	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032121201	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 100CAP	Brand	FDA	01/03/2023	18.84	395.56	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032121207	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 250CAP	Brand	FDA	01/03/2023	47.09	988.88	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032122401	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 100CAP	Brand	FDA	01/03/2023	37.34	784.07	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032122407	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 250CAP	Brand	FDA	01/03/2023	91.84	1928.59	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032120370	(lipase/protease/amylase) CREON 3000USP DELAYED-RELEASE 70CAP	Brand	FDA	01/03/2023	5.57	117.00	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032301613	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 100CAP	Brand	FDA	01/03/2023	56.69	1190.51	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032301628	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 250CAP	Brand	FDA	01/03/2023	141.71	2975.91	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032120601	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 100CAP	Brand	FDA	01/03/2023	9.42	197.89	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00032120607	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 250CAP	Brand	FDA	01/03/2023	23.56	494.78	06/08/2037	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074204202	(risankizumab-rzaa) SKYRIZI 75MG/0.83ML PFS x2 US/PR	Brand	Medispan	01/03/2023	1461.82	19734.61	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074230630	(upadacitinib) RINVOQ 15MG 30 DAY BOTTLE	Brand	FDA	01/03/2023	453.70	6124.96	10/17/2036	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074057634	(venetoclax) VENCLEXTA 100MG BOTTLE 180 TABLETS*	Brand	FDA	01/03/2023	1451.76	22191.12	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074057622	(venetoclax) VENCLEXTA 100MG BOTTLE, 120 TABLETS*	Brand	FDA	01/03/2023	967.84	14794.08	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074057611	(venetoclax) VENCLEXTA 100MG UNIT DOSE, 1 TABLET*	Brand	FDA	01/03/2023	8.06	123.27	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074056111	(venetoclax) VENCLEXTA 10MG UNIT DOSE, 2 TABLETS*	Brand	FDA	01/03/2023	1.61	24.65	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074056114	(venetoclax) VENCLEXTA 10MG WALLET, 2 TABLETS X 7*	Brand	FDA	01/03/2023	11.29	172.59	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074056611	(venetoclax) VENCLEXTA 50MG UNIT DOSE, 1 TABLET*	Brand	FDA	01/03/2023	4.03	61.64	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074056607	(venetoclax) VENCLEXTA 50MG WALLET, 1 TABLET X 7*	Brand	FDA	01/03/2023	28.23	431.50	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2023	00074057928	(venetoclax) VENCLEXTA START PACK, 4X7 DAY WALLET*	Brand	FDA	01/03/2023	208.89	3193.05	09/06/2033	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	12/31/2023	63090034030	Nuplazid Oral Capsule 34mg, 30 Each, Bottle	Brand	FDA	10/01/2023	430.00	4995.00	04/29/2030	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	Prior to 2020, Acadia did not have any patent dates that extended beyond 2030. Companies typically rely on the furthest out expiration date when determining LOE, hence the 2030 date that was provided on our submission. The patents with expiration dates past 2030 in the FDA’s database are of a different type (formulation and method of use compared to composition of the matter). It’s unreasonable to assume they will remain in effect for their full terms. Once we have any clarity on the expiration date of those patents, we may adjust our LOE thinking.
Rx0000018	ACADIA Pharmaceuticals Inc.	12/31/2023	63090010030	Nuplazid Oral Tablet 10mg, 30 Each, Bottle	Brand	FDA	10/01/2023	430.00	4995.00	04/29/2030	Single Source Drug	None	1	ACADIA prices our medicines to reflect their value to patients, payers and society. Our goals are to reduce the burden of disease and deliver better health outcomes with our therapies.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	Prior to 2020, Acadia did not have any patent dates that extended beyond 2030. Companies typically rely on the furthest out expiration date when determining LOE, hence the 2030 date that was provided on our submission. The patents with expiration dates past 2030 in the FDA’s database are of a different type (formulation and method of use compared to composition of the matter). It’s unreasonable to assume they will remain in effect for their full terms. Once we have any clarity on the expiration date of those patents, we may adjust our LOE thinking.
Rx0000278	Acella Pharamceuticals, LLC	03/31/2023	42192060845	Gabapentin Oral Solution 250 MG/5ML Pkg size 5	Generic	FDA	02/01/2023	12.36	149.74	None	Non-innovator Multiple Source Drug	2432	None	increase in manufacturing costs	None	none	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000278	Acella Pharamceuticals, LLC	03/31/2023	42192060840	Gabapentin Oral Solution 300 MG/6ML Pkg size 6	Generic	FDA	02/01/2023	12.36	149.74	None	Non-innovator Multiple Source Drug	42418	None	increase in manufacturing costs	None	none	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000513	Acertis Pharmaceuticals LLC	09/30/2023	72989037230	Prometrium (progesterone, USP) Capsules 100mg 30ct	Brand	FDA	08/01/2023	100.25	500.25	None	Single Source Drug	None	1	Factors Leading to WAC Price Increase (Including but not limited to): - Current Economic Conditions: The current economic environment has posed challenges, including increased production and operational costs, necessitating a WAC price adjustment. - Current Inflationary Environment: Escalating inflation rates have impacted various aspects of our operations, leading to increased expenses and, consequently, a WAC price increase. - Increased Costs in Sales and Marketing: Our commitment to maintaining high-quality sales and marketing efforts has required increased investments, contributing to the need for a WAC price adjustment. - Rising Distribution Costs: The costs associated with product distribution have risen significantly, driven by various market factors, prompting the WAC price increase.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000513	Acertis Pharmaceuticals LLC	09/30/2023	72989037330	Prometrium (progesterone, USP) Capsules 200mg 30ct	Brand	FDA	08/01/2023	190.06	950.28	None	Single Source Drug	None	1	Factors Leading to WAC Price Increase (Including but not limited to): - Current Economic Conditions: The current economic environment has posed challenges, including increased production and operational costs, necessitating a WAC price adjustment. - Current Inflationary Environment: Escalating inflation rates have impacted various aspects of our operations, leading to increased expenses and, consequently, a WAC price increase. - Increased Costs in Sales and Marketing: Our commitment to maintaining high-quality sales and marketing efforts has required increased investments, contributing to the need for a WAC price adjustment. - Rising Distribution Costs: The costs associated with product distribution have risen significantly, driven by various market factors, prompting the WAC price increase.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000021	Acorda Therapeutics, Inc.	03/31/2023	10144042760	Ampyra Oral Tablet Extended Release 12 Hour 10 MG Package Size 60 Package Quantity 1	Brand	FDA	01/01/2023	351.81	3869.92	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000021	Acorda Therapeutics, Inc.	03/31/2023	10144034260	Inbrija Inhalation Capsule 42 MG Package Size 60 Package Quantity 1	Brand	FDA	01/01/2023	104.74	1152.12	11/16/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000157	Acrotech Biopharma LLC	09/30/2023	72893000201	Beleodaq Intravenous Solution Reconstituted 500 MG, 1 Each, Unit-Dose, Vial	Brand	FDA	07/01/2023	34.83	2357.05	10/27/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NDC change from 68152-0108-09 to 72893-0002-01 on 1/1/2020.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215050115	OPSUMIT® (macitentan)Strength:10 mg Package Size:15 Form:Tablet	Brand	FDA	01/20/2023	447.39	6039.82	04/18/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215050130	OPSUMIT® (macitentan)Strength:10 mg Package Size:30 Form:Tablet	Brand	FDA	01/20/2023	894.79	12079.65	04/18/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215061006	UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215061206	UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215061406	UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215061606	UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060214	UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet	Brand	FDA	01/20/2023	1554.74	33284.04	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060206	UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	666.32	14264.59	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215062820	UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet	Brand	FDA	01/20/2023	1554.72	33283.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060406	UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060606	UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2023	66215060806	UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	1036.23	22183.77	12/01/2036	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000328	Adamas Pharmaceuticals, Inc.	03/31/2023	70482017060	Gocovri Oral Capsule Extended Release 24 Hour 137 MG Package Size 60 Package Quantity 1	Brand	FDA	01/01/2023	149.67	3142.96	08/23/2038	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	2715.00	2636.00	2017	2375.00	None	None
Rx0000328	Adamas Pharmaceuticals, Inc.	03/31/2023	70482008560	Gocovri Oral Capsule Extended Release 24 Hour 68.5 MG Package Size 60 Package Quantity 1	Brand	FDA	01/01/2023	149.67	3142.96	08/23/2038	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	2715.00	2636.00	2017	2375.00	None	None
Rx0000328	Adamas Pharmaceuticals, Inc.	03/31/2023	70482007530	Osmolex ER Oral Tablet Extended Release 24 Hour 129 MG Package Size 30 Package Quantity 1	Brand	FDA	01/01/2023	48.96	543.51	02/15/2038	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	450.00	450.00	2018	450.00	None	None
Rx0000328	Adamas Pharmaceuticals, Inc.	03/31/2023	70482007630	Osmolex ER Oral Tablet Extended Release 24 Hour 193 MG Package Size 30 Package Quantity 1	Brand	FDA	01/01/2023	48.96	543.51	02/15/2038	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	450.00	450.00	2018	450.00	None	None
Rx0000477	Agile Therapeutics	09/30/2023	71671010003	Twirla Transdermal Patch Weekly 120-30 MCG/24HR, 1 Each, Unit-of-Use, Box Qty 3	Brand	FDA	07/17/2023	13.37	204.57	08/26/2028	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000477	Agile Therapeutics	09/30/2023	71671010011	Twirla Transdermal Patch Weekly 120-30 MCG/24HR, 1 Each, Unit-of-Use, Package	Brand	FDA	07/17/2023	4.46	68.19	08/26/2028	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010415	PALFORZIA - 1-20mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=735	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010730	PALFORZIA - 1-20mg/1-100mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=738	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881011115	PALFORZIA - 15 Sachet-300mg per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=742	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010930	PALFORZIA - 2-100mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=740	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010345	PALFORZIA - 2-1mg/1-10mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=734	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010530	PALFORZIA - 2-20mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=736	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881011060	PALFORZIA - 2-20mg/2-100mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=741	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881011130	PALFORZIA - 30 Sachet-300mg per package	Brand	FDA	01/07/2023	278.52	168.52	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=743	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010145	PALFORZIA - 3-1mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=732	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010860	PALFORZIA - 3-20mg/1-100mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=739	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010660	PALFORZIA - 4-20mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=737	None
Rx0000222	Aimmune Therapeutics	03/31/2023	71881010290	PALFORZIA - 6-1mg Capsules per package	Brand	FDA	01/07/2023	139.26	584.26	03/12/2034	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=733	None
Rx0000222	Aimmune Therapeutics	12/31/2023	73562010410	VIOKACE - 100 Tablet - 10,440 unit - 39,150 unit - 39,150 unit per package	Brand	FDA	12/31/2023	100.71	422.51	None	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	05/11/2020	Allergan	None	1	None	293.88	293.88	2012	221.00	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=714	None
Rx0000222	Aimmune Therapeutics	12/31/2023	73562020810	VIOKACE - 100 Tablet - 20,800 unit - 78,300 unit - 78,300 unit per package	Brand	FDA	12/31/2023	198.67	833.54	None	Single Source Drug	None	1	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	Prices are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical benefits of the product, production costs, research and development costs, market dynamics, competitor pricing practices, discounts, commercial and government rebates, and patient support programs and other initiatives.	None	05/11/2020	Allergan	None	1	None	579.79	579.79	2012	436.00	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=715	None
Rx0000400	AkaRx, Inc., a Sobi Company	03/31/2023	71369002010	DOPTELET, 1 BLISTER PACK in 1 CARTON > 10 TABLET, EQ 20MG BASE	Brand	FDA	01/01/2023	186.70	3920.10	05/05/2025	Single Source Drug	None	1	AkaRx Inc. pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi Company	03/31/2023	71369002015	DOPTELET, 1 BLISTER PACK in 1 CARTON > 15 TABLET, EQ 20MG BASE	Brand	FDA	01/01/2023	280.05	5880.15	05/05/2025	Single Source Drug	None	1	AkaRx Inc. pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000400	AkaRx, Inc., a Sobi Company	03/31/2023	71369002030	DOPTELET, 2 BLISTER PACK in 1 CARTON / 15 TABLET, FILM COATED in 1 BLISTER PACK, EQ 20MG BASE	Brand	FDA	01/01/2023	560.10	11760.30	05/05/2025	Single Source Drug	None	1	AkaRx Inc. pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000417	Akebia Therapeutics, Inc.	03/31/2023	59922063101	Auryxia (Ferric Citrate) 210 mg, 200 Tablets per Bottle	Brand	FDA	01/01/2023	64.00	1458.00	07/21/2030	Single Source Drug	None	1	Akebia Therapeutics’ pricing decisions factor in multiple variables and considerations including but not limited to: competitive and market dynamics, increasing supply chain and overhead costs, distribution and wholesaler fees, and research and development costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Auryxia was developed by Keryx Biopharmaceuticals. In December 2018, Keryx Biopharmaceuticals and Akebia Therapeutics merged. Keryx Biopharmaceuticals is now a wholly owned subsidiary of Akebia Therapeutics. Auryxia is not an acquired product based on this history.
Rx0000417	Akebia Therapeutics, Inc.	09/30/2023	59922063101	Auryxia (Ferric Citrate) 210 mg, 200 Tablets per Bottle	Brand	FDA	07/01/2023	32.00	1490.00	07/21/2030	Single Source Drug	None	1	Akebia Therapeutics’ pricing decisions factor in multiple variables and considerations including but not limited to: competitive and market dynamics, increasing supply chain and overhead costs, distribution and wholesaler fees, and research and development costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Auryxia was developed by Keryx Biopharmaceuticals. In December 2018, Keryx Biopharmaceuticals and Akebia Therapeutics merged. Keryx Biopharmaceuticals is now a wholly owned subsidiary of Akebia Therapeutics. Auryxia is not an acquired product based on this history.
Rx0000235	Alembic Pharmaceuticals, Inc.	03/31/2023	62332001491	Lithium Carbonate Capsules USP 300mg 1000ct	Generic	FDA	01/30/2023	1314.40	1369.90	None	Non-innovator Multiple Source Drug	1	None	75% - Our current Active Ingredient supplier will no longer supply this product to Alembic. We have contacted an alternate supplier and the cost for Lithium Carbonate active ingredient has increased significantly. In addition, we must run additional tests and submit information to FDA prior to selling our Lithium Carbonate capsules with a different active ingredient supplier than what is currently in our ANDA filing. 25% - Market conditions and lack of supply has made it possible to increase price to offset added costs and provide additional profit for this product moving forward.	None	There has been no change or improvement to Lithium Carbonate, just a change of supplier for the active ingredient.	None	None	None	None	None	None	None	None	None	None	None	There were no sales for this product in the previous year. The system would not allow 0 as a submission, so 1 was used instead.
Rx0000235	Alembic Pharmaceuticals, Inc.	03/31/2023	62332001431	Lithium Carbonate Capsules USP 300mg 100ct	Generic	FDA	01/30/2023	130.53	136.99	None	Non-innovator Multiple Source Drug	1	None	75% - Our current Active Ingredient supplier will no longer supply this product to Alembic. We have contacted an alternate supplier and the cost for Lithium Carbonate active ingredient has increased significantly. In addition, we must run additional tests and submit information to FDA prior to selling our Lithium Carbonate capsules with a different active ingredient supplier than what is currently in our ANDA filing. 25% - Market conditions and lack of supply has made it possible to increase price to offset added costs and provide additional profit for this product moving forward.	None	There has been no change or improvement to Lithium Carbonate, just a change of supplier for the active ingredient.	None	None	None	None	None	None	None	None	None	None	None	There were no sales for this product in the previous year. The system would not allow 0 as a submission, so 1 was used instead.
Rx0000235	Alembic Pharmaceuticals, Inc.	03/31/2023	62332001531	Lithium Carbonate Capsules USP 600mg 100ct	Generic	FDA	01/30/2023	128.52	150.00	None	Non-innovator Multiple Source Drug	1	None	75% - Our current Active Ingredient supplier will no longer supply this product to Alembic. We have contacted an alternate supplier and the cost for Lithium Carbonate active ingredient has increased significantly. In addition, we must run additional tests and submit information to FDA prior to selling our Lithium Carbonate capsules with a different active ingredient supplier than what is currently in our ANDA filing. 25% - Market conditions and lack of supply has made it possible to increase price to offset added costs and provide additional profit for this product moving forward.	None	There has been no change or improvement to Lithium Carbonate, just a change of supplier for the active ingredient.	None	None	None	None	None	None	None	None	None	None	None	There were no sales for this product in the previous year. The system would not allow 0 as a submission, so 1 was used instead.
Rx0000272	Alexion Pharmaceuticals	12/31/2023	00310061028	CAPSULE 10MG 28 Count Bottle	Brand	FDA	10/01/2023	73.59	2526.45	12/12/2026	Innovator Multiple Source Drug	2296	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	12/31/2023	00310061060	CAPSULE 10MG 60 Count Bottle	Brand	FDA	10/01/2023	157.68	5413.69	12/12/2026	Innovator Multiple Source Drug	18068	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	12/31/2023	00310062528	CAPSULE 25MG 28 Count Bottle	Brand	FDA	10/01/2023	183.96	6315.97	12/12/2026	Innovator Multiple Source Drug	1264	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	12/31/2023	00310062560	CAPSULE 25MG 60 Count Bottle	Brand	FDA	10/01/2023	394.20	13534.23	12/12/2026	Innovator Multiple Source Drug	8290	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	06/30/2023	00310061028	KOSELUGO Caps 10mg (28ct)	Brand	FDA	04/01/2023	94.34	2452.86	12/12/2026	Innovator Multiple Source Drug	1451	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	06/30/2023	00310061060	KOSELUGO Caps 10mg (60ct)	Brand	FDA	04/01/2023	202.15	5256.01	12/12/2026	Innovator Multiple Source Drug	17650	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 04/10/2020.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	06/30/2023	00310062528	KOSELUGO Caps 25mg (28ct)	Brand	FDA	04/01/2023	235.85	6132.01	12/12/2026	Innovator Multiple Source Drug	820	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 05/20/2021.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000272	Alexion Pharmaceuticals	06/30/2023	00310062560	KOSELUGO Caps 25mg (60ct)	Brand	FDA	04/01/2023	505.39	13140.03	12/12/2026	Innovator Multiple Source Drug	7869	None	When setting the price of medicines Alexion, AstraZeneca Rare Disease aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). Alexion’s pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 04/10/2020.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	09/30/2023	52427065830	Loreev XR Capsule, 1mg 30 Count	Brand	FDA	08/07/2023	21.25	446.25	01/08/2034	Single Source Drug	3557	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	09/30/2023	52427066330	Loreev XR Capsules 2mg 30 Count	Brand	FDA	08/07/2023	21.25	446.25	01/08/2034	Single Source Drug	2301	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000208	Almatica	09/30/2023	52427066730	Loreev XR Capsules, 3mg 30 Count	Brand	FDA	08/07/2023	21.25	446.25	01/08/2034	Single Source Drug	1943	None	Almatica considers various factors in deciding the wholesale acquisition cost (WAC) at which to set its prescription drugs, including Loreev.  These factors include, but are not limited to: market based factors such as the competitive landscape and pricing environment; manufacturing and supply considerations; profitability; inflation and costs, including increased cost of administrative and commercial activities; therapeutic class and patient population, as well as patient needs and access; and contracts and relationships with customers.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000459	AltaThera Pharmaceuticals LLC	03/31/2023	69724011210	Sotalol hydrochloride 15mg/mL 10mL Vial	Brand	FDA	01/01/2023	265.00	2999.00	08/21/2039	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042510	DONNATAL 16.2MG 100 Bottle	Brand	Medispan	04/01/2023	60.00	1263.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042304	DONNATAL 16.2MG/5ML 118ML GRP Bottle	Brand	Medispan	04/01/2023	23.00	473.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042204	DONNATAL 16.2MG/5ML 118ML MINT, Bottle	Brand	Medispan	04/01/2023	23.00	473.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042316	DONNATAL 16.2MG/5ML 473ML GRP Bottle	Brand	Medispan	04/01/2023	94.00	1889.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212042216	DONNATAL 16.2MG/5ML 473ML MINT Bottle	Brand	Medispan	04/01/2023	94.00	1889.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212000301	DYRENIUM 100MG 100 Capsule	Brand	FDA	04/01/2023	60.00	1340.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212000201	DYRENIUM 50MG 100 Capsule	Brand	FDA	04/01/2023	77.00	1340.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212065860	KAPVAY 0.1MG 60 ER 60 Each, Bottle	Brand	Medispan	04/01/2023	30.00	530.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212024055	LANOXIN 0.0625MG 100 Bottle	Brand	FDA	04/01/2023	90.00	1655.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212024255	LANOXIN 0.125MG 100 Bottle	Brand	FDA	04/01/2023	90.00	1655.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212024256	LANOXIN 0.125MG 10X10UD Box	Brand	FDA	04/01/2023	90.00	1655.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212024955	LANOXIN 0.25MG 100 Bottle	Brand	FDA	04/01/2023	90.00	1655.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212044710	PARNATE 10MG 100 Tablet	Brand	FDA	04/01/2023	39.00	889.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	09/30/2023	59212056210	Plaquenil Oral Tablet 200 MG, 100 Each, Bottle	Brand	FDA	07/01/2023	58.00	1268.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212020010	UROXATRAL 10MG 100 ER Bottle	Brand	FDA	04/01/2023	115.00	2675.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212068010	ZONEGRAN 100MG 100 Each, Bottle	Brand	FDA	04/01/2023	101.00	2121.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000436	Amdipharm Limited	06/30/2023	59212068110	ZONEGRAN 25MG 100 Each, Bottle	Brand	FDA	04/01/2023	78.00	1638.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000231	American Health Packaging	03/31/2023	68084038801	BENZTROPINE MESYLATE 1mg Tab 100UD	Generic	FDA	02/24/2023	7.19	49.00	None	Non-innovator Multiple Source Drug	4992	None	Market Conditions	None	No Change Improvement in the drug product	None	01/26/2023	PAR	7	None	None	7.96	None	2013	25.29	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2023	68084092125	CYCLOSPORINE CAPSULE 100MG 30UD	Generic	FDA	11/27/2023	56.56	433.65	None	Non-innovator Multiple Source Drug	306	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2023	60687068001	METHIMAZOLE TAB 10MG 100UD	Generic	FDA	01/31/2023	18.48	82.93	None	Non-innovator Multiple Source Drug	84	None	Market Conditions	None	No Change Improvement in the drug product	None	02/15/2023	Strides Pharma Science	28	None	None	28.14	None	2022	64.45	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2023	60687066901	METHIMAZOLE TAB 5MG 100UD	Generic	FDA	01/31/2023	9.67	59.67	None	Non-innovator Multiple Source Drug	592	None	Market Conditions	None	No Change Improvement in the drug product	None	02/14/2023	Strides Pharma Science	10	None	None	10.82	None	2022	50.00	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2023	68084080521	METHYLPHENIDATE HCL TABLET CII 5MG 30UD	Generic	FDA	10/06/2023	5.00	54.96	None	Non-innovator Multiple Source Drug	5801	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	09/30/2023	68084029121	NALTREXONE HCL TABLET 50MG 30UD	Generic	FDA	07/14/2023	10.52	75.23	None	Non-innovator Multiple Source Drug	5832	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68001056600	POTASSIUM CHl ER TAB 10MeQ 100	Generic	FDA	05/01/2023	14.30	47.68	None	Non-innovator Multiple Source Drug	3638	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68001056603	POTASSIUM CHl ER TAB 10mEq 500	Generic	FDA	05/01/2023	71.48	238.38	None	Non-innovator Multiple Source Drug	2042	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68001056700	POTASSIUM CHl ER TAB 20mEq 100	Generic	FDA	05/01/2023	15.06	50.19	None	Non-innovator Multiple Source Drug	16094	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68001056703	POTASSIUM CHl ER TAB 20mEq 500	Generic	FDA	05/01/2023	75.26	250.93	None	Non-innovator Multiple Source Drug	11528	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2023	68084049401	PYRIDOSTIGMINE BROMIDE TABLET 60MG 100UD	Generic	FDA	06/05/2023	14.90	138.43	None	Non-innovator Multiple Source Drug	642	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2023	68084005921	ZAFIRLUKAST TABLET 20MG 30UD	Generic	FDA	11/27/2023	13.75	86.10	None	Non-innovator Multiple Source Drug	357	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000128	American Regent	09/30/2023	00517750425	ACETYLCYSTEINE SOLUTION 10%, 4ML, PKG OF 25	Generic	FDA	08/01/2023	6.00	236.50	None	Non-innovator Multiple Source Drug	49139	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	03/31/2023	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	Generic	Medispan	02/01/2023	18.60	276.10	None	Non-innovator Multiple Source Drug	None	1	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	Caffeine & Sodium Benzoate is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	Generic	Medispan	08/01/2023	20.00	296.10	None	Non-innovator Multiple Source Drug	7115	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	03/31/2023	00517420125	HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25	Generic	FDA	02/01/2023	46.50	627.00	None	Non-innovator Multiple Source Drug	None	1	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Hydroxyzine HCL is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517420125	HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25	Generic	FDA	08/01/2023	10.75	637.75	None	Non-innovator Multiple Source Drug	6650	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	03/31/2023	00517560125	HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25	Generic	FDA	02/01/2023	51.25	691.50	None	Non-innovator Multiple Source Drug	None	1	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Hydroxyzine HCL is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517560125	HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25	Generic	FDA	08/01/2023	11.25	703.25	None	Non-innovator Multiple Source Drug	9277	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	09/30/2023	00517065001	Injectafer Intravenous Solution 750 MG/15ML	Brand	FDA	07/03/2023	26.43	1347.63	None	Single Source Drug	607593	None	American Regent’s US Standards of Business Conduct (available at https://americanregent.com/media/3206/us-sobc-ver-10-01102022.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	There was no change or improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the acquisition fields: Injectafer is not an acquired product. The licensor has granted American Regent the right to develop, manufacture, distribute and sell the product in the United States. American Regent is the NDA holder of this NDC but markets the drug through our parent company, Daiichi Sankyo, Inc.
Rx0000128	American Regent	09/30/2023	00517231005	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 10ML, PKG. OF 5	Brand	FDA	08/01/2023	34.65	612.15	None	Single Source Drug	399870	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the patent expiration date field: American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. We provide the following comment regarding the acquisition fields: Venofer is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517232510	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 2.5ML, PKG. OF 10	Brand	FDA	08/01/2023	19.80	306.10	None	Single Source Drug	10683	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the patent expiration date field: American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. We provide the following comment regarding the acquisition fields: Venofer is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517234010	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 5ML, PKG. OF 10	Brand	FDA	08/01/2023	34.70	612.20	None	Single Source Drug	896950	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the patent expiration date field: American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. We provide the following comment regarding the acquisition fields: Venofer is not an acquired product.
Rx0000128	American Regent	09/30/2023	00517234025	Venofer (Iron Sucrose) Injection USP, 20 MG/ML 5ML, PKG. OF 25	Brand	FDA	08/01/2023	86.75	1530.50	None	Single Source Drug	70061	None	Our US Standards of Business Conduct (https://americanregent.com/media/3206/us-sobc-version-100-01102022.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	We provide the following comment regarding the patent expiration date field: American Regent does not hold any patents for the drug Venofer that is the subject of the report and therefore has left the patent expiration data element blank. We provide the following comment regarding the acquisition fields: Venofer is not an acquired product.
Rx0000069	Amgen	03/31/2023	55513084301	Aimovig, 140 mg/mL single-dose prefilled SureClick autoinjector	Brand	FDA	01/04/2023	41.11	737.86	04/01/2039	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513084101	Aimovig, 70 mg/mL single-dose prefilled SureClick autoinjector	Brand	FDA	01/04/2023	41.11	737.86	04/01/2039	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513016001	Blincyto, 35 mcg lyophilized vial, 1 pk	Brand	FDA	01/04/2023	273.00	4900.15	04/06/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Blincyto reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513081328	Corlanor, 5mg oral solution AMP, 28 pk	Brand	FDA	01/04/2023	14.76	264.94	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2023	55513080060	Corlanor, 5mg tablet, 60 pk	Brand	FDA	01/04/2023	31.63	567.73	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	03/31/2023	55513081060	Corlanor, 7.5mg tablet, 60 pk	Brand	FDA	01/04/2023	31.63	567.73	06/12/2027	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities.
Rx0000069	Amgen	03/31/2023	58406004401	Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack	Brand	FDA	01/04/2023	121.42	1762.33	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406004404	Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack	Brand	FDA	01/04/2023	485.70	7049.34	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406003201	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack	Brand	FDA	01/04/2023	121.42	1762.33	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406003204	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack	Brand	FDA	01/04/2023	485.70	7049.34	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406042534	Enbrel, 25mg (1 mL), Vial (EA), 4 pack	Brand	FDA	01/04/2023	242.85	3524.69	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406042541	Enbrel, 25mg (1mL), Vial (EA), 1 pack	Brand	FDA	01/04/2023	60.71	881.17	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406001001	Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack	Brand	FDA	01/04/2023	60.71	881.17	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406001004	Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack	Brand	FDA	01/04/2023	242.85	3524.69	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406005501	Enbrel, 25mg/0.5mL, Vial (EA), 1 pack	Brand	FDA	01/04/2023	60.71	881.17	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406005504	Enbrel, 25mg/0.5mL, Vial (EA), 4 pack	Brand	FDA	01/04/2023	242.85	3524.69	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406002101	Enbrel, 50mg/mL, Syringe (ML), 1 pack	Brand	FDA	01/04/2023	121.42	1762.33	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	58406002104	Enbrel, 50mg/mL, Syringe (ML), 4 pack	Brand	FDA	01/04/2023	485.70	7049.34	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513088001	Evenity, 105mg, 1.17mL prefilled syringe, 1 pk	Brand	FDA	01/04/2023	62.19	1116.25	04/09/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	06/30/2023	55513088001	Evenity, 105mg, 1.17mL prefilled syringe, 1 pk	Brand	FDA	06/30/2023	42.97	1159.22	04/09/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513088002	Evenity, 105mg, 1.17mL prefilled syringe, 2 pk	Brand	FDA	01/04/2023	124.38	2232.49	04/09/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	06/30/2023	55513088002	Evenity, 105mg, 1.17mL prefilled syringe, 2 pk	Brand	FDA	06/30/2023	85.95	2318.44	04/09/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513007801	Imlygic, 106 (1 million) PFU/mL (1.0 mL) single-use vial	Brand	FDA	01/04/2023	3.53	63.37	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513007901	Imlygic, 108 (100 million) PFU/mL (1.0 mL) single-use vial	Brand	FDA	01/04/2023	353.01	6336.31	11/23/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	76075010301	Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk	Brand	FDA	01/04/2023	27.66	496.53	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	76075010201	Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk	Brand	FDA	01/04/2023	82.99	1489.60	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	76075010101	Kyprolis, 60 mg lyophilized vial, 1 pk	Brand	FDA	01/04/2023	165.98	2979.20	05/08/2033	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513022301	Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial	Brand	FDA	01/04/2023	66.44	1192.50	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513022101	Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial	Brand	FDA	01/04/2023	132.87	2384.97	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513022201	Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial	Brand	FDA	01/04/2023	265.75	4769.93	02/12/2028	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513036955	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack	Brand	FDA	01/04/2023	256.30	4600.48	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513013760	Otezla, 30mg, Tablet, 60 pack	Brand	FDA	01/04/2023	256.30	4600.48	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513071001	Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe	Brand	FDA	01/04/2023	87.15	1564.31	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	06/30/2023	55513071001	Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe	Brand	FDA	06/30/2023	60.23	1624.54	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	72511076002	Repatha, 140 mg, 1.0 mL (140 mg/mL) autoinjector, 2 pack	Brand	FDA	01/04/2023	30.67	550.48	10/08/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Repatha reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	72511075001	Repatha, 140 mg, 1.0 mL (140 mg/mL) prefilled syringe	Brand	FDA	01/04/2023	15.33	275.24	10/08/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Repatha reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	72511077001	Repatha, 420 mg, 3.5 mL (120 mg/mL)  Pushtronex system	Brand	FDA	01/04/2023	33.22	596.35	10/08/2030	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Repatha reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2023	55513095401	Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial	Brand	FDA	01/04/2023	87.44	1569.46	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2023	55513095601	Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial	Brand	FDA	01/04/2023	349.76	6277.82	None	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000069	Amgen	03/31/2023	55513073001	Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial	Brand	FDA	01/04/2023	160.31	2877.46	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Xgeva reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	06/30/2023	55513073001	Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial	Brand	FDA	06/30/2023	110.78	2988.24	02/19/2025	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Xgeva reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000122	Amneal Pharmaceuticals	12/31/2023	70121171109	Dexmedetomine HCl 9% NaCl IV 24 Single Dose Bags	Generic	FDA	11/17/2023	237.50	427.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	Amneal considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066930	Emverm Oral Tablet Chewable 100 MG	Generic	FDA	02/01/2023	55.64	617.65	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069701	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 100	Generic	FDA	02/01/2023	139.15	838.42	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069713	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 60	Generic	FDA	02/01/2023	83.49	503.06	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069801	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 100	Generic	FDA	02/01/2023	192.97	1162.66	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069813	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 60	Generic	FDA	02/01/2023	115.78	697.61	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069901	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 100	Generic	FDA	02/01/2023	246.81	1487.03	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069913	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 60	Generic	FDA	02/01/2023	148.08	892.22	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896070001	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 100	Generic	FDA	02/01/2023	355.23	2140.33	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896070013	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 60	Generic	FDA	02/01/2023	213.14	1284.21	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896070101	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 100	Generic	FDA	02/01/2023	463.67	2793.66	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896070113	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 60	Generic	FDA	02/01/2023	278.20	1676.20	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069501	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 100	Generic	FDA	02/01/2023	72.47	436.63	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069513	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 60	Generic	FDA	02/01/2023	43.48	261.96	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069601	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 100	Generic	FDA	02/01/2023	105.81	637.49	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896069613	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 60	Generic	FDA	02/01/2023	63.48	382.49	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066101	Rytary Oral Capsule Extended Release 23.75-95 MG	Brand	FDA	02/01/2023	30.78	415.48	12/26/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066201	Rytary Oral Capsule Extended Release 36.25-145 MG	Brand	FDA	02/01/2023	30.78	415.48	12/26/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066301	Rytary Oral Capsule Extended Release 48.75-195 MG	Brand	FDA	02/01/2023	30.78	415.48	12/26/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	64896066401	Rytary Oral Capsule Extended Release 61.25-245 MG	Brand	FDA	02/01/2023	38.67	522.08	12/26/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080501	Unithroid Oral Tablet 100 MCG	Brand	FDA	02/01/2023	29.33	400.48	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080601	Unithroid Oral Tablet 112 MCG	Brand	FDA	02/01/2023	29.38	401.28	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080701	Unithroid Oral Tablet 125 MCG	Brand	FDA	02/01/2023	29.43	401.95	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080801	Unithroid Oral Tablet 137 MCG	Brand	FDA	02/01/2023	29.46	402.37	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080901	Unithroid Oral Tablet 150 MCG	Brand	FDA	02/01/2023	29.48	402.69	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846081001	Unithroid Oral Tablet 175 MCG	Brand	FDA	02/01/2023	29.53	403.30	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846081101	Unithroid Oral Tablet 200 MCG	Brand	FDA	02/01/2023	29.56	403.68	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080101	Unithroid Oral Tablet 25 MCG	Brand	FDA	02/01/2023	29.15	398.21	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846081201	Unithroid Oral Tablet 300 MCG	Brand	FDA	02/01/2023	29.58	404.08	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080201	Unithroid Oral Tablet 50 MCG	Brand	FDA	02/01/2023	29.17	398.47	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080301	Unithroid Oral Tablet 75 MCG	Brand	FDA	02/01/2023	29.21	398.92	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000122	Amneal Pharmaceuticals	03/31/2023	60846080401	Unithroid Oral Tablet 88 MCG	Brand	FDA	02/01/2023	29.27	399.80	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Increases in discounts offered to marketplace across portfolio
Rx0000176	ANIP	03/31/2023	62559030690	Lipofen Capsules 150mg 90ct	Brand	FDA	03/20/2023	84.50	938.08	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2023	62559030590	Lipofen Capsules 50mg 90ct	Brand	FDA	03/20/2023	38.56	428.09	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000412	Antares Pharma, Inc	03/31/2023	54436020004	Xyosted (Testosterone Enanthate) once weekly subcutaneous autoinjector 100MG/0.5ML; 4 syringes in 1 carton	Brand	FDA	01/03/2023	28.86	606.21	08/30/2038	Single Source Drug	10000	None	Cost of marketing & distribution	None	Improved marketing/distribution channels	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000412	Antares Pharma, Inc	03/31/2023	54436025004	Xyosted (Testosterone Enanthate) once weekly subcutaneous autoinjector 50MG/0.5ML; 4 syringes in 1 carton	Brand	FDA	01/03/2023	28.86	606.21	08/30/2038	Single Source Drug	15000	None	Cost of marketing & distribution	None	Improved marketing/distribution channels	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000412	Antares Pharma, Inc	03/31/2023	54436027504	Xyosted (Testosterone Enanthate) once weekly subcutaneous autoinjector 75MG/0.5ML; 4 syringes in 1 carton	Brand	FDA	01/03/2023	28.86	606.21	08/30/2038	Single Source Drug	40000	None	Cost of marketing & distribution	None	Improved marketing/distribution channels	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	09/30/2023	60505437703	PAXIL CR FCT 12.5MG 30BTL USA	Brand	FDA	07/01/2023	4.67	276.01	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505437803	PAXIL CR FCT 25MG 30BTL USA	Brand	FDA	07/01/2023	4.67	288.01	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505437903	PAXIL CR FCT 37.5MG 30BTL USA	Brand	FDA	07/01/2023	4.67	296.69	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505451703	PAXIL FCT 10MG 30BTL USA	Brand	FDA	07/01/2023	4.67	267.98	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505451803	PAXIL FCT 20MG 30BTL USA	Brand	FDA	07/01/2023	4.67	279.59	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505451903	PAXIL FCT 30MG 30BTL USA	Brand	FDA	07/01/2023	4.67	288.06	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000271	Apotex Corp	09/30/2023	60505452003	PAXIL FCT 40MG 30BTL USA	Brand	FDA	07/01/2023	4.67	304.29	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	A number of considerations impact pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, corporate investments in important clinical development initiatives, as well as the cost of labor and goods.
Rx0000141	Ascend Laboratories, LLC	03/31/2023	67877067870	Tobramycin Inhalation Solution 300mg 5ML	Generic	FDA	03/01/2023	301.30	657.42	None	Non-innovator Multiple Source Drug	1300	None	Newly launched product and new contracts with additional rebates and administrative fees. Increased API costs in India.	None	Newly launched product and new contracts with additional rebates and administrative fees. Increased API costs in India.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2023	75854060203	Balcoltra Oral Tablet 0.1-20 MG-MCG(21) pkg size 28 pkg quantity 3	Brand	FDA	01/02/2023	66.15	801.14	None	Non-innovator Multiple Source Drug	95100	None	increase in manufacturing costs	None	none	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2023	75854060228	Balcoltra Oral Tablet inner sleeve 0.1-20 MG-MCG(21) pkg size 28 pkg quantity 1	Brand	FDA	01/02/2023	22.05	267.05	None	Non-innovator Multiple Source Drug	0	1	increase in manufacturing costs	None	none	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	03/31/2023	42291026130	Entecavir 0.5mg Tablet	Generic	FDA	02/03/2023	292.14	395.00	None	Non-innovator Multiple Source Drug	None	1	AvKARE is a repackager of pharmaceuticals. Our increase factors are due to an increase in cost of goods which include the cost of the pill, bottle, bottle cap, inserts and packaging costs from the packager.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	03/31/2023	42291026230	Entecavir 1mg Tablet	Generic	FDA	02/03/2023	288.58	395.00	None	Non-innovator Multiple Source Drug	None	1	AvKARE is a repackager of pharmaceuticals. Our increase factors are due to an increase in cost of goods which include the cost of the pill, bottle, bottle cap, inserts and packaging costs from the packager.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000429	Axsome Therapeutics, Inc.	03/31/2023	81968035101	Sunosi Tablets 150mg 1	Brand	FDA	01/01/2023	67.95	822.95	06/17/2024	Single Source Drug	0	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals, Inc.	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million, a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on Axsome’s U.S. net sales of Sunosi in future indications.	755.00	699.60	2019	660.00	None	None
Rx0000429	Axsome Therapeutics, Inc.	03/31/2023	68727035101	Sunosi Tablets 150mg 30 Jazz	Brand	Medispan	01/01/2023	67.95	822.95	06/17/2024	Single Source Drug	0	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals, Inc.	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million, a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on Axsome’s U.S. net sales of Sunosi in future indications.	755.00	699.60	2019	660.00	None	None
Rx0000429	Axsome Therapeutics, Inc.	03/31/2023	81968035001	Sunosi Tablets 75mg 1	Brand	FDA	01/01/2023	67.95	822.95	06/17/2024	Single Source Drug	0	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals, Inc.	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million, a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on Axsome’s U.S. net sales of Sunosi in future indications.	755.00	699.60	2019	660.00	None	None
Rx0000429	Axsome Therapeutics, Inc.	03/31/2023	68727035001	Sunosi Tablets 75mg 30 Jazz	Brand	Medispan	01/01/2023	67.95	822.95	06/17/2024	Single Source Drug	0	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals, Inc.	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million, a high single-digit royalty on Axsome’s U.S. net sales of Sunosi in the current indication, and a mid single-digit royalty on Axsome’s U.S. net sales of Sunosi in future indications.	755.00	699.60	2019	660.00	None	None
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264763400	0.075% KCL IN 5% DEXTROSE AND 0.45% NACL INJECTION USP, 5 g in 100 mL DEXTROSE 0.2 g in 100 mL SODIUM CHLORIDE 0.15 g in 100 mL POT, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	9.48	108.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264764500	0.15% KCL IN 5% DEXTROSE AND 0.20% NACL INJECTION USP, 5 g in 100 mL DEXTROSE 0.2 g in 100 mL SODIUM CHLORIDE 0.15 g in 100 mL POT, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	3.84	96.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264762500	0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP, 5 g in 100 mL DEXTROSE 0.15 g in 100 mL POTASSIUM CHLORIDE, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	10.44	120.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264763600	0.22% KCL IN 5% DEXDTROSE AND 0.45% NACL INJECTION USP, 5 g in 100 mL DEXTROSE 0.2 g in 100 mL SODIUM CHLORIDE 0.15 g in 100 mL POT, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	13.44	112.44	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264230400	0.25% ACETIC ACID IRRIGATION USP, 0.25 g in 100 mL ACETIC ACID, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	9.44	124.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264230410	0.25% ACETIC ACID IRRIGATION USP, 0.25 g in 100 mL ACETIC ACID, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	8.48	110.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264763800	0.30% KCL IN 5% DEXTROSE AND 0.45% NACL INJECTION USP, 5 g in 100 mL DEXTROSE 0.2 g in 100 mL SODIUM CHLORIDE 0.15 g in 100 mL POT, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	8.40	108.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264959420	0.4% LIDOCAINE HCL AND 5% DEXTROSE INJECTION, 0.8 g in 100 mL LIDOCAINE HYDROCHLORIDE ANHYDROUS 5 g in 100 mL DEXTROSE MO, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	1.92	177.12	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264780020	0.9% SODIUM CHLORIDE INJECTION USP, 0.9 g in 100 mL SODIUM CHLORIDE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	6.00	68.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264180032	0.9% SODIUM CHLORIDE INJECTION USP, 9 mg in 1 mL SODIUM CHLORIDE, SOLUTION, 100 mL bag	Brand	FDA	06/01/2023	15.36	174.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264180036	0.9% SODIUM CHLORIDE INJECTION USP, 9 mg in 1 mL SODIUM CHLORIDE, SOLUTION, 25 mL bag	Brand	FDA	06/01/2023	24.36	315.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264180031	0.9% SODIUM CHLORIDE INJECTION USP, 9 mg in 1 mL SODIUM CHLORIDE, SOLUTION, 50 mL bag	Brand	FDA	06/01/2023	18.48	226.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264762320	10% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP, 2.5 g in 100 mL DEXTROSE 0.45 g in 100 mL SODIUM CHLORIDE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	7.92	89.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264762200	10% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP, 2.5 g in 100 mL DEXTROSE 0.45 g in 100 mL SODIUM CHLORIDE, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	9.12	104.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264752000	10% DEXTROSE INJECTION USP, 5 g in 100 mL DEXTROSE, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	6.36	72.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264752020	10% DEXTROSE INJECTION USP, 5 g in 100 mL DEXTROSE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	8.40	96.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264752010	10% DEXTROSE INJECTION USP, 5 g in 100 mL DEXTROSE, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	9.36	106.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264761620	5% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP, 2.5 g in 100 mL DEXTROSE 0.45 g in 100 mL SODIUM CHLORIDE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	8.64	98.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264751020	5% DEXTROSE INJECTION USP, 5 g  in 100 mL DEXTROSE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	6.96	81.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264751010	5% DEXTROSE INJECTION USP, 5 g  in 100 mL DEXTROSE, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	7.92	89.28	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264319511	CEFEPIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEX, 1 g  in 50 mL CEFEPIME, POWDER, 50 mL bag	Brand	FDA	06/01/2023	34.56	716.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738960	LACTATED RINGERS IN PLASTIC CONTAINER, 600 mg in 100 mL SODIUM CHLORIDE 310 mg in 100 mL SODIUM LACTATE 30 mg in 1, SOLUTION, 3000 mL bag	Brand	FDA	06/01/2023	16.60	73.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264757810	MANNITOL INJECTION USP, 20 g in 100 mL MANNITOL, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	93.60	1205.04	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264318511	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER 1 G, 500 mg  in 50 mL MEROPENEM, POWDER, 50 mL bag	Brand	FDA	06/01/2023	18.24	717.84	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264446030	NUTRILIPID 20%, 20 g in 100 mL SOYBEAN OIL, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	23.04	305.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264446010	NUTRILIPID 20%, 20 g in 100 mL SOYBEAN OIL, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	29.28	387.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264220500	PHYSIOLYTE, 0.53 g in 100 mL SODIUM CHLORIDE 0.5 g in 100 mL SODIUM GLUCONATE 0.37 g in, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	9.76	119.36	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264778000	RINGER'S INJECTION USP, 0.86 g in 100 mL SODIUM CHLORIDE 0.033 g in 100 mL CALCIUM CHLORIDE 0.03 g, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	10.44	120.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264220200	RINGER'S IRRIGATION USP, 0.86 g in 100 mL SODIUM CHLORIDE 0.03 g in 100 mL POTASSIUM CHLORIDE 0.033, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	15.04	101.28	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738850	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, 0.9 g in 100 mL SODIUM CHLORIDE, SOLUTION, 2000 mL bag	Brand	FDA	06/01/2023	8.11	54.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738860	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, 0.9 g in 100 mL SODIUM CHLORIDE, SOLUTION, 3000 mL bag	Brand	FDA	06/01/2023	5.96	72.92	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264785000	STERILE WATER FOR INJECTION USP, 1 mL in 1 mL WATER, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	3.96	51.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738550	STERILE WATER FOR INJECTION USP, 1 mL in 1 mL WATER, SOLUTION, 2000 mL bag	Brand	FDA	06/01/2023	4.20	48.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738660	STERILE WATER FOR IRRIGATION USP, 100 mL in 100 mL WATER, SOLUTION, 3000 mL bag	Brand	FDA	06/01/2023	6.64	76.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738650	STERILE WATER FOR IRRIGATION USP, 100 mL in 100 mL WATER, SOLUTION, 2000 mL bag	Brand	FDA	06/01/2023	4.88	59.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208035310	ALREX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.2%, 10mL Bottle	Brand	FDA	01/01/2023	31.94	564.24	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208035305	ALREX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.2%, 5mL Bottle	Brand	FDA	01/01/2023	15.97	282.13	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208062901	BEPREVE™ (bepotastine besilate), Ophthalmic Solution USP, 1.5%, 10mL Bottle	Brand	FDA	01/01/2023	29.39	519.21	09/05/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208062902	BEPREVE™ (bepotastine besilate), Ophthalmic Solution USP, 1.5%, 5mL Bottle	Brand	FDA	01/01/2023	15.37	271.48	09/05/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208044605	BESIVANCE® (besifloxacin), Ophthalmic Suspension Drops, 0.6%, 5mL Bottle	Brand	FDA	01/01/2023	12.10	213.81	01/09/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208044335	LOTEMAX® (loteprednol etabonate), Ointment, 0.5%, 3.5g Tube	Brand	FDA	01/01/2023	19.18	338.82	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208050307	LOTEMAX® (loteprednol etabonate), Ophthalmic Gel, 0.5%, 5g Bottle	Brand	FDA	01/01/2023	13.63	240.79	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208029910	LOTEMAX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.5%, 10mL Bottle	Brand	FDA	01/01/2023	33.97	600.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208029915	LOTEMAX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.5%, 15mL Bottle	Brand	FDA	01/01/2023	50.51	892.30	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208029905	LOTEMAX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.5%, 5mL Bottle	Brand	FDA	01/01/2023	16.99	300.12	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208050707	LOTEMAX® SM (loteprednol etabonate), Ophthalmic Gel, 0.38%, 5g Bottle	Brand	FDA	01/01/2023	13.63	240.79	12/23/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208053920	MIOCHOL®-E (acetylcholine chloride),Intraocular Solution Kit, 20mg/2 mL, 1 Vial	Brand	FDA	01/01/2023	6.87	121.36	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208060203	PROLENSA™ (bromfenac), Ophthalmic Solution, 0.07%, 3mL Bottle	Brand	FDA	01/01/2023	19.06	336.67	11/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	00187149825	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL Single-Use Drop Dispenser, 60	Brand	FDA	01/01/2023	29.89	528.06	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	00187149605	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL Single-Use Drop Dispenser, 60	Brand	FDA	01/01/2023	34.08	602.16	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208000202	VITRASE® (hyaluronidase, ovine injection) Solution, Vial (ML), 200 Units/mL, 2 Single Dose Vials	Brand	FDA	01/01/2023	13.68	241.65	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208050402	VYZULTA™ (latanoprostene bunod), Ophthalmic Drops, 0.024%, 2.5mL Bottle	Brand	FDA	01/01/2023	13.64	240.89	10/03/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208050405	VYZULTA™ (latanoprostene bunod), Ophthalmic Drops, 0.024%, 5mL Bottle	Brand	FDA	01/01/2023	27.27	481.76	10/03/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208053535	ZIRGAN™ (Ganciclovir), Ophthalmic Gel, 0.15%, 5mL Bottle	Brand	FDA	01/01/2023	25.10	443.46	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208035810	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3%), Ophthalmic Suspension Drops, 0.3%-0.5%, 10mL Bottle	Brand	FDA	01/01/2023	35.36	624.67	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208035805	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3%), Ophthalmic Suspension Drops, 0.3%-0.5%, 5mL Bottle	Brand	FDA	01/01/2023	17.68	312.33	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187581030	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct	Brand	FDA	01/01/2023	107.46	1840.62	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187581130	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct	Brand	FDA	01/01/2023	141.66	2426.40	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187581230	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct	Brand	FDA	01/01/2023	322.36	5521.75	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187006410	ATIVAN® Tablets 1mg 1,000s	Brand	FDA	01/01/2023	2843.49	43464.69	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187006301	ATIVAN® Tablets .5mg 100s	Brand	FDA	01/01/2023	217.34	3322.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187006401	ATIVAN® Tablets 1mg 100s	Brand	FDA	01/01/2023	290.33	4437.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187006501	ATIVAN® Tablets 2mg 100s	Brand	FDA	01/01/2023	462.70	7072.75	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187000201	BRYHALI™ (halobetasol propionate) Lotion 0.01%, 100g	Brand	FDA	01/01/2023	42.87	519.28	11/02/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187000260	BRYHALI™ (halobetasol propionate) Lotion 0.01%, 60g	Brand	FDA	01/01/2023	25.73	311.57	11/02/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	25010030515	DEMSER® (metyrosine), 250mg Capsules, 100ct	Brand	FDA	01/01/2023	2992.25	45136.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187065301	DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, 1	Brand	FDA	01/01/2023	81.57	1008.54	06/06/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187540004	JUBLIA® (efinaconazole) Topical Solution 10%, 4mL	Brand	FDA	01/01/2023	63.45	745.69	04/25/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187540008	JUBLIA® (efinaconazole) Topical Solution 10%, 8mL	Brand	FDA	01/01/2023	126.89	1491.37	04/25/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187301220	MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle	Brand	FDA	01/01/2023	97.73	1601.33	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187301030	MESTINON 60mg TABLETS 100s (pyridostigmine bromide)	Brand	FDA	01/01/2023	120.32	1971.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187301330	MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT	Brand	FDA	01/01/2023	68.46	1121.79	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	66490069110	MYSOLINE 250 mg TABLETS, 100s (primidone)	Brand	FDA	01/01/2023	404.59	6354.44	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	66490069010	MYSOLINE 50 mg TABLETS, 100s (primidone)	Brand	FDA	01/01/2023	117.57	1846.54	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187305050	ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 50g Pump	Brand	FDA	01/01/2023	57.27	723.24	08/05/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187000402	SILIQ™ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes)	Brand	FDA	01/01/2023	427.87	4749.80	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014090	VASOTEC® 2.5mg Tablets, 90s	Brand	FDA	01/01/2023	90.00	1541.73	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014210	VASOTEC® 10mg Tablets, 1,000s	Brand	FDA	01/01/2023	1275.72	21851.72	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014230	VASOTEC® 10mg Tablets, 30s	Brand	FDA	01/01/2023	38.27	655.49	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014290	VASOTEC® 10mg Tablets, 90s	Brand	FDA	01/01/2023	114.82	1966.84	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014030	VASOTEC® 2.5mg Tablets, 30s	Brand	FDA	01/01/2023	30.00	513.93	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014310	VASOTEC® 20mg Tablets, 1,000s	Brand	FDA	01/01/2023	1815.16	31092.04	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014330	VASOTEC® 20mg Tablets, 30s	Brand	FDA	01/01/2023	54.46	932.83	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014390	VASOTEC® 20mg Tablets, 90s	Brand	FDA	01/01/2023	163.37	2798.39	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014130	VASOTEC® 5mg Tablets, 30s	Brand	FDA	01/01/2023	34.80	596.12	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014190	VASOTEC® 5mg Tablets, 90s	Brand	FDA	01/01/2023	149.39	1788.07	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187073030	WELLBUTRIN® XL 150mg Tablets, 30ct	Brand	FDA	01/01/2023	106.09	1817.26	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187073090	WELLBUTRIN® XL 150mg Tablets, 90ct	Brand	FDA	01/01/2023	318.29	5452.11	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187073130	WELLBUTRIN® XL 300mg Tablets, 30ct	Brand	FDA	01/01/2023	140.05	2398.86	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187045302	ZELAPAR (selegiline HCI) 1.25mg Orally Disintegrating Tablets, 60ct	Brand	FDA	01/01/2023	261.51	5491.72	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000529	Bavarian Nordic Inc	09/30/2023	69401000002	Vivotif, Typhoid Vaccine Live Oral Ty21a, 4 cap	Brand	FDA	07/15/2023	7.44	106.67	07/06/2035	Single Source Drug	229766	None	Bavarian Nordic Inc. acquired Vivotif from Emergent Travel Health (ETH) on May 15th, 2023. Upon review of customer contract incentives and subsequent gross-to-net implications, it was determined the prices and discounts being offered by ETH were not sustainable.  A decision was made to implement a moderate increase of 7.5% to slightly improve the product’s bottom line.  It should be noted that the moderate increase offered an improvement but did not entirely alleviate the deficit.  Bavarian Nordic is committed to providing access to Vivotif across all market segments;  and took action to ensure its continued sustainability and availability	None	None	1	05/15/2023	Emergent Travel Health Inc	None	1	None	99.23	94.50	2023	99.23	None	Product was removed from market in 2020, reintroduced in 2022 by Emergent Travel Health Inc. The product wasthen acquired by Bavarian Nordic in 2023
Rx0000024	Bayer	03/31/2023	50419025091	ADEMPAS 0.5 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025001	ADEMPAS 0.5 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025191	ADEMPAS 1 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025101	ADEMPAS 1 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025291	ADEMPAS 1.5 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025201	ADEMPAS 1.5 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025391	ADEMPAS 2 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025301	ADEMPAS 2 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025491	ADEMPAS 2.5 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025401	ADEMPAS 2.5 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419048858	Nexavar 200mg 120 Tablets	Brand	FDA	01/01/2023	1255.20	24069.60	09/10/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419017101	Stivarga 40 mg tab 28 count bottle	Brand	FDA	01/01/2023	392.00	7209.44	07/09/2032	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419017103	Stivarga 40 mg tab 3x28 count bottle	Brand	FDA	01/01/2023	1176.00	21628.32	07/09/2032	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000483	Benuvia Operations, LLC	05/08/2024	78613020130	SYNDROS oral solution 5mg/mL	Brand	FDA	12/18/2023	3112.51	4862.00	06/08/2028	Single Source Drug	None	None	Syndros was acquired by Benuvia Operations, LLC on August 18, 2022. Product required new manufacturing site for API and finished product as well as new sNDA which involved significant costs for a small company. Consequently, R&D costs are the main reason for the price increase. In addition, cost of raw materials, increase in product distribution supply chain fees (new manufacturing site registration and wholesaler, GPO fee increases), general inflation also taken into account.	None	Recent R&D update to the manufacturing process (new DMF) and finished drug product (sNDA) will increase efficiency and manufacturing timeline but has resulted in significant spend for the company as a start up, which only has this one small commercial product.	None	08/18/2022	Benuvia, Inc.	8100000	None	Acquisition included Syndros, manufacturing facility and otehr development assets from Benuvia, Inc in a UCC public sale. The acquisition price is not limited to just Syndros..	1166.66	1166.66	2017	973.00	None	Syndros was launched in 2017 and has gone through several ownership changes. Since it's launch Syndros was not marketed during covid and given the size of Benuvia we have had to incraese the price to pay to move full maufacturing to a new site, supplemental NDA was also submitted this year as well as conducting work on PREA requirement.
Rx0000103	Biocodex USA	09/30/2023	68418793906	Diacomit 250mg Capsule 60ct	Brand	FDA	07/10/2023	138.47	1786.97	None	Single Source Drug	None	1	Since product launch in April 2019, only one price increase (this calendar year) however, due to inflation and operations costs a price increase is needed to offset escalating costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	09/30/2023	68418794106	Diacomit 250mg Packet 60ct	Brand	FDA	07/10/2023	138.47	1786.97	None	Single Source Drug	None	1	Since product launch in April 2019, only one price increase (this calendar year) however, due to inflation and operations costs a price increase is needed to offset escalating costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	09/30/2023	68418794006	Diacomit 500mg Capsule 60 ct	Brand	FDA	07/10/2023	276.95	3573.95	None	Single Source Drug	None	1	Since product launch in April 2019, only one price increase (this calendar year) however, due to inflation and operations costs a price increase is needed to offset escalating costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	09/30/2023	68418794206	Diacomit 500mg Packet 60ct	Brand	FDA	07/10/2023	276.95	3573.95	None	Single Source Drug	None	1	Since product launch in April 2019, only one price increase (this calendar year) however, due to inflation and operations costs a price increase is needed to offset escalating costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135081102	BRINEURA 30MG/ML INJ,KIT	Brand	FDA	12/01/2023	871.00	31979.00	05/05/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135002001	NAGLAZYME 1MG/ML INJ	Brand	FDA	12/01/2023	62.00	2300.00	11/07/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135075620	PALYNZIQ 10MG/0.5ML INJ,SYR,0.5ML	Brand	FDA	12/01/2023	26.00	615.00	02/03/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135005890	PALYNZIQ 2.5MG/0.5ML INJ,SYR,0.5ML	Brand	FDA	12/01/2023	26.00	615.00	02/03/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135067345	PALYNZIQ 20MG/ML INJ,SYR,1ML	Brand	FDA	12/01/2023	260.00	6150.00	02/03/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135067340	PALYNZIQ 20MG/ML INJ,SYR,1ML - D	Brand	FDA	12/01/2023	26.00	615.00	02/03/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135010001	VIMIZIM 1MG/ML INJ,SOLN,5ML	Brand	FDA	12/01/2023	37.00	1394.00	01/10/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000517	Blue Water Biotech, Inc.	06/30/2023	69681012530	Entadfi Oral Capsule 5-5 MG 30 Capsules per bottle	Brand	FDA	06/30/2023	454.88	550.00	None	Single Source Drug	None	1	None	1	None	1	04/20/2023	Veru Inc.	None	1	$20 million upfront, additional $80 based on predetermined annual sales milestones	95.12	95.12	2022	95.12	None	None
Rx0000038	Boehringer Ingelheim	03/31/2023	00597014130	GILOTRIF 20MG TABLET 30	Brand	FDA	01/01/2023	629.14	11114.86	01/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=675	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597013730	GILOTRIF 30MG TABLET 30	Brand	FDA	01/01/2023	629.14	11114.86	01/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=673	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597013830	GILOTRIF 40MG TABLET 30	Brand	FDA	01/01/2023	629.14	11114.86	01/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=674	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597014360	OFEV 100MG CAPSULE 60	Brand	FDA	01/01/2023	471.22	12251.64	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=676	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	09/30/2023	00597014360	OFEV 100MG CAPSULE 60	Brand	FDA	07/01/2023	245.03	12496.67	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597014560	OFEV 150MG CAPSULE 60	Brand	FDA	01/01/2023	471.22	12251.64	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=677	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	09/30/2023	00597014560	OFEV 150MG CAPSULE 60	Brand	FDA	07/01/2023	245.03	12496.67	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597019705	PRAXBIND 2.5g/50mL Vials 2	Brand	FDA	01/01/2023	267.03	4717.46	07/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=678	For Column F, this drug is not listed in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), and there are no patents listed in the FDA database “Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations”. Patent expiration is provided from the Orange Book listing for an associated drug. Not acquired within the last five years.
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089321	ELIQUIS 2.5 MG Tablet, Bottle of 60 Tablets	Brand	FDA	01/01/2023	31.74	560.75	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089331	ELIQUIS 2.5 MG Tablet, Bottle x 100 Tablets	Brand	FDA	01/01/2023	52.91	934.67	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089470	ELIQUIS 5 MG Tablet Bottle of 74 Tablets	Brand	FDA	01/01/2023	39.15	691.61	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003376474	ELIQUIS 5 MG Tablet, 74 Tablets (1 blister pack of 42 tabs and 1 blister pack of 32 tabs)	Brand	FDA	01/01/2023	39.15	691.61	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089421	ELIQUIS 5 MG Tablet, Bottle of 60 Tablets	Brand	FDA	01/01/2023	31.74	560.75	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089431	ELIQUIS 5 MG Tablet, Hospital Unit-Dose, Blister Package of 100	Brand	FDA	01/01/2023	52.91	934.67	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	59572071030	Idhifa 100mg 30 Tablets in a bottle	Brand	FDA	07/01/2023	782.20	32070.28	09/16/2034	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	25742.52	24872.00	2017	24872.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572070530	Idhifa 50mg 30 Tablets in a bottle	Brand	FDA	07/01/2023	782.20	32070.28	09/16/2034	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	25742.52	24872.00	2017	24872.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572072012	Inrebic 100mg 120 Capsules in a bottle	Brand	FDA	07/01/2023	607.71	24916.19	09/24/2039	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	21000.00	None	2019	21000.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	00003218713	Orencia 250 MG Intravenous Solution, 1 Vial	Brand	FDA	07/01/2023	32.34	1379.90	12/19/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050100	Pomalyst 1mg 100 Capsules in a bottle	Brand	FDA	07/01/2023	2513.40	103049.21	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050121	Pomalyst 1mg 21 Capsules in abottle	Brand	FDA	07/01/2023	527.81	21640.34	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050200	Pomalyst 2mg 100 Capsules in a bottle	Brand	FDA	07/01/2023	2513.40	103049.21	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050221	Pomalyst 2mg 21 Capsules in a bottle	Brand	FDA	07/01/2023	527.81	21640.34	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050300	Pomalyst 3mg 100 Capsules in a bottle	Brand	FDA	07/01/2023	2513.40	103049.21	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050321	Pomalyst 3mg 21 Capsules in a bottle	Brand	FDA	07/01/2023	527.81	21640.34	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050400	Pomalyst 4mg 100 Capsules in a bottle	Brand	FDA	07/01/2023	2513.40	103049.21	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050421	Pomalyst 4mg 21 Capsules in a bottle	Brand	FDA	07/01/2023	527.81	21640.34	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	00003085222	Sprycel 100 mg tablet bottle of 30	Brand	FDA	07/01/2023	419.84	17213.52	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003085722	Sprycel 140 mg tablet bottle of 30	Brand	FDA	07/01/2023	419.84	17213.52	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003052711	Sprycel 20 mg tablet bottle of 60	Brand	FDA	07/01/2023	232.94	9550.71	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003052811	Sprycel 50 mg tablet bottle of 60	Brand	FDA	07/01/2023	465.89	19101.39	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003052411	Sprycel 70 mg tablet bottle of 60	Brand	FDA	07/01/2023	465.89	19101.39	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003085522	Sprycel 80 mg tablet bottle of 30	Brand	FDA	07/01/2023	419.84	17213.52	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	59572089028	Zeposia 0.230.460.92 mg 28 capsules Starter Kit	Brand	FDA	07/01/2023	190.92	7827.56	05/14/2029	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	7636.64	7636.64	2023	7636.64	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572082030	Zeposia 0.92 mg capsules 30 count bottle	Brand	FDA	07/01/2023	204.55	8386.66	05/14/2029	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	7068.49	7068.49	2020	7068.49	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572081007	Zeposia 4 0.23 mg tablets 4 0.46mg tablets 7 Day Starter Pack	Brand	FDA	07/01/2023	47.73	1956.90	05/14/2029	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	1649.32	1649.32	2020	1649.32	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000340	Carlsbad Technology, Inc.	12/31/2023	61442011501	Glimepiride 1mg Tab 100	Generic	FDA	11/01/2023	35.00	42.00	None	Non-innovator Multiple Source Drug	41091	None	Manufacturing Costs Increase	None	Manufacturing Costs Increase	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000340	Carlsbad Technology, Inc.	12/31/2023	61442011505	Glimepiride 1mg Tab 500	Generic	FDA	11/01/2023	175.00	210.00	None	Non-innovator Multiple Source Drug	9918	None	Manufacturing Costs Increase	None	Manufacturing Costs Increase	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000340	Carlsbad Technology, Inc.	12/31/2023	61442011601	Glimepiride 2mg Tab 100	Generic	FDA	11/01/2023	61.00	69.00	None	Non-innovator Multiple Source Drug	84217	None	Manufacturing Costs Increase	None	Manufacturing Costs Increase	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000340	Carlsbad Technology, Inc.	12/31/2023	61442011605	Glimepiride 2mg Tab 500	Generic	FDA	11/01/2023	305.00	345.00	None	Non-innovator Multiple Source Drug	26434	None	Manufacturing Costs Increase	None	Manufacturing Costs Increase	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000340	Carlsbad Technology, Inc.	12/31/2023	61442011701	Glimepiride 4mg Tab 100	Generic	FDA	11/01/2023	113.00	126.00	None	Non-innovator Multiple Source Drug	117386	None	Manufacturing Costs Increase	None	Manufacturing Costs Increase	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000340	Carlsbad Technology, Inc.	12/31/2023	61442011705	Glimepiride 4mg Tab 500	Generic	FDA	11/01/2023	565.00	630.00	None	Non-innovator Multiple Source Drug	33103	None	Manufacturing Costs Increase	None	Manufacturing Costs Increase	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000498	Catalyst Pharmaceuticals Inc	03/31/2023	69616021103	Firdapse 10mg Tablet 240/Bottle	Brand	FDA	01/09/2023	2787.72	52479.72	02/25/2037	Single Source Drug	None	1	response to recent economic conditions and inflation	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000498	Catalyst Pharmaceuticals Inc	03/31/2023	69616021106	FIRDAPSE Blister shelf pack of 120 - 10mg tablets	Brand	FDA	01/09/2023	1393.86	26239.86	02/25/2037	Single Source Drug	None	1	response to recent economic conditions and inflation	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000139	Chiesi USA	03/31/2023	10122051001	Curosurf® 1.5ml	Brand	FDA	01/01/2023	35.61	544.31	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired.
Rx0000139	Chiesi USA	03/31/2023	10122051003	Curosurf® 3.0ml	Brand	FDA	01/01/2023	70.22	1073.32	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns N-T were intentionally left blank for this submission, as the drug was not acquired.
Rx0000139	Chiesi USA	03/31/2023	10122010401	FERRIPROX® TD 1000mg Pack FILM COATED TABLETS	Brand	FDA	01/04/2023	681.89	10423.12	10/25/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000139	Chiesi USA	03/31/2023	10122062010	Kengreal for injection 50mg/10ML	Brand	FDA	01/01/2023	583.55	8919.92	07/10/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000139	Chiesi USA	03/31/2023	10122050201	Revcovi® (elapegademase-IvIr 1.6mg/ml) Injection	Brand	FDA	01/04/2023	899.65	12145.24	None	Single Source Drug	None	1	None	1	None	1	11/24/2020	Leadiant Biosciences	None	1	None	10109.30	9856.00	2018	9856.00	None	New labeler code was launched 4/18/2022.
Rx0000320	CMP Pharma	12/31/2023	46287002004	Carospir Suspension Dosage Strength 25 mg/5mL 118 mL in 1 Bottle	Brand	FDA	11/01/2023	16.70	432.20	10/28/2036	Single Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads. A price increase is taken annually to keep up with inflation & rising costs.	None	The price increase is not necessitated by a change or improvement to the product.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2023	46287002001	Carospir Suspension Dosage Strength 25 mg/5mL 473 mL in 1 Bottle	Brand	FDA	11/01/2023	66.60	1731.60	10/28/2036	Single Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads. A price increase is taken annually to keep up with inflation & rising costs.	None	The price increase is not necessitated by a change or improvement to the product.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2023	46287001430	Oracit Solution Dosage Strength 640 mg/5mL, 490 mg/5mL 30 ml in 1 Bottle, 10 Bottle, Unit Dose 1 Carton	Brand	Medispan	11/01/2023	8.80	53.00	None	Non-innovator Multiple Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads. A price increase is taken annually to keep up with inflation & rising costs.	None	The price increase is not necessitated by a change or improvement to the product.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2023	46287001401	Oracit Solution Dosage Strength 640 mg/5mL, 490 mg/5mL 500 ml in 1 Bottle	Brand	Medispan	11/01/2023	7.20	43.10	None	Non-innovator Multiple Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads. A price increase is taken annually to keep up with inflation & rising costs.	None	The price increase is not necessitated by a change or improvement to the product.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000320	CMP Pharma	12/31/2023	46287002410	POTASSIUM PHOSPHATES, Injection, 300 mg/mL, 175 mg/mL, 10 VIAL, in 1 CARTON > 15 mL in 1 VIAL	Brand	FDA	12/06/2023	75.00	374.00	04/19/2039	Single Source Drug	None	1	Increasing costs related to inflationary environment – materials, shipping, labor, overheads. A price increase is taken annually to keep up with inflation & rising costs.	None	The price increase is not necessitated by a change or improvement to the product.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510010010	Nucynta 100mg, tablet, 100 pack	Brand	FDA	01/01/2023	123.84	1499.80	06/27/2025	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1088.71	990.64	2009	265.00	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510005010	Nucynta 50mg, tablet, 100 pack	Brand	FDA	01/01/2023	79.72	963.11	06/27/2025	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	699.13	636.15	2009	170.00	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510007510	Nucynta 75mg, tablet, 100 pack	Brand	FDA	01/01/2023	92.92	1125.31	06/27/2025	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	816.86	743.28	2009	199.00	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510011660	Nucynta ER 100mg, tablet, 60 pack	Brand	FDA	01/01/2023	82.36	1138.26	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	835.46	760.20	2011	269.40	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510017460	Nucynta ER 150 mg, tablet, 60 pack	Brand	FDA	01/01/2023	106.26	1468.55	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1077.89	980.79	2011	346.80	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510023260	Nucynta ER 200 mg, tablet, 60 pack	Brand	FDA	01/01/2023	134.89	1864.24	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1368.32	1245.06	2011	441.60	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510029160	Nucynta ER 250 mg, tablet, 60 pack	Brand	FDA	01/01/2023	168.76	2332.36	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1711.91	1557.70	2011	441.60	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510005860	Nucynta ER 50mg, tablet, 60 pack	Brand	FDA	01/01/2023	44.53	615.46	09/22/2028	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	451.74	411.05	2011	145.80	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510011510	Xtampza ER 13.5mg, capsule, 100 pack	Brand	FDA	01/01/2023	43.54	914.27	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510012010	Xtampza ER 18mg, capsule, 100 pack	Brand	FDA	01/01/2023	55.21	1159.44	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510013010	Xtampza ER 27mg, capsule, 100 pack	Brand	FDA	01/01/2023	76.80	1612.88	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510014010	Xtampza ER 36mg, capsule, 100 pack	Brand	FDA	01/01/2023	94.53	1985.21	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000200	Collegium Pharmaceuticals	03/31/2023	24510011010	Xtampza ER 9mg, capsule, 100 pack	Brand	FDA	01/01/2023	29.58	621.18	09/02/2036	Single Source Drug	None	1	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Xtampza ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Xtampza ER, and reinvestment in the product. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 million since our inception. In addition, we continue to reinvest in Xtampza ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to increase the wholesale acquisition cost of Xtampza ER.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000154	Corcept Therapeutics Incorporated	03/31/2023	76346007302	Korlym (mifepristone) 300mg Tablets 280-ct Bottle	Brand	FDA	01/01/2023	15330.00	176890.00	08/22/2038	Single Source Drug	None	1	Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which their are few -or no- good treatment options. In setting Korlym's price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates, and (iii) our commitment that no patient be denied Korlym for financial reasons.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000154	Corcept Therapeutics Incorporated	03/31/2023	76346007301	Korlym (mifepristone) 300mg Tablets 28-ct Bottle	Brand	FDA	01/01/2023	1533.00	17689.00	08/22/2038	Single Source Drug	None	1	Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which their are few -or no- good treatment options. In setting Korlym's price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates, and (iii) our commitment that no patient be denied Korlym for financial reasons.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000184	Cosette Pharmaceuticals, Inc.	06/30/2023	00713088530	Clomid (Clomiphene Citrate) Tablets 50 mg 30-count carton	Generic	FDA	05/23/2023	76.50	195.00	None	Single Source Drug	None	1	None	1	None	1	09/01/2022	Par Pharmaceuticals	None	1	None	56.00	56.00	2022	118.50	None	None
Rx0000184	Cosette Pharmaceuticals, Inc.	06/30/2023	00713088509	Clomid (Clomiphene Citrate) Tablets, USP 50 mg 10-count carton	Generic	FDA	05/23/2023	25.30	65.00	None	Single Source Drug	None	1	None	1	None	1	09/01/2022	Par Pharmaceuticals	None	1	None	20.00	20.00	2022	37.50	None	None
Rx0000184	Cosette Pharmaceuticals, Inc.	12/31/2023	00713085004	Griseofulvin Oral Suspension, USP Microsize 125 mg/5 mL 4 fl oz (118 mL)	Generic	FDA	12/01/2023	147.22	200.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000184	Cosette Pharmaceuticals, Inc.	03/31/2023	00713016612	Migergot Suppositories 2mg/100mg (ergotamine tartrate and caffeine suppositories, 2mg/100mg)	Generic	FDA	02/01/2023	201.87	2240.97	None	Single Source Drug	None	1	Operating primarily as a manufacturer of generic and over-the-counter drug products, Cosette Pharmaceuticals has a history of providing cost effective, high quality medications that help patients affected by various medical conditions. With that purpose in mind, Cosette carefully and holistically evaluates and weighs a variety of factors when pricing its medications, including: maintaining accessibility and affordability of its products for both patients and payors, market conditions, the overall increase in the cost of labor and goods, the required capital investment in manufacturing facilities and systems, and most importantly, the funding of research and new product development designed to meet the needs of patients and healthcare professionals today and in the future. It is critical to note that research and new product development is a high-risk endeavor, with significant costs being incurred on medications that eventually fail due to clinical, technical or commercial reasons. By considering all of these factors in pricing decisions, Cosette is taking the necessary steps to ensure the long-term availability of high quality prescription and over-the-counter drug products within its portfolio.	None	None	1	06/28/2019	Horizon Therapeutics PLC	None	1	None	842.76	766.80	1983	0.01	None	WAC of the Product when it was introduced in 1983 is unknown. Per recommendation of Rodney Garcia, while the WAC Five Year History recites Cosette's NDC number, it actually incorporates three separate NDC numbers from the following owners: Horizon, Crealta and G&W.
Rx0000425	CSL Behring LLC	03/31/2023	63833082502	Berinert 500 Units (500 IU / Solution / Pkg Size 1)	Brand	FDA	01/01/2023	204.94	3620.69	None	Single Source Drug	None	1	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Please note that Berinert® is supplied with a Mix2Vial filter transfer set that is under patent until October 9, 2024
Rx0000425	CSL Behring LLC	09/30/2023	44206045291	Hizentra 10 ml (2g) - inner / 2gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	8.42	429.10	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045795	Hizentra 10 ml (2g) PFS - inner / 2gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	8.42	429.10	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045722	Hizentra 10 ml (2g) PFS / 2gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	8.42	429.10	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045202	Hizentra 10 ml (2g) / 2gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	8.42	429.10	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045492	Hizentra 20 ml (4g) - inner / 4gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	16.84	858.20	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045896	Hizentra 20 ml (4g) PFS - inner / 4gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	16.84	858.20	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045824	Hizentra 20 ml (4g) PFS / 4gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	16.84	858.20	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045404	Hizentra 20 ml (4g) / 4gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	16.84	858.20	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045190	Hizentra 5 ml (1g) - inner / 1gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	4.21	214.55	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045101	Hizentra 5 ml (1g) / 1gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	4.21	214.55	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045694	Hizentra 5 ml (1g) PFS - inner / 1gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	4.21	214.55	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045621	Hizentra 5 ml (1g) PFS / 1gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	4.21	214.55	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045593	Hizentra 50 ml (10g) - inner / 10gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	42.10	2145.50	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206045510	Hizentra 50 ml (10g) / 10gm Solution / UOM EA = 1 vial	Brand	FDA	07/01/2023	42.10	2145.50	06/09/2032	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206043710	Privigen 100 ml (10g) / 10g Solution / UOM=1 EA vial	Brand	FDA	07/01/2023	33.50	1708.20	08/03/2028	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206043791	Privigen 100 ml (10g) / inner 10g Solution / UOM=1 EA vial	Brand	FDA	07/01/2023	33.50	1708.20	08/03/2028	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206043820	Privigen 200 ml (20g) / 20g Solution / UOM=1 EA vial	Brand	FDA	07/01/2023	67.00	3416.40	08/03/2028	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206043892	Privigen 200 ml (20g) / inner 20g Solution / UOM=1 EA vial	Brand	FDA	07/01/2023	67.00	3416.40	08/03/2028	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206043940	Privigen 400 ml (40g) / 40g Solution / UOM=1 EA vial	Brand	FDA	07/01/2023	134.00	6832.80	08/03/2028	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206043993	Privigen 400 ml (40g) / inner 40g Solution / UOM=1 EA vial	Brand	FDA	07/01/2023	134.00	6832.80	08/03/2028	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206043605	Privigen 50 ml (5g) / 5 gm Solution / UOM=1 EA vial	Brand	FDA	07/01/2023	16.75	854.10	08/03/2028	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	09/30/2023	44206043690	Privigen 50 ml (5g) / inner 5 gm Solution / UOM=1 EA vial	Brand	FDA	07/01/2023	16.75	854.10	08/03/2028	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000399	CTI BioPharma Corp.	03/31/2023	72482010012	VONJO 100 mg capsule, 120 capsules	Brand	FDA	01/04/2023	2120.00	23550.00	03/25/2030	Single Source Drug	3080	None	A number of factors go into the pricing of VONJO including manufacturing, sales and marketing costs, and investments in continued research and development.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	Sales volume reported reflects from launch (02/28/2022) through 12/31/2022 period.
Rx0000399	CTI BioPharma Corp.	12/31/2023	72482010012	VONJO 100 mg capsule, 120 capsules	Brand	FDA	10/01/2023	2331.45	25881.45	03/25/2030	Single Source Drug	3080	None	A number of factors were considered into increasing price, including overall increases in operational costs, that are impacted by inflation.	None	No change or improvement necessitated the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000230	Cumberland Pharmaceuticals	09/30/2023	66220028422	CALDOLOR IV BAGS 800mg/200mL - 20 200mL Bags Per Case	Brand	FDA	07/05/2023	9.02	459.80	03/16/2032	Single Source Drug	5178	None	INCREASE IN COST OF GOODS.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000230	Cumberland Pharmaceuticals	09/30/2023	66220028708	CALDOLOR VIALS 25 5mL VIALS PER CASE	Brand	FDA	07/05/2023	16.75	575.18	09/14/2030	Single Source Drug	3512	None	INCREASE IN COST OF GOODS.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000230	Cumberland Pharmaceuticals	09/30/2023	66220031522	VIBATIV 750MG CASE OF 12 SINGLE DOSE VIALS	Brand	FDA	07/05/2023	208.02	7142.09	01/01/2027	Single Source Drug	1731	None	INCREASE IN COST OF GOODS.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000230	Cumberland Pharmaceuticals	09/30/2023	66220031511	VIBATIV 750MG SINGLE DOSE VIAL	Brand	FDA	07/05/2023	17.34	583.62	01/01/2027	Single Source Drug	21184	None	INCREASE IN COST OF GOODS.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000216	Deciphera Pharmaceuticals, LLC	03/31/2023	73207010130	Qinlock Oral Tablet 50 MG, 90 Each, Bottle	Brand	FDA	01/01/2023	1494.00	37800.00	12/30/2040	Single Source Drug	None	1	The establishment of price and associated price changes may take into consideration a number of factors such as current market dynamics, competitive environment, the clinical and economic value of therapy, therapeutic category, payer environment, government rebates, patient support, overall research and development costs, as well as business operational continuation needs. In our commitment to patients and ensuring patient access, we have a patient support program that provides reimbursement and financial assistance programs for eligible patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000216	Deciphera Pharmaceuticals, LLC	04/29/2024	73207010130	Qinlock Oral Tablet 50 MG, 90 Each, Bottle	Brand	FDA	07/01/2023	1305.00	39105.00	10/06/2042	Single Source Drug	None	None	The establishment of price and associated price changes may take into consideration a number of factors such as current market dynamics, competitive environment, the clinical and economic value of therapy, therapeutic category, payer environment, government rebates, patient support, overall research and development costs, as well as business operational continuation needs. In our commitment to patients and ensuring patient access, we have a patient support program that provides reimbursement and financial assistance programs for eligible patients.	None	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=770	None
Rx0000492	Dynavax Technologies Corporation	03/31/2023	43528000305	HEPLISAV-B [Hepatitis B Vaccine (Recombinant)] Adjuvanted 20 MCG / 0.5 ML PFS Injection, Solution 5 SYRINGE in 1 CARTON (43528-003-05) / .5 mL in 1 SYRINGE (43528-003-01)	Brand	FDA	03/01/2023	36.00	703.00	04/16/2032	Single Source Drug	327131	None	Supply chain cost impacted by pandemic and inflation rate	None	No changes or improvements caused the increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856071405	Lenvatinib Mesylate 10 & 4 MG Capsule Therapy Pack 10 EA UU	Brand	FDA	07/13/2023	231.00	3907.33	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856071805	Lenvatinib Mesylate 10 MG & 2 x 4 MG Capsule Therapy Pack 15 EA UU	Brand	FDA	07/13/2023	231.00	3907.33	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856071005	Lenvatinib Mesylate 10 MG Capsule Therapy Pack 5 EA UU	Brand	FDA	07/13/2023	231.00	3907.33	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856072405	Lenvatinib Mesylate 2 x 10 MG & 4 MG Capsule Therapy Pack 15 EA UU	Brand	FDA	07/13/2023	231.00	3907.33	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856072005	Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 10 EA UU	Brand	FDA	07/13/2023	231.00	3907.33	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856070805	Lenvatinib Mesylate 2 x 4 MG Capsule Therapy Pack 10 EA UU	Brand	FDA	07/13/2023	231.00	3907.33	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856071205	Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 15 EA UU	Brand	FDA	07/13/2023	231.00	3907.33	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856071230	Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 90 EA UU	Brand	FDA	07/13/2023	1386.00	23444.00	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856070430	Lenvatinib Mesylate 4 MG Capsule Therapy Pack 30 EA UU	Brand	FDA	07/13/2023	1386.00	23444.00	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856070405	Lenvatinib Mesylate 4 MG Capsule Therapy Pack 5 EA UU	Brand	FDA	07/13/2023	231.00	3907.33	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856070830	LENVIMA (lenvatinib mesylate) 8 mg/day (4 mg x 2) 60 count	Brand	FDA	07/13/2023	1386.00	23444.00	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856071030	LENVIMA (lenvatinib mesylate)10 mg/day (10 mg x 1) 30 count	Brand	FDA	07/13/2023	1386.00	23444.00	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856071430	LENVIMA (lenvatinib mesylate)14 mg/day (10 mg x 1 and 4 mg x 1) 60 count	Brand	FDA	07/13/2023	1386.00	23444.00	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856071830	LENVIMA (lenvatinib) 18 mg/day (10 mg x 1 and 4 mg x 2) 30 day supply	Brand	FDA	07/13/2023	1386.00	23444.00	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856072030	LENVIMA (lenvatinib) 20 mg/day (10 mg x 2) 30 day supply	Brand	FDA	07/13/2023	1386.00	23444.00	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	09/30/2023	62856072430	LENVIMA (lenvatinib) 24 mg/day (10 mg x 2 and 4 mg x 1) 30 day supply	Brand	FDA	07/13/2023	1386.00	23444.00	02/23/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000114	Eli Lilly and Company	03/31/2023	00002143380	Trulicity Package Size: 4 Strength: 0.75 mg/0.5 mL Dosage Form: PEN INJECTOR	Brand	FDA	01/01/2023	44.32	930.88	12/07/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2023	00002143480	Trulicity Package Size: 4 Strength: 1.5 mg/0.5 mL Dosage Form: PEN INJECTOR	Brand	FDA	01/01/2023	44.32	930.88	12/07/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2023	00002223680	Trulicity Package Size: 4 Strength: 3.0 mg/0.5 mL Dosage Form: PEN INJECTOR	Brand	FDA	01/01/2023	44.32	930.88	12/07/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2023	00002318280	Trulicity Package Size: 4 Strength: 4.5 mg/0.5 mL Dosage Form: PEN INJECTOR	Brand	FDA	01/01/2023	44.32	930.88	12/07/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2023	00002481554	Verzenio Package Size: 14 Strength: 100 mg Dosage Form: TABLET	Brand	FDA	01/01/2023	189.42	3633.42	12/15/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2023	00002533754	Verzenio Package Size: 14 Strength: 150 mg Dosage Form: TABLET	Brand	FDA	01/01/2023	189.42	3633.42	12/15/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2023	00002621654	Verzenio Package Size: 14 Strength: 200 mg Dosage Form: TABLET	Brand	FDA	01/01/2023	189.42	3633.42	12/15/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000114	Eli Lilly and Company	03/31/2023	00002448354	Verzenio Package Size: 14 Strength: 50 mg Dosage Form: TABLET	Brand	FDA	01/01/2023	189.42	3633.42	12/15/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available.
Rx0000079	EMD Serono, Inc.	03/31/2023	44087122501	Cetrotide Subcutaneous Kit 0.25 MG, 1 Each, Box	Brand	FDA	01/26/2023	19.38	286.73	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087907001	Gonal-f Injection Solution Reconstituted 1050 UNIT, 1 Each, Unit-Dose, Vial	Brand	FDA	01/26/2023	228.57	3381.14	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087903001	Gonal-f Injection Solution Reconstituted 450 UNIT, 1 Each, Unit-Dose, Vial	Brand	FDA	01/26/2023	97.96	1449.06	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087111501	Gonal-f RFF Rediject Subcutaneous Solution Pen-injector 300 UNIT/0.5ML, .5 ML, Unit-of-Use, Pen	Brand	FDA	01/26/2023	65.31	966.04	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087111601	Gonal-f RFF Rediject Subcutaneous Solution Pen-injector 450 UNT/0.75ML, .75 ML, Unit-of-Use, Pen	Brand	FDA	01/26/2023	97.96	1449.06	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087111701	Gonal-f RFF Rediject Subcutaneous Solution Pen-injector 900 UNIT/1.5ML, 1.5 ML, Unit-of-Use, Pen	Brand	FDA	01/26/2023	195.92	2898.12	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087900501	Gonal-f RFF Subcutaneous Solution Reconstituted 75 UNIT, 1 Each, Unit-Dose, Vial	Brand	FDA	01/26/2023	16.33	241.51	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087900506	Gonal-f RFF Subcutaneous Solution Reconstituted 75 UNIT, 1 Each, Unit-Dose, Vial Qty 10	Brand	FDA	01/26/2023	163.26	2415.10	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087400000	Mavenclad (10 Tabs) Oral Tablet Therapy Pack 10 MG, 10 Each, Unit-of-Use, Box	Brand	FDA	01/26/2023	3199.70	94618.60	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2023	44087400000	Mavenclad (10 Tabs) Oral Tablet Therapy Pack 10 MG, 10 Each, Unit-of-Use, Box	Brand	FDA	07/06/2023	3642.80	98261.40	11/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087400004	Mavenclad (4 Tabs) Oral Tablet Therapy Pack 10 MG, 4 Each, Unit-of-Use, Box	Brand	FDA	01/26/2023	1279.88	37847.44	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2023	44087400004	Mavenclad (4 Tabs) Oral Tablet Therapy Pack 10 MG, 4 Each, Unit-of-Use, Box	Brand	FDA	07/06/2023	1457.12	39304.56	11/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087400005	Mavenclad (5 Tabs) Oral Tablet Therapy Pack 10 MG, 5 Each, Unit-of-Use, Box	Brand	FDA	01/26/2023	1599.85	47309.30	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2023	44087400005	Mavenclad (5 Tabs) Oral Tablet Therapy Pack 10 MG, 5 Each, Unit-of-Use, Box	Brand	FDA	07/06/2023	1821.40	49130.70	11/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087400006	Mavenclad (6 Tabs) Oral Tablet Therapy Pack 10 MG, 6 Each, Unit-of-Use, Box	Brand	FDA	01/26/2023	1919.82	56771.16	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2023	44087400006	Mavenclad (6 Tabs) Oral Tablet Therapy Pack 10 MG, 6 Each, Unit-of-Use, Box	Brand	FDA	07/06/2023	2185.68	58956.84	11/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087400007	Mavenclad (7 Tabs) Oral Tablet Therapy Pack 10 MG, 7 Each, Unit-of-Use, Box	Brand	FDA	01/26/2023	2239.79	66233.02	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2023	44087400007	Mavenclad (7 Tabs) Oral Tablet Therapy Pack 10 MG, 7 Each, Unit-of-Use, Box	Brand	FDA	07/06/2023	2549.96	68782.98	11/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087400008	Mavenclad (8 Tabs) Oral Tablet Therapy Pack 10 MG, 8 Each, Unit-of-Use, Box	Brand	FDA	01/26/2023	2559.76	75694.88	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2023	44087400008	Mavenclad (8 Tabs) Oral Tablet Therapy Pack 10 MG, 8 Each, Unit-of-Use, Box	Brand	FDA	07/06/2023	2914.24	78609.12	11/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087400009	Mavenclad (9 Tabs) Oral Tablet Therapy Pack 10 MG, 9 Each, Unit-of-Use, Box	Brand	FDA	01/26/2023	2879.73	85156.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	09/30/2023	44087400009	Mavenclad (9 Tabs) Oral Tablet Therapy Pack 10 MG, 9 Each, Unit-of-Use, Box	Brand	FDA	07/06/2023	3278.52	88435.26	11/23/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087115001	Ovidrel Subcutaneous Injectable 250 MCG/0.5ML, .5 ML, Unit-Dose, Syringe	Brand	FDA	01/26/2023	14.73	217.93	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087332209	Rebif Rebidose Subcutaneous Solution Auto-injector 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe	Brand	FDA	01/26/2023	57.68	826.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087332201	Rebif Rebidose Subcutaneous Solution Auto-injector 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12	Brand	FDA	01/26/2023	692.15	9920.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087334409	Rebif Rebidose Subcutaneous Solution Auto-injector 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe	Brand	FDA	01/26/2023	57.68	826.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087334401	Rebif Rebidose Subcutaneous Solution Auto-injector 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12	Brand	FDA	01/26/2023	692.15	9920.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087018801	Rebif Rebidose Titration Pack Subcutaneous Solution Auto-injector 6X8.8 & 6X22 MCG, 4.2 ML, Unit-of-Use, Box	Brand	FDA	01/26/2023	692.15	9920.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087002209	Rebif Subcutaneous Solution Prefilled Syringe 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe	Brand	FDA	01/26/2023	57.68	826.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087002203	Rebif Subcutaneous Solution Prefilled Syringe 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12	Brand	FDA	01/26/2023	692.15	9920.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087004409	Rebif Subcutaneous Solution Prefilled Syringe 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe	Brand	FDA	01/26/2023	57.68	826.74	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087004403	Rebif Subcutaneous Solution Prefilled Syringe 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12	Brand	FDA	01/26/2023	692.15	9920.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087882201	Rebif Titration Pack Subcutaneous Solution Prefilled Syringe 6X8.8 & 6X22 MCG, 4.2 ML, Unit-of-Use, Box	Brand	FDA	01/26/2023	692.15	9920.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087000407	Serostim Subcutaneous Solution Reconstituted 4 MG, 1 Each, Unit-Dose, Vial Qty 7	Brand	FDA	01/26/2023	109.20	3228.68	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087000507	Serostim Subcutaneous Solution Reconstituted 5 MG, 1 Each, Unit-Dose, Vial Qty 7	Brand	FDA	01/26/2023	136.50	4035.85	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	03/31/2023	44087000607	Serostim Subcutaneous Solution Reconstituted 6 MG, 1 Each, Unit-Dose, Vial Qty 7	Brand	FDA	01/26/2023	163.80	4843.02	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2023	67979051143	Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial	Brand	FDA	04/01/2023	79.25	1713.17	05/08/2027	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 7/21/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2023	67979051143	Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial	Brand	FDA	10/01/2023	83.95	1797.12	05/08/2027	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 1/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244001002	Edex®, Alprostadil For Inj Kit 10 MCG, 2	Brand	FDA	01/01/2023	9.11	160.87	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244001006	Edex®, Alprostadil For Inj Kit 10 MCG, 6	Brand	FDA	01/01/2023	27.32	482.66	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244002002	Edex®, Alprostadil For Inj Kit 20 MCG, 2	Brand	FDA	01/01/2023	11.76	207.82	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244002006	Edex®, Alprostadil For Inj Kit 20 MCG, 6	Brand	FDA	01/01/2023	35.29	623.43	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244004002	Edex®, Alprostadil For Inj Kit 40 MCG, 2	Brand	FDA	01/01/2023	16.06	283.79	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244004006	Edex®, Alprostadil For Inj Kit 40 MCG, 6	Brand	FDA	01/01/2023	48.19	851.34	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	63481002509	FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9	Brand	FDA	01/01/2023	105.18	1167.59	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	63481068706	LIDODERM®, Lidocaine Patch 5%, 30	Brand	FDA	01/01/2023	71.63	795.20	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	63481062970	PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100	Generic	FDA	01/01/2023	307.77	3416.56	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	63481062770	PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100	Generic	FDA	01/01/2023	155.66	1728.02	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	63481062370	PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100	Generic	FDA	01/01/2023	217.86	2418.50	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	63481062385	PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 500	Generic	FDA	01/01/2023	1061.91	11788.29	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	63481062870	PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100	Generic	FDA	01/01/2023	235.37	2612.87	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244010010	THEO-24®, Theophylline Cap ER 24HR 100 MG, 100	Generic	FDA	01/01/2023	28.86	320.35	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244020010	THEO-24®, Theophylline Cap ER 24HR 200 MG, 100	Generic	FDA	01/01/2023	42.89	476.10	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244030010	THEO-24®, Theophylline Cap ER 24HR 300 MG, 100	Generic	FDA	01/01/2023	52.71	585.16	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	03/31/2023	52244040010	THEO-24®, Theophylline Cap ER 24HR 400 MG, 100	Generic	FDA	01/01/2023	74.17	823.40	None	Non-innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/24/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2023	67979000101	Valstar, 40 mg/1ml solution, 4x5mL	Brand	FDA	04/01/2023	391.74	8468.79	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/21/2023, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2023	67979000101	Valstar, 40 mg/1ml solution, 4x5mL	Brand	FDA	10/01/2023	410.74	8879.53	None	Innovator Multiple Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 1/24/2024, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	06/30/2023	66887000301	Xiaflex, 0.9mg powder for solution, single use vial	Brand	FDA	04/01/2023	228.95	6099.39	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000091	Endo Pharmaceuticals Inc.	12/31/2023	66887000301	Xiaflex, 0.9mg powder for solution, single use vial	Brand	FDA	10/01/2023	237.88	6337.27	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administration’s Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000405	Esperion	03/31/2023	72426011803	Nexletol 30 Tab 180 mg/1 Tablet Film Coated	Brand	FDA	01/01/2023	11.53	395.96	12/03/2025	Single Source Drug	None	1	Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions.	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000405	Esperion	03/31/2023	72426081803	Nexlizet 30 Tab 180 mg/1, 10 mg/1 Tablet Film Coated	Brand	FDA	01/01/2023	11.53	395.96	03/14/2036	Single Source Drug	None	1	Esperion takes into account a number of different considerations in undertaking its pricing decisions. These factors include but are not limited to the value the product brings to patients, product market competitiveness, patient out-of-pocket costs, our investments in important clinical development initiatives, as well as the cost of labor and goods. Esperion does not maintain records documenting how these and other individual factors influence particular pricing decisions.	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000104	EUSA Pharma (US) LLC	06/30/2023	73090042001	Siltuximab For IV Infusion 100 MG, 1 Each, Unit-Dose, Vial	Brand	FDA	04/01/2023	92.86	1419.37	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000104	EUSA Pharma (US) LLC	06/30/2023	73090042101	Siltuximab For IV Infusion 400 MG, 1 Each, Unit-Dose, Vial	Brand	FDA	04/01/2023	371.44	5677.48	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000329	Evoke Pharma, Inc.	12/31/2023	72089030715	METOCLOPRAMIDE HYDROCHLORIDE 1 BOTTLE, PUMP in 1 CARTON (72089-307-15) / 9.8 mL in 1 BOTTLE, PUMP	Brand	FDA	12/27/2023	190.00	2113.00	05/16/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000485	Exela Pharma Sciences, LLC	03/31/2023	51754100703	ELCYS INFUSION 10 VIAL 10 ML 500 MG	Brand	FDA	01/01/2023	123.53	947.03	01/15/2039	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000501	FH2 Pharma LLC	03/31/2023	72887064812	OXYCODONE & PARACETAMOL ORAL SOLUTION 1 BOTTLE 120 ML 240 MG/7200 MG	Generic	FDA	02/01/2023	925.00	2625.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323036061	Calcium Gluconate Intravenous Solution 10 % 100 ML, Vial Qty 20	Brand	FDA	02/02/2023	93.60	1079.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323036059	Calcium Gluconate Intravenous Solution 10 % 50 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	58.50	674.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323038510	cefoTEtan Disodium Injection Solution Reconstituted 1 GM 1 Each, Unit-Dose, Vial Qty 10	Generic	FDA	02/02/2023	31.60	242.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323038620	cefoTEtan Disodium Injection Solution Reconstituted 2 GM 1 Each, Unit-Dose, Vial Qty 10	Generic	FDA	02/02/2023	63.20	484.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323001115	Chloramphenicol Sodium Succinate For IV Inj 1 GM, 1 Each, Unit-Dose, Vial Qty 10	Generic	FDA	02/02/2023	97.30	486.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2023	63323012710	Dacarbazine Intravenous Solution Reconstituted 100 MG 10 vials per package	Generic	FDA	10/31/2023	15.20	123.90	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323050601	Dexamethasone Sod Phosphate PF Injection Solution 10 MG/ML 1 ML, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	16.25	187.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323051610	Dexamethasone Sodium Phosphate Injection Solution 100 MG/10ML 10 ML, Vial Qty 10	Generic	FDA	02/02/2023	13.40	154.90	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323001002	Gentamicin Sulfate Inj 40 MG/ML, 2 ML, Vial Qty 25	Generic	FDA	02/02/2023	13.25	101.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323001020	Gentamicin Sulfate Inj 40 MG/ML, 20 ML, Vial Qty 25	Generic	FDA	02/02/2023	95.25	730.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323017302	Gentamicin Sulfate Injection Solution 10 MG/ML 2 ML, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	17.75	135.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	09/30/2023	63323017394	Gentamicin Sulfate Injection Solution 10 MG/ML Package size: 2ML Vial Package Quantity: 25 Vials	Generic	FDA	08/01/2023	5.50	55.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	06/30/2023	63323059303	Glucagon HCl (Diagnostic) Injection Solution Reconstituted 1 MG Package Size 1 Package Quantity 1	Brand	FDA	06/01/2023	51.15	221.65	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	06/30/2023	63323059613	Glucagon HCl (Diagnostic) Injection Solution Reconstituted 1 MG Package Size 1 Package Quantity 10	Brand	FDA	06/01/2023	511.50	2216.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323085225	HYDROmorphone HCl PF Injection Solution 1 MG/ML 1 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	18.00	108.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323085150	HYDROmorphone HCl PF Injection Solution 10 MG/ML 50 ML, Unit-Dose, Vial	Brand	FDA	02/02/2023	28.34	170.04	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323085325	HYDROmorphone HCl PF Injection Solution 2 MG/ML 1 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	18.00	108.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323085410	HYDROmorphone HCl PF Injection Solution 4 MG/ML 1 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	18.75	112.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323034925	Imipenem-Cilastatin Intravenous Solution Reconstituted 250 MG 1 Each, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	32.50	374.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323032225	Imipenem-Cilastatin Intravenous Solution Reconstituted 500 MG Each, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	65.00	749.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323020805	Lidocaine HCl (Cardiac) IV PF Soln 100 MG/5ML (2%), 5 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	11.25	86.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323006411	Magnesium Sulfate Inj 50%, 10 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	7.00	54.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323006403	Magnesium Sulfate Inj 50%, 2 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	6.50	49.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323064220	Magnesium Sulfate Injection Solution 50 % 20 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	29.50	226.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323064250	Magnesium Sulfate Injection Solution 50 % 50 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	76.00	582.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323002425	Mannitol Intravenous Solution 25 % 50 ML, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	11.50	133.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323025410	Muri-Lube Oil 10 ML, Unit-Dose, Vial Qty 25	Brand	Medispan	02/02/2023	57.25	438.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323025402	Muri-Lube Oil 2 ML, Unit-Dose, Vial Qty 25	Brand	Medispan	02/02/2023	49.50	379.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323020500	Omegaven Intravenous Emulsion 10 GM/100ML 100 ML, Unit-Dose, Vial Qty 10	Brand	FDA	02/02/2023	47.30	835.70	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323020550	Omegaven Intravenous Emulsion 5 GM/50ML 50 ML, Unit-Dose, Vial Qty 10	Brand	FDA	02/02/2023	33.10	585.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323001230	Oxytocin Inj 10 Unit/ML, 30 ML, Vial Qty 10	Brand	FDA	02/02/2023	41.10	473.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	65219005229	Potassium Phosphates Intravenous Solution 15 MMOLE/5ML 22 mEq/5ML (K), 5 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	52.00	599.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	65219005629	Potassium Phosphates Intravenous Solution 150 MMOLE/50ML 220 mEq/50ML (K), 50 ML, Vial Qty 25	Brand	FDA	02/02/2023	257.50	2967.75	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	65219005429	Potassium Phosphates Intravenous Solution 45 MMOLE/15ML 66 mEq/15ML (K), 15 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	104.00	1199.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323022930	Protamine Sulfate Inj 10 MG/ML, 25 ML, Unit-Dose, Vial	Generic	FDA	02/02/2023	6.05	46.41	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323022905	Protamine Sulfate Intravenous Solution 10 MG/ML 5 ML, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	50.50	387.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323018001	Pyridoxine HCl Injection Solution 100 MG/ML 1 ML, Vial Qty 25	Generic	FDA	02/02/2023	62.25	476.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323046157	Sensorcaine/EPINEPHrine Injection Solution 0.25% -1:200000 50 ML, Vial Qty 25	Generic	FDA	02/02/2023	22.00	390.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323046357	Sensorcaine/EPINEPHrine Injection Solution 0.5% -1:200000 50 ML, Vial Qty 25	Generic	FDA	02/02/2023	23.75	418.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323046817	Sensorcaine-MPF/EPINEPHrine Injection Solution 0.25% -1:200000 10 ML, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	8.75	154.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323046837	Sensorcaine-MPF/EPINEPHrine Injection Solution 0.25% -1:200000 30 ML, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	13.75	243.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323046217	Sensorcaine-MPF/EPINEPHrine Injection Solution 0.5% -1:200000 10 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	9.00	158.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323046237	Sensorcaine-MPF/EPINEPHrine Injection Solution 0.5% -1:200000 30 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	14.75	262.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323046037	Sensorcaine-MPF/EPINEPHrine Injection Solution 0.75-1:200000 % 30 ML, Unit-Dose, Vial Qty 25	Brand	FDA	02/02/2023	16.75	294.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323009040	Sodium Chloride Injection Solution 2.5 MEQ/ML (14.6%), 40 ML, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	25.00	191.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323009330	Sodium Chloride Intravenous Solution 4 MEQ/ML (23.4%), 30 ML, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	21.75	167.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323018510	Sterile Water for Injection Injection Solution 10 ML, Unit-Dose, Vial Qty 25	Generic	FDA	02/02/2023	14.25	109.75	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323030502	Tobramycin Sulfate Injection Solution 10 MG/ML (Base Equivalent), 2 ML, Vial Qty 25	Generic	FDA	02/02/2023	21.50	153.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	12/31/2023	63323027810	vinBLAStine Sulfate Intravenous Solution 1 MG/ML 1 vial per package	Generic	FDA	10/31/2023	6.60	53.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323048217	Xylocaine/EPINEPHrine Injection Solution 1 %-1:100000 10 ML, Vial Qty 25	Brand	FDA	02/02/2023	5.00	86.75	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	03/31/2023	63323048257	Xylocaine/EPINEPHrine Injection Solution 1 %-1:100000 50 ML, Vial Qty 25	Brand	FDA	02/02/2023	14.25	250.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000463	GE Healthcare, Inc.	03/31/2023	00407141509	OMNIPAQUE ORAL SOLUTION 10 BOTTLE 500 ML 4500 MG	Brand	FDA	01/01/2023	21.00	101.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000463	GE Healthcare, Inc.	03/31/2023	00407141612	OMNIPAQUE ORAL SOLUTION 10 BOTTLE 500 ML 6000 MG	Brand	FDA	01/01/2023	22.50	105.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000437	Genus Lifesciences Inc.	09/30/2023	64950034316	Hydrocodone with Acetaminophen oral solution, 7.5mg and 325mg per 15mL, 473 mL bottle	Generic	FDA	09/08/2023	159.00	195.00	None	Non-innovator Multiple Source Drug	20000	None	Increased state licensing cost, increased manufacturing costs, increased materials and components costs	None	we're working with suppliers to try to reduce costs, and improve batch efficiencies	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958250501	BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide), Tablet, 30/120/15 mg, 30 ct, US, Bottle	Brand	FDA	01/01/2023	211.44	3795.24	11/08/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958250103	BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide), Tablet, 50/200/25 mg, 30 ct, US, Blister Pack	Brand	FDA	01/01/2023	211.44	3795.24	11/08/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958250101	BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide), Tablet, 50/200/25 mg, 30 ct, US, Bottle	Brand	FDA	01/01/2023	211.44	3795.24	11/08/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958090101	CAYSTON (aztreonam), Sterile Liquid for Inhalation, 75 mg/vial, 84 Vials, US, 28 Day Kit	Brand	FDA	01/01/2023	1029.00	11423.16	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958110101	COMPLERA (emtricitabine, rilpivirine, tenofovir disoproxil fumarate), Tablet, 200/25/300 mg, 30 ct, US, Bottle	Brand	FDA	01/01/2023	192.43	3453.96	01/14/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958200202	DESCOVY (emtricitabine and tenofovir alafenamide), Tablet, 200/25 mg, 30 ct, US, Blister Pack	Brand	FDA	01/01/2023	120.29	2159.12	02/15/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958200201	DESCOVY (emtricitabine and tenofovir alafenamide), Tablet, 200/25 mg, 30 ct, US, Bottle	Brand	FDA	01/01/2023	120.29	2159.12	02/15/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958190101	GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), Tablet,150/150/200/10mg,30ct,US,Bottle	Brand	FDA	01/01/2023	211.44	3795.24	04/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958080205	LETAIRIS (ambrisentan), Tablet, 10 mg, 10 ct, US, Bottle	Brand	FDA	01/01/2023	371.56	4124.72	10/14/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958080201	LETAIRIS (ambrisentan), Tablet, 10 mg, 30 ct, US, Bottle	Brand	FDA	01/01/2023	1114.69	12374.23	10/14/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958080105	LETAIRIS (ambrisentan), Tablet, 5 mg, 10 ct, US, Bottle	Brand	FDA	01/01/2023	371.56	4124.72	10/14/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958080101	LETAIRIS (ambrisentan), Tablet, 5 mg, 30 ct, US, Bottle	Brand	FDA	01/01/2023	1114.69	12374.23	10/14/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958210101	ODEFSEY (emtricitabine, rilpivirine, and tenofovir alafenamide), Tablet, 200/25/25 mg, 30 ct, US, Bottle	Brand	FDA	01/01/2023	192.43	3453.96	02/15/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958120101	STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), Tablet, 150/150/200/300 mg, 30 ct, US, Bottle	Brand	FDA	01/01/2023	221.81	3981.22	04/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958140101	TYBOST (cobicistat), Tablet,150mg,30ct,US,Bottle	Brand	FDA	01/01/2023	15.78	283.30	04/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958230101	VEMLIDY (tenofovir alafenamide), Tablet, 25 mg, 30 ct, US, Bottle	Brand	FDA	01/01/2023	76.56	1374.25	02/15/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958170101	ZYDELIG (idelalisib), Tablet, 100 mg, 60 ct, US, Bottle	Brand	FDA	01/01/2023	733.36	13163.19	09/02/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	03/31/2023	61958170201	ZYDELIG (idelalisib), Tablet, 150 mg, 60 ct, US, Bottle	Brand	FDA	01/01/2023	733.36	13163.19	09/02/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000406	Glaukos Corporation	03/31/2023	25357002503	PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 1 Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. Please see complete product description in general comments.	Brand	FDA	01/01/2023	335.00	3770.00	None	Single Source Drug	None	1	In making the decision to increase the price of Photrexa, Glaukos considered the value in cost savings when it comes to direct medical costs as well as the improved quality of life for keratoconus patients, as compared to corneal transplantation. According to a study published in the Journal of Medical Economics in 2020, corneal cross-linking with Photrexa was found to be cost-effective within 2 years and cost-saving within 4.5 years. We also considered the value it provides to patients in terms of its durability and safety profile, and our significant investment in ongoing research and development, reimbursement and patient support programs, noting that approximately 30-35% of our revenue goes to R&D costs.	None	No changes or improvements caused the increase.	None	11/21/2019	Avedro, Inc.	437751000	None	Glaukos Corporation acquired all of the outstanding stock of Avedro, Inc. in a merger transaction. At the closing of the Merger each share of common stock of Avedro, Inc. issued and outstanding immediately prior to the closing was automatically cancelled and converted into the right to receive 0.365 of a share of common stock of Glaukos Corporation. No cash was exchanged. The Acquisition Cost provided in this submission is the fair value of the Glaukos stock issued in the merger transaction.	2850.00	2850.00	2016	595.00	None	PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 1 Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. Syringe 1 - PHOTREXA VISCOUS in a 3 mL glass syringe containing sterile 1.56 mg/mL riboflavin 5’-phosphate in 20% dextran ophthalmic solution, Syringe 2 - PHOTREXA in a 3 mL glass syringe containing sterile 1.46 mg/mL riboflavin 5’-phosphate ophthalmic solution
Rx0000406	Glaukos Corporation	12/31/2023	25357002503	PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 1 Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. Please see complete product description in general comments.	Brand	FDA	10/01/2023	380.00	4150.00	None	Single Source Drug	None	1	In making the decision to increase the price of Photrexa, Glaukos considered the value in cost savings when it comes to direct medical costs as well as the improved quality of life for keratoconus patients, as compared to corneal transplantation. According to a study published in the Journal of Medical Economics in 2020, corneal cross-linking with Photrexa was found to be cost-effective within 2 years and cost-saving within 4.5 years. We also considered the value it provides to patients in terms of its durability and safety profile, and our significant investment in ongoing research and development, reimbursement and patient support programs, noting that approximately 30-35% of our revenue goes to R&D costs.	None	No changes or improvements caused the increase.	None	11/21/2019	Avedro, Inc.	437751000	None	Glaukos Corporation acquired all of the outstanding stock of Avedro, Inc. in a merger transaction. At the closing of the Merger each share of common stock of Avedro, Inc. issued and outstanding immediately prior to the closing was automatically cancelled and converted into the right to receive 0.365 of a share of common stock of Glaukos Corporation. No cash was exchanged. The Acquisition Cost provided in this submission is the fair value of the Glaukos stock issued in the merger transaction.	2850.00	2850.00	2016	595.00	None	PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 1 Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. Syringe 1 - PHOTREXA VISCOUS in a 3 mL glass syringe containing sterile 1.56 mg/mL riboflavin 5’-phosphate in 20% dextran ophthalmic solution, Syringe 2 - PHOTREXA in a 3 mL glass syringe containing sterile 1.46 mg/mL riboflavin 5’-phosphate ophthalmic solution
Rx0000406	Glaukos Corporation	03/31/2023	25357002501	PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 10 Kits in each Box. Each Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT in 1 SYRINGE, GLASS. See complete product description in general comments.	Brand	FDA	01/01/2023	3350.00	37700.00	None	Single Source Drug	0	1	This product is not offered for sale; we are working to update and correct the listing in MediSpan.	None	This product is not offered for sale; we are working to update and correct the listing in MediSpan.	None	11/21/2019	Avedro, Inc.	437751000	None	Glaukos Corporation acquired all of the outstanding stock of Avedro, Inc. in a merger transaction. At the closing of the Merger each share of common stock of Avedro, Inc. issued and outstanding immediately prior to the closing was automatically cancelled and converted into the right to receive 0.365 of a share of common stock of Glaukos Corporation. No cash was exchanged. The Acquisition Cost provided in this submission is the fair value of the Glaukos stock issued in the merger transaction.	31300.00	31300.00	2016	5950.00	None	This product is not offered for sale; we are working to update and correct the listing in MediSpan. PHOTREXA (riboflavin 5 -phosphate ophthalmic solution) 0.146%. 10 Kits in each Box. Each Kit contains 2 POUCH in 1 BOX / 1 POUCH in 1 POUCH / 1 SYRINGE, GLASS in 1 POUCH / 1 KIT 1 SYRINGE, GLASS. Syringe 1 - PHOTREXA VISCOUS in a 3 mL glass syringe containing sterile 1.56 mg/mL riboflavin 5’-phosphate in 20% dextran ophthalmic solution, Syringe 2 - PHOTREXA in a 3 mL glass syringe containing sterile 1.46 mg/mL riboflavin 5’-phosphate ophthalmic solution.
Rx0000029	GlaxoSmithKline	03/31/2023	00173087410	Arnuity Ellipta; 100 ug/1; 1 INHALER in 1 CARTON (0173-0874-10) / 30 POWDER in 1 INHALER	Brand	FDA	01/01/2023	9.64	208.49	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173087414	Arnuity Ellipta; 100 ug/1; 1 INHALER in 1 CARTON (0173-0874-14) / 14 POWDER in 1 INHALER	Brand	FDA	01/01/2023	4.50	97.29	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173087610	Arnuity Ellipta; 200 ug/1; 1 INHALER in 1 CARTON (0173-0876-10) / 30 POWDER in 1 INHALER	Brand	FDA	01/01/2023	12.92	279.14	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173087614	Arnuity Ellipta; 200 ug/1; 1 INHALER in 1 CARTON (0173-0876-14) / 14 POWDER in 1 INHALER	Brand	FDA	01/01/2023	6.02	130.26	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173088810	Arnuity Ellipta; 50 ug/1; 1 INHALER in 1 CARTON (0173-0888-10) / 30 POWDER in 1 INHALER	Brand	FDA	01/01/2023	9.64	208.49	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	49401008835	BENLYSTA; 200 mg/mL; 4 PREFILLED AUTO-INJECTOR in 1 CARTON (49401-0088-35) > 1 mL in 1 PREFILLED AUTO-INJECTOR (49401-0088-01)	Brand	FDA	01/01/2023	329.73	4611.90	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	49401008847	BENLYSTA; 200 mg/mL; 4 PREFILLED GLASS SYRINGE in 1 CARTON (49401-0088-47) > 1 mL in 1 PREFILLED GLASS SYRINGE (49401-0088-42)	Brand	FDA	01/01/2023	329.73	4611.90	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	58160097620	BEXSERO 0.5ML Pre-filled Syringe; Dosage form: Injection; 10 Pack	Brand	FDA	01/01/2023	100.27	2113.22	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This product was acquired by GSK in 2015 which is outside of the 5 year reporting period. Therefore, the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173059402	LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0594-02) / 1 KIT in 1 BLISTER PACK	Brand	FDA	01/01/2023	56.90	795.83	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173075800	LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0758-00) / 1 KIT in 1 BLISTER PACK	Brand	FDA	01/01/2023	35.03	489.99	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173075900	LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0759-00) / 1 KIT in 1 BLISTER PACK	Brand	FDA	01/01/2023	100.08	1399.77	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173076000	LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0760-00) / 1 KIT in 1 BLISTER PACK	Brand	FDA	01/01/2023	50.04	699.92	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173077800	LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0778-00) / 1 KIT in 1 BLISTER PACK	Brand	FDA	01/01/2023	47.86	669.46	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173077900	LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0779-00) / 1 KIT in 1 BLISTER PACK	Brand	FDA	01/01/2023	33.51	468.66	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173078000	LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0780-00) / 1 KIT in 1 BLISTER PACK	Brand	FDA	01/01/2023	95.72	1338.88	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173081728	LAMICTAL; 1 BLISTER PACK in 1 PACKAGE, COMBINATION (0173-0817-28) / 1 KIT in 1 BLISTER PACK	Brand	FDA	01/01/2023	113.79	1591.62	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173077602	LAMICTAL; 100 mg/1; 1 DOSE PACK in 1 CARTON (0173-0776-02) / 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK	Brand	FDA	01/01/2023	32.80	458.81	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173064255	LAMICTAL; 100 mg/1; 100 TABLET in 1 BOTTLE (0173-0642-55)	Brand	FDA	01/01/2023	129.99	1818.21	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173075600	LAMICTAL; 100 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0756-00)	Brand	FDA	01/01/2023	64.32	899.69	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173064360	LAMICTAL; 150 mg/1; 60 TABLET in 1 BOTTLE (0173-0643-60)	Brand	FDA	01/01/2023	85.49	1195.69	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173077702	LAMICTAL; 200 mg/1; 1 DOSE PACK in 1 CARTON (0173-0777-02) / 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK	Brand	FDA	01/01/2023	39.14	547.51	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173075700	LAMICTAL; 200 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0757-00)	Brand	FDA	01/01/2023	68.59	959.40	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173064460	LAMICTAL; 200 mg/1; 60 TABLET in 1 BOTTLE (0173-0644-60)	Brand	FDA	01/01/2023	93.06	1301.63	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173077202	LAMICTAL; 25 mg/1; 1 DOSE PACK in 1 CARTON (0173-0772-02) / 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK	Brand	FDA	01/01/2023	28.72	401.73	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173063302	LAMICTAL; 25 mg/1; 100 TABLET in 1 BOTTLE (0173-0633-02)	Brand	FDA	01/01/2023	113.80	1591.78	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173052700	LAMICTAL; 25 mg/1; 100 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0527-00)	Brand	FDA	01/01/2023	118.21	1653.45	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173075400	LAMICTAL; 25 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0754-00)	Brand	FDA	01/01/2023	30.03	420.01	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173063310	LAMICTAL; 25 mg/1; 35 TABLET in 1 DOSE PACK (0173-0633-10)	Brand	FDA	01/01/2023	39.83	557.14	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173078100	LAMICTAL; 250 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0781-00)	Brand	FDA	01/01/2023	93.54	1308.32	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173076100	LAMICTAL; 300 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0761-00)	Brand	FDA	01/01/2023	102.89	1439.14	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173052600	LAMICTAL; 5 mg/1; 100 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0526-00)	Brand	FDA	01/01/2023	110.12	1540.21	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173077402	LAMICTAL; 50 mg/1; 1 DOSE PACK in 1 CARTON (0173-0774-02) / 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK	Brand	FDA	01/01/2023	30.76	430.30	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173075500	LAMICTAL; 50 mg/1; 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0173-0755-00)	Brand	FDA	01/01/2023	60.05	839.92	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173089201	Nucala; 100 mg/mL; 1 SYRINGE in 1 CARTON (0173-0892-01) / 1 mL in 1 SYRINGE	Brand	FDA	01/01/2023	256.05	3581.39	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	00173089242	Nucala; 100 mg/mL; 1 SYRINGE in 1 CARTON (0173-0892-42) / 1 mL in 1 SYRINGE	Brand	FDA	01/01/2023	256.05	3581.39	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	58160081912	SHINGRIX 0.5mL Vial; Dosage form: Injection; 1 Pack	Brand	FDA	01/01/2023	11.84	183.41	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	58160082311	SHINGRIX 0.5mL Vial; Dosage form: Injection; 10 Pack	Brand	FDA	01/01/2023	118.38	1834.06	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	Note on Acquisition Fields: This drug was developed by GSK, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000029	GlaxoSmithKline	03/31/2023	69656010330	ZEJULA 100 mg 30 CAPSULE in 1 BOTTLE	Brand	FDA	01/01/2023	489.32	8644.65	None	Single Source Drug	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	01/22/2019	TESARO, INC	None	1	None	6584.00	None	2018	6584.00	None	Note on Acquisition Fields ACQUIRED_FROM_COMPANY: GSK acquired Zejula as a part of its overall acquisition of TESARO Inc, the company that developed Zejula, and there was no specific acquisition of Zejula itself ACQUISITION_PRICE: GSK acquired Zejula as a part of its overall acquisition of TESARO Inc, the company that developed Zejula, and there was no specific acquisition of Zejula itself WAC_YEAR_PRIOR_TO_ACQ: Zejula did not have a WAC one year prior to acquisition as it was not yet approved at that time
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2023	00054252731	Lithium Carbonate Oral Capsule 300 MG, 1 Bottle of 1000 Capsules	Brand	FDA	01/06/2023	143.71	213.81	None	Non-innovator Multiple Source Drug	None	1	Increased costs incurred with the acquisition of raw materials, rate of inflation and ongoing changes in the competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	03/31/2023	00054452731	Lithium Carbonate Oral Tablet 300 MG, 1 Bottle of 1000 Tabs	Brand	FDA	01/06/2023	34.41	206.44	None	Non-innovator Multiple Source Drug	None	1	Increased costs incurred with the acquisition of raw materials, rate of inflation and ongoing changes in the competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	06/30/2023	00641605010	LORazepam Injection Solution 2 MG/ML 10 vials	Brand	FDA	06/21/2023	38.66	106.46	None	Innovator Multiple Source Drug	None	1	This Product was last increased by Hikma in 2012. Factors which led to this WAC increase included a double-digit increase in the raw materials, as well costs associated with validating a second supplier of such raw materials. Additionally, increased costs associated with the rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics played a part.	None	Not applicable.	None	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000145	Horizon Therapeutics USA, Inc.	09/30/2023	75987008010	Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial	Brand	FDA	07/28/2023	655.36	27960.56	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Please note the Patent Expiration date for Krystexxa is not publicly available.
Rx0000160	Incyte Corporation	03/31/2023	50881001060	Jakafi Oral Tablet 10 mg 60 Pack	Brand	FDA	01/09/2023	486.00	16686.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	12/31/2023	50881001060	Jakafi Oral Tablet 10 mg 60 Pack	Brand	FDA	10/01/2023	334.00	17020.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	03/31/2023	50881001560	Jakafi Oral Tablet 15 mg 60 Pack	Brand	FDA	01/09/2023	486.00	16686.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	12/31/2023	50881001560	Jakafi Oral Tablet 15 mg 60 Pack	Brand	FDA	10/01/2023	334.00	17020.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	03/31/2023	50881002060	Jakafi Oral Tablet 20 mg 60 Pack	Brand	FDA	01/09/2023	486.00	16686.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	12/31/2023	50881002060	Jakafi Oral Tablet 20 mg 60 Pack	Brand	FDA	10/01/2023	334.00	17020.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	03/31/2023	50881002560	Jakafi Oral Tablet 25 mg 60 Pack	Brand	FDA	01/09/2023	486.00	16686.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	12/31/2023	50881002560	Jakafi Oral Tablet 25 mg 60 Pack	Brand	FDA	10/01/2023	334.00	17020.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	03/31/2023	50881000560	Jakafi Oral Tablet 5 mg 60 Pack	Brand	FDA	01/09/2023	486.00	16686.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000160	Incyte Corporation	12/31/2023	50881000560	Jakafi Oral Tablet 5 mg 60 Pack	Brand	FDA	10/01/2023	334.00	17020.00	12/12/2028	Single Source Drug	None	1	Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2023	50742044745	Carboplatin Injection 450mg, 45ml	Generic	FDA	08/20/2023	33.27	75.00	None	Non-innovator Multiple Source Drug	120000	None	Carboplatin 450mg/45mL and 600mg/60mL (ANDA 208487) has been priced in accordance with Ingenus Pharmaceuticals Contracts and Management Team policies and procedures. Establishing the WAC price at $75.00 and $100.00 constitutes a reasonable WAC price as we reenter the market after previously exiting due to competitive reasons. Our pricing analysis has been complete, our new WAC should help us compete in a market in which we were previously unable to. Several factors were taken into consideration while determining Ingenus’ WAC pricing including but limited to API, production, packaging, and shipping costs. Ingenus’ WAC pricing will enable it to: i) recoup the costs it incurred in evaluating the economic landscape surrounding prospective products; ii) cover distribution costs; iii) provide rebates and discounts as required by partners in the supply chain; and iv) earn a reasonable return on investment.	None	There was no change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000040	Ingenus Pharmaceuticals, LLC	09/30/2023	50742044860	Carboplatin Injection 600mg, 60ml	Generic	FDA	08/20/2023	48.29	100.00	None	Non-innovator Multiple Source Drug	65000	None	Carboplatin 450mg/45mL and 600mg/60mL (ANDA 208487) has been priced in accordance with Ingenus Pharmaceuticals Contracts and Management Team policies and procedures. Establishing the WAC price at $75.00 and $100.00 constitutes a reasonable WAC price as we reenter the market after previously exiting due to competitive reasons. Our pricing analysis has been complete, our new WAC should help us compete in a market in which we were previously unable to. Several factors were taken into consideration while determining Ingenus’ WAC pricing including but limited to API, production, packaging, and shipping costs. Ingenus’ WAC pricing will enable it to: i) recoup the costs it incurred in evaluating the economic landscape surrounding prospective products; ii) cover distribution costs; iii) provide rebates and discounts as required by partners in the supply chain; and iv) earn a reasonable return on investment.	None	There was no change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000287	Insmed Incorporated	03/31/2023	71558059028	Arikayce Inhalation Suspension 590 MG/8.4ML Package Size 8.4 ML Package Quantity/Vial Quantity 28	Brand	FDA	01/01/2023	1069.78	14441.99	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000266	Intercept Pharmaceuticals, Inc.	09/30/2023	69516001030	Ocaliva Oral Tablet 10mg 30 count in 1 bottle	Brand	FDA	08/01/2023	502.63	9021.77	04/26/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000266	Intercept Pharmaceuticals, Inc.	09/30/2023	69516000530	Ocaliva Oral Tablet 5mg 30 count in 1 bottle	Brand	FDA	08/01/2023	502.63	9021.77	04/26/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000266	Intercept Pharmaceuticals, Inc.	03/31/2023	69516001030	Ocaliva® (obeticholic acid) tablets 10mg, 30 Count Bottle	Brand	FDA	01/19/2023	474.63	8519.14	04/26/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This is a revision to the previously filed increase notice and report.
Rx0000266	Intercept Pharmaceuticals, Inc.	03/31/2023	69516000530	Ocaliva® (obeticholic acid) tablets 5mg 30 Count Bottle	Brand	FDA	01/19/2023	474.63	8519.14	04/26/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This is a revision to the previously filed increase notice and report.
Rx0000214	Intra-Cellular Therapies, Inc.	06/30/2023	72060014230	Caplyta Oral Capsule 42 MG 30 Pack	Brand	FDA	05/29/2023	87.42	1569.17	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2023	15054104005	Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 1 vial (4ml).	Brand	FDA	01/01/2023	253.00	5882.00	03/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084	Ipsen Biopharmaceuticals, Inc.	12/31/2023	15054004301	Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml.	Brand	FDA	10/01/2023	67.00	2766.00	10/15/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01
Rx0000084	Ipsen Biopharmaceuticals, Inc.	03/31/2023	72607010000	Drug product name: Tazverik. Drug product strength: 200mg. Drug product dosage form: tablet. Drug product package size: 1 bottle (240 tablets).	Brand	FDA	02/15/2023	1104.00	18850.00	12/19/2035	Single Source Drug	None	1	None	1	None	1	08/12/2022	Epizyme, Inc.	None	None	For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased Epizyme, Inc. in August 2022, including Tazverik. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of Epizyme, Inc. is available on p. 82, Note 1.2 of section 3.2.5 of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2023/04/06183729/EN_UNIVERSAL-REGISTRATION-DOCUMENT-2022-BD.pdf	17746.00	16585.00	2020	15500.00	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000248	Janssen Biotech, Inc.	03/31/2023	57894050301	DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)Strength: 1800mg / 15 mL Package Size:1 Form:1 single vial	Brand	FDA	01/20/2023	392.67	9118.60	11/03/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 3, 2023.
Rx0000248	Janssen Biotech, Inc.	03/31/2023	57894050205	DARZALEX™ (daratumumab)Strength:100 mg 5 mL Package Size:1 Form:1 single vial	Brand	FDA	01/20/2023	28.81	669.00	09/25/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 4, 2023.
Rx0000248	Janssen Biotech, Inc.	03/31/2023	57894050220	DARZALEX™ (daratumumab)Strength:400 mg 20 mL Package Size:1 Form:1 single vial	Brand	FDA	01/20/2023	115.23	2675.99	09/25/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 4, 2023.
Rx0000248	Janssen Biotech, Inc.	03/31/2023	57894007101	SIMPONI® (golimumab) Prefilled Syringe Strength: 100mg/1mL Package Size:1 Form:1 Single syringe	Brand	FDA	01/20/2023	339.62	6747.57	02/03/2024	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023
Rx0000248	Janssen Biotech, Inc.	03/31/2023	57894007001	SIMPONI® (golimumab) Prefilled Syringe Strength: 50mg/0.5mL Package Size:1 Form:1 Single syringe	Brand	FDA	01/20/2023	295.32	5867.44	02/03/2024	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023
Rx0000248	Janssen Biotech, Inc.	03/31/2023	57894007102	SIMPONI® (golimumab) SmartJect® xAutoinjector Strength: 100mg/1mL Package Size:1 Form:1 Single Autoinjector	Brand	FDA	01/20/2023	339.62	6747.57	02/03/2024	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023
Rx0000248	Janssen Biotech, Inc.	03/31/2023	57894007002	SIMPONI® (golimumab) SmartJect® xAutoinjector Strength: 50mg/0.5mL Package Size:1 Form:1 Single Autoinjector	Brand	FDA	01/20/2023	295.32	5867.44	02/03/2024	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458009801	ELMIRON® Strength:100 mg Package Size:100 Form:Capsule	Brand	FDA	01/20/2023	38.95	1091.55	01/19/2010	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	No unexpired patents
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458056201	INVEGA® SUSTENNA® Strength:117 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	01/20/2023	78.20	1674.04	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458056301	INVEGA® SUSTENNA® Strength:156 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	01/20/2023	104.27	2232.14	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458056401	INVEGA® SUSTENNA® Strength:234 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	01/20/2023	156.39	3348.12	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458056001	INVEGA® SUSTENNA® Strength:39 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	01/20/2023	26.06	557.98	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458056101	INVEGA® SUSTENNA® Strength:78 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	01/20/2023	52.13	1116.01	01/26/2031	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458060601	INVEGA® TRINZA® Strength:273 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	01/20/2023	156.39	3348.02	04/05/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458060701	INVEGA® TRINZA® Strength:410 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	01/20/2023	234.59	5022.11	04/05/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458060801	INVEGA® TRINZA® Strength:546 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	01/20/2023	312.80	6696.41	04/05/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458060901	INVEGA® TRINZA® Strength:819 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	01/20/2023	469.18	10044.38	04/05/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2022.
Rx0000253	Janssen Pharmaceuticals, Inc.	12/31/2023	50458030911	RISPERDAL® CONSTA® Strength:12.5 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	10/13/2023	14.08	307.31	None	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book as of December 19, 2023
Rx0000253	Janssen Pharmaceuticals, Inc.	12/31/2023	50458030611	RISPERDAL® CONSTA® Strength:25 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	10/13/2023	28.15	614.56	None	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book as of December 19, 2023
Rx0000253	Janssen Pharmaceuticals, Inc.	12/31/2023	50458030711	RISPERDAL® CONSTA® Strength:37.5 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	10/13/2023	42.22	921.88	None	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book as of December 19, 2023
Rx0000253	Janssen Pharmaceuticals, Inc.	12/31/2023	50458030811	RISPERDAL® CONSTA® Strength:50 mg Package Size:1 Form:Disposable Syringe/Dose Pack	Brand	FDA	10/13/2023	56.30	1229.21	None	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book as of December 19, 2023
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458002802	SPRAVATO™ Strength:56 mg Package Size:2 Form:Nasal Spray	Brand	FDA	01/20/2023	51.96	735.63	09/10/2035	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023
Rx0000253	Janssen Pharmaceuticals, Inc.	03/31/2023	50458002803	SPRAVATO™ Strength:84 mg Package Size:3 Form:Nasal Spray	Brand	FDA	01/20/2023	77.94	1103.44	09/10/2035	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023
Rx0000250	Janssen Products, LP	03/31/2023	59676003056	BALVERSA® (erdafitinib) Strength:3 MG Package Size:56 Form:Tablet	Brand	FDA	01/20/2023	637.12	18840.60	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676003084	BALVERSA® (erdafitinib) Strength:3 MG Package Size:84 Form:Tablet	Brand	FDA	01/20/2023	955.68	28260.89	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676004028	BALVERSA® (erdafitinib) Strength:4 MG Package Size:28 Form:Tablet	Brand	FDA	01/20/2023	424.75	12560.40	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676004056	BALVERSA® (erdafitinib) Strength:4 MG Package Size:56 Form:Tablet	Brand	FDA	01/20/2023	849.50	25120.81	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676005028	BALVERSA® (erdafitinib) Strength:5 MG Package Size:28 Form:Tablet	Brand	FDA	01/20/2023	530.93	15700.50	02/02/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676057530	PREZCOBIX™ (darunavir 800mg, cobicistat 150mg) Strength:800 MG/150 MG Package Size:30 Form:Tablet	Brand	FDA	01/20/2023	100.93	2394.87	10/06/2032	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676056401	PREZISTA® Strength:150 MG Package Size:240 Form:Tablet	Brand	FDA	01/20/2023	88.31	2095.29	06/26/2027	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676056201	PREZISTA® Strength:600 MG Package Size:60 Form:Tablet	Brand	FDA	01/20/2023	88.31	2095.29	06/26/2027	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676056301	PREZISTA® Strength:75 MG Package Size:480 Form:Tablet	Brand	FDA	01/20/2023	88.31	2095.29	06/26/2027	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676056630	PREZISTA® Strength:800 MG Package Size:30 Form:Tablet	Brand	FDA	01/20/2023	88.31	2095.29	06/26/2027	Innovator Multiple Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676056501	PREZISTA® ORAL SUSPENSION Strength:100MG/mL Package Size:200mL Form:Oral Suspension	Brand	FDA	01/20/2023	49.06	1163.97	06/26/2027	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 4, 2023.
Rx0000250	Janssen Products, LP	03/31/2023	59676080030	SYMTUZA™ (darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg) Strength: 800 MG/150 MG/200 MG/10 MG Package Size:30 Form:Tablet	Brand	FDA	01/20/2023	300.47	4592.90	07/19/2038	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000008	Jazz Pharmaceuticals, Inc.	03/31/2023	70127010010	Epidiolex Solution 100mg/ml - 100ml bottle	Brand	FDA	01/11/2023	30.00	1570.00	03/01/2041	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 30, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was not was acquired from another manufacturer within the last five years.
Rx0000008	Jazz Pharmaceuticals, Inc.	03/31/2023	68727010001	Xyrem 500 MG/ML Oral Solution 180 ml	Brand	FDA	01/11/2023	310.00	6320.00	09/15/2033	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 30, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was not was acquired from another manufacturer within the last five years."
Rx0000008	Jazz Pharmaceuticals, Inc.	09/30/2023	68727071201	Zepzelca (lurbinectedin) 4mg Vial	Brand	FDA	07/11/2023	190.00	7830.00	12/13/2024	Single Source Drug	0	1	"Jazz Pharmaceuticals manufactures Specialty Pharmacy drugs for rare diseases that require a higher level of administration and effort to support patients. Product prices are determined by conducting extensive market research with Healthcare Providers (HCPs) to assess their perceptions of the clinical value delivered by our products. Jazz also evaluates relevant market analogues to support a price increase. Jazz engages its Pricing Committee to make price increase decisions. In doing so, the Pricing Committee balances capturing the product’s value with the priority of ensuring patient access. Specifically, the Pricing Committee considers the following factors in determining whether a price increase is warranted: • Clinical value; • HCP and Payer perceptions of a product’s clinical value; • Patient access and affordability, in order to ensure our products are broadly available to HCPs and patients; • Research and Development costs associated with production of the drug; • Historic WAC price; • Jazz’s fiduciary responsibility to its shareholders."	None	None	1	12/19/2019	PharmaMar	200000000	None	None	6633.00	None	2020	6633.00	None	"The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of October 25, 2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. "
Rx0000127	Karyopharm Therapeutics Inc.	09/30/2023	72237010305	Xpovio (100 MG Once Weekly) Oral Tablet Therapy Pack 50 MG, 2 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	07/01/2023	1048.00	27907.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	09/30/2023	72237010207	Xpovio (40 MG Once Weekly) Oral Tablet Therapy Pack 40 MG, 1 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	07/01/2023	1048.00	27907.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	09/30/2023	72237010206	Xpovio (40 MG Twice Weekly) Oral Tablet Therapy Pack 40 MG, 2 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	07/01/2023	1048.00	27907.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	09/30/2023	72237010401	Xpovio (60 MG Once Weekly) Oral Tablet Therapy Pack 60 MG, 1 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	07/01/2023	1048.00	27907.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	09/30/2023	72237010103	Xpovio (60 MG Twice Weekly) Oral Tablet Therapy Pack 20 MG, 6 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	07/01/2023	1048.00	27907.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	09/30/2023	72237010202	Xpovio (80 MG Once Weekly) Oral Tablet Therapy Pack 40 MG, 2 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	07/01/2023	1048.00	27907.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	09/30/2023	72237010104	Xpovio (80 MG Twice Weekly) Oral Tablet Therapy Pack 20 MG, 8 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	07/01/2023	1048.00	27907.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	03/31/2023	72237010103	Xpovio, Selinexor Tab Therapy Pack 20 MG (60 MG Twice Weekly), 6 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	01/01/2023	1497.00	26859.00	08/14/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	03/31/2023	72237010104	Xpovio, Selinexor Tab Therapy Pack 20 MG (80 MG Twice Weekly), 8 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	01/01/2023	1497.00	26859.00	08/14/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	03/31/2023	72237010207	Xpovio, Selinexor Tab Therapy Pack 40 MG (40 MG Once Weekly), 1 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	01/01/2023	1497.00	26859.00	08/14/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	03/31/2023	72237010206	Xpovio, Selinexor Tab Therapy Pack 40 MG (40 MG Twice Weekly), 2 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	01/01/2023	1497.00	26859.00	08/14/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	03/31/2023	72237010305	Xpovio, Selinexor Tab Therapy Pack 50 MG (100 MG Once Weekly), 2 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	01/01/2023	1497.00	26859.00	08/14/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	03/31/2023	72237010401	Xpovio, Selinexor Tab Therapy Pack 60 MG (60 MG Once Weekly), 1 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	01/01/2023	1497.00	26859.00	08/14/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	03/31/2023	72237010202	Xpovio,Selinexor Tab Therapy Pack 40 MG (80 MG Once Weekly), 2 Each, Unit-of-Use, Disp Pack Qty 4	Brand	FDA	01/01/2023	1497.00	26859.00	08/14/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000264	Kedrion Biopharma Inc.	03/31/2023	76125090020	Gammaked 200ml 1 vial in package	Brand	FDA	01/16/2023	265.40	3756.20	12/31/2023	Single Source Drug	84129	None	rising cost of plasma and manufacturing	None	na	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000264	Kedrion Biopharma Inc.	03/31/2023	76125090010	Gammaked 100ml 1 vial in package	Brand	FDA	01/16/2023	132.70	1878.10	12/31/2023	Single Source Drug	66461	None	rising cost of plasma and manufacturing	None	na	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000264	Kedrion Biopharma Inc.	03/31/2023	76125090050	Gammaked 50ml 1 vial in package	Brand	FDA	01/16/2023	66.35	939.05	12/31/2023	Single Source Drug	29199	None	rising cost of plasma and manufacturing	None	na	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000386	KVK Tech, Inc.	06/30/2023	10702006601	DEXTROAMPHETAMINE SULFATE TABLET 10 MG 100	Generic	FDA	06/02/2023	44.00	96.00	None	Non-innovator Multiple Source Drug	5828800	None	Market conditions and dynamics	None	n/a	None	None	None	None	None	None	None	None	None	None	None	Drug was not acquired within the last 5 years
Rx0000386	KVK Tech, Inc.	06/30/2023	10702007101	OXYMORPHONE HCL TABLET 10 MG 100	Generic	FDA	06/02/2023	78.00	248.00	None	Non-innovator Multiple Source Drug	323100	None	Market conditions and dynamics	None	n/a	None	None	None	None	None	None	None	None	None	None	None	Drug was not acquired within the last 5 years
Rx0000060	Kyowa Kirin, Inc.	09/30/2023	69794010201	CRYSVITA® (burosumab-twza) injection, for subcutaneous use, 10 mg/mL, 1 ML, single dose vial	Brand	FDA	07/03/2023	123.48	4239.48	None	Single Source Drug	None	1	None	1	A change or improvement in the product does not necessitate the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000060	Kyowa Kirin, Inc.	09/30/2023	69794020301	CRYSVITA® (burosumab-twza) injection, for subcutaneous use, 20 mg/mL, 1 ML, single dose vial	Brand	FDA	07/03/2023	246.96	8478.96	None	Single Source Drug	None	1	None	1	A change or improvement in the product does not necessitate the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000060	Kyowa Kirin, Inc.	09/30/2023	69794030401	CRYSVITA® (burosumab-twza) injection, for subcutaneous use, 30 mg/mL, 1 ML, single dose vial	Brand	FDA	07/03/2023	370.44	12718.44	None	Single Source Drug	None	1	None	1	A change or improvement in the product does not necessitate the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000060	Kyowa Kirin, Inc.	03/31/2023	42747060290	Nourianz Oral Tablet 20 MG, 90 Each, Bottle	Brand	FDA	01/03/2023	257.51	5407.76	09/05/2027	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000060	Kyowa Kirin, Inc.	03/31/2023	42747060490	Nourianz Oral Tablet 40 MG, 90 Each, Bottle	Brand	FDA	01/03/2023	257.51	5407.76	09/05/2027	Single Source Drug	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000083	Laboratoire HRA Pharma	06/30/2023	76336008060	Lysodren 500 mg tablets 100 count bottles	Brand	FDA	04/01/2023	116.42	1281.82	None	Single Source Drug	6000000	None	Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors	None	Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000083	Laboratoire HRA Pharma	06/30/2023	76336045518	Metopirone 250 mg capsules 18 count bottles	Brand	FDA	04/01/2023	108.70	833.35	None	Single Source Drug	5000000	None	Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors	None	Pricing may change for reasons including: discovery of new uses or patient populations, need for clinical trial investment for such new uses or populations, improving quality and supply chain logistics, and other market factors	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150237	Dextroamphetamine-Amphetamine IR Tablets 10mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150337	Dextroamphetamine-Amphetamine IR Tablets 12.5mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150437	Dextroamphetamine-Amphetamine IR Tablets 15mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150537	Dextroamphetamine-Amphetamine IR Tablets 20mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150637	Dextroamphetamine-Amphetamine IR Tablets 30mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150037	Dextroamphetamine-Amphetamine IR Tablets 5mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	06/30/2023	00527150137	Dextroamphetamine-Amphetamine IR Tablets 7.5mg 100 Pack	Generic	FDA	04/04/2023	28.14	50.51	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	12/31/2023	54838050280	Hydroxyzine HCl Syrup 10mg/5mL 473mg	Generic	FDA	10/16/2023	32.10	96.30	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	03/31/2023	00527194866	levofloxacin Oral Solution 25mg/ mL bottle of 100mL	Generic	FDA	03/15/2023	145.16	256.82	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficiently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	03/31/2023	00527194868	levofloxacin Oral Solution 25mg/ mL bottle of 200mL	Generic	FDA	03/15/2023	290.32	513.64	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficiently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	03/31/2023	00527194870	levofloxacin Oral Solution 25mg/ mL bottle of 480mL	Generic	FDA	03/15/2023	689.78	1220.38	None	Non-innovator Multiple Source Drug	None	1	The change in WAC price reflects the increased cost to supply efficiently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Lannett and many drug manufacturers have seen increase in the cost of doing business due to shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, the supply chain disruptions of COVID and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.	None	There was no change or improvement to the drug	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2023	11994001116	DEFINITY US 16Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS	Brand	FDA	01/01/2023	286.52	5061.88	05/04/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2023	11994001104	DEFINITY US 4Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS	Brand	FDA	01/01/2023	97.31	1313.68	05/04/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000413	Leadiant Biosciences, Inc.	03/31/2023	54482002002	Cystaran (cysteamine ophthalmic solution) 0.44/15 ml bottle	Brand	FDA	01/09/2023	359.50	2105.00	None	Single Source Drug	None	1	Leadiant Biosciences, Inc. is a company exclusively focused on rare diseases. Leadiant employees work with rare dedication to provide therapies for patients with rare diseases. We partner with patient communities, physicians, and researchers worldwide to overcome challenges and be a resource of hope. We take decisions related to the pricing of our medicines very seriously. Given the complexities of manufacturing products for extremely small patient populations, and the difficulties of maintaining their availability to patients over time, Leadiant strives to find the right balance between ensuring that patients have access to the medicines they need while investing in new therapies for new groups of underserved populations. In light of recent inflation pressures, as well as our R&D expenditures into new technologies for patient benefit, we have adjusted the price of Cystaran as indicated in this report.	None	Not Applicable.	None	None	None	None	None	None	None	None	None	None	None	With regard to Cystaran, our company transitioned to a new manufacturer and during the transition timeframe, we invested in an alternate bottle design to improve the patient experience. The new bottle design was assigned a new NDC number and was introduced to the market in 2022. WAC prices for earlier years relate to the predecessor NDC number 54482-0020-01, which utilized the old bottle design. The WAC prices under the previous NDC are: 3. WAC Effective Date: 1/1/2021, WAC Increase Amt: $42.14, WAC After Increase: $1,662.75                                                                                                                4. WAC Effective Date: 1/1/2020, WAC Increase Amt: $40.61, WAC After Increase: $1,620.61 5. WAC Effective Date: 1/1/2019, WAC Increase Amt: $46.00, WAC After Increase: $1,580.00
Rx0000413	Leadiant Biosciences, Inc.	03/31/2023	54482005401	Matulane (procarbazine hydrochloride) 50mg Capsules (100 p/bottle)	Brand	FDA	01/03/2023	957.53	12926.64	None	Single Source Drug	None	1	Our pricing has been adjusted substantially in consideration of increased manufacturing and supply costs, increased regulatory maintenance costs, and decreasing volumes that make it incrementally onerous for Leadiant to keep Matulane in the market and available to patients.	None	Not Applicable.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	03/31/2023	67386082019	Northera 100mg. 90 Capsules	Brand	FDA	01/02/2023	168.16	3531.38	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386082119	Northera 200mg. 90 Capsules	Brand	FDA	01/02/2023	336.32	7062.73	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386082219	Northera 300mg. 90 Capsules	Brand	FDA	01/02/2023	504.48	10594.12	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386031401	Onfi 10mg. 100 Tablets	Brand	FDA	01/02/2023	215.28	2748.02	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386031501	Onfi 20mg. 100 Tablets	Brand	FDA	01/02/2023	430.56	5495.98	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386031321	Onfi Oral Suspension 2.5mg/mL 120mL Bottle	Brand	FDA	01/02/2023	113.11	1443.83	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386011101	Sabril 500mg. 100 Tablets	Brand	FDA	01/02/2023	961.05	20182.05	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386021165	Sabril 500mg. 50 Packets 500mg. each	Brand	FDA	01/02/2023	480.53	10091.04	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386042101	Xenazine 12.5mg. 112 Tablets	Brand	FDA	01/02/2023	927.47	19476.92	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2023	67386042101	Xenazine 12.5mg. 112 Tablets	Brand	FDA	07/01/2023	779.08	20256.00	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2023	67386042201	Xenazine 25.0mg. 112 Tablets	Brand	FDA	01/02/2023	1854.95	38953.86	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	09/30/2023	67386042201	Xenazine 25.0mg. 112 Tablets	Brand	FDA	07/01/2023	1558.15	40512.01	None	Innovator Multiple Source Drug	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000297	MannKind Corporation	09/30/2023	47918089190	Afrezza 12 Unit Inhalation Powder Metered 1 Carton	Brand	FDA	07/03/2023	76.58	1352.94	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2023	47918087490	Afrezza 4 Unit Inhalation Powder Metered 1 Carton	Brand	FDA	07/03/2023	25.53	450.97	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2023	47918088018	Afrezza 4 Unit; 8 Unit Inhalation Powder Metered 1 Carton	Brand	FDA	07/03/2023	76.58	1352.94	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2023	47918090218	Afrezza 4 Unit; 8 Unit; 12 Unit Inhalation Powder Metered 1 Carton	Brand	FDA	07/03/2023	102.11	1803.93	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2023	47918087890	Afrezza 8 Unit Inhalation Powder Metered 1 Carton	Brand	FDA	07/03/2023	51.05	901.96	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000297	MannKind Corporation	09/30/2023	47918089818	Afrezza 8 Unit; 12 Unit Inhalation Powder Metered 1 Carton	Brand	FDA	07/03/2023	127.64	2254.91	07/12/2032	Single Source Drug	None	1	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000072	Mayne Pharma Inc	06/30/2023	73499000101	Wynzora Cream 0.005%/0.064%, 60g	Brand	FDA	05/19/2023	54.08	1255.83	None	Single Source Drug	27000	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000202	Medimetriks Pharmaceuticals, Inc	03/31/2023	43538044060	Nicadan, 800-10-100, TAB, 60 EA	Brand	Medispan	01/10/2023	28.05	547.54	None	Single Source Drug	None	1	Increase in operating costs, inflation, changes in the market	None	No changes or improvements were made to this drug	None	None	None	None	None	None	None	None	None	None	None	This product was not acquired within the last 5 years
Rx0000382	Melinta Therapeutics, LLC	03/31/2023	70842016010	MINOCIN (Minocycline-Hydrochloride) is administered via intravenous form and packaged as 10 VIAL in 1 CARTON > 1 INJECTION in 1 VIAL (100mg dose)	Brand	FDA	02/16/2023	114.00	2390.00	05/12/2031	Single Source Drug	None	1	Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision is ensure that all people who need our therapies will receive them. Melinta is committed to the responsible pricing of our products and our pricing methodology includes consideration of several financial and nonfinancial factors. Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in MINOCIN (minocycline) for Injection, as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary.	None	None - see cost increase factors statement.	None	01/05/2018	The Medicines Company	None	1	None	1544.13	1544.13	2015	1470.60	None	None
Rx0000382	Melinta Therapeutics, LLC	03/31/2023	70842012006	VABOMERE (meropenem/vaborbactam) is administered via intravenous injection and packaged as 6 VIAL, SINGLE-DOSE in 1 CARTON / 2 g in 1 VIAL.	Brand	FDA	02/16/2023	62.00	1296.00	04/06/2039	Single Source Drug	None	1	Melinta seeks to provide innovative therapies to people impacted by acute and life-threatening illnesses and our vision is ensure that all people who need our therapies will receive them. Melinta is committed to the responsible pricing of our products and our pricing methodology includes consideration of several financial and nonfinancial factors. Initial pricing, as well as any change in pricing, aims to reflect the clinical value of the product to patients and the healthcare system, while at the same time ensuring patient access. Financial factors include both our current investments in VABOMERE as well as consideration for potential future investments in research or other lifecycle related matters that may be necessary.	None	None - see cost increase factors statement.	None	01/05/2018	The Medicines Company	None	1	None	990.00	990.00	2017	990.00	None	None
Rx0000138	Merck Sharp & Dohme LLC	03/31/2023	00006542312	BRIDION 10 200 mg/2 mL Vial (ML)	Brand	FDA	01/06/2023	80.80	1235.00	01/27/2026	Single Source Drug	None	1	Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: . capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity. . investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to HCAi is subject to the following assumptions and context:  (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e.,  disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck Sharp & Dohme LLC	03/31/2023	00006542515	BRIDION 10 500 mg/5 mL Vial (ML)	Brand	FDA	01/06/2023	148.00	2262.00	01/27/2026	Single Source Drug	None	1	Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: . capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity. . investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to HCAi is subject to the following assumptions and context:  (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e.,  disclosure required if acquired by a manufacturer in the previous five years).
Rx0000138	Merck Sharp & Dohme LLC	09/30/2023	00006412102	GARDASIL 9 0.5 mL Syringes 10	Brand	FDA	08/12/2023	187.62	2867.85	12/10/2028	Single Source Drug	None	1	Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: . capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity. . investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to HCAi is subject to the following assumptions and context:  (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e.,  disclosure required if acquired by a manufacturer in the previous five years). The WAC price does not include the Federal Excise Tax (FET).
Rx0000138	Merck Sharp & Dohme LLC	09/30/2023	00006411903	GARDASIL 9 0.5 mL Vials 10	Brand	FDA	08/12/2023	187.62	2867.85	12/10/2028	Single Source Drug	None	1	Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: . capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity. . investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to HCAi is subject to the following assumptions and context:  (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e.,  disclosure required if acquired by a manufacturer in the previous five years). The WAC price does not include the Federal Excise Tax (FET).
Rx0000138	Merck Sharp & Dohme LLC	09/30/2023	00006482700	VARIVAX 0.5 mL Vials 10	Brand	FDA	08/12/2023	143.32	1735.73	None	Single Source Drug	None	1	Merck periodically increases the list prices of our medicines and vaccines, as reflected in our Pricing Action Transparency Report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: . capital investments in the U.S. of more than $8 billion in the last three years, with planned investment of nearly $10 billion in the U.S. between 2021 and 2025 to increase manufacturing capacity. . investments in research and development that last year alone totaled nearly $13.5 billion ($128 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular and infectious diseases, as well as other major health challenges that affect large numbers of people.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to HCAi is subject to the following assumptions and context:  (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e.,  disclosure required if acquired by a manufacturer in the previous five years). The WAC price does not include the Federal Excise Tax (FET).
Rx0000051	MILLICENT U.S., INC.	03/31/2023	72495020105	FEMRING, RING, 0.05MG/DAY, (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGE PER BOX	Brand	FDA	01/01/2023	60.43	696.54	None	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	485.37	443.67	2003	76.50	None	None
Rx0000051	MILLICENT U.S., INC.	03/31/2023	72495020210	FEMRING, RING, 0.10MG/DAY, (ESTRADIOL ACETATE VAGINAL RING) 1 RING FOR 3 MONTH'S USAGE PER BOX	Brand	FDA	01/01/2023	64.39	742.25	None	Single Source Drug	None	1	None	1	None	1	05/18/2018	Allergan	None	1	None	517.23	472.79	2003	81.50	None	None
Rx0000051	MILLICENT U.S., INC.	03/31/2023	72495040128	Intrarosa, Insert, 6.5mg/1, 28 blister packs per box	Brand	FDA	01/01/2023	14.40	254.42	03/19/2031	Single Source Drug	None	1	None	1	None	1	04/26/2020	AMAG	None	1	None	212.30	202.00	2017	175.00	None	There was an NDC change for this product in 2021 from 64011060128 (AMAG) to 72495040128 (Milicent)
Rx0000046	Mylan Specialty LP	03/31/2023	00037440101	Depen (Penicillamine Tabs) 250mg 1s	Brand	FDA	01/03/2023	471.21	7202.76	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	00037480170	Elestrin 0.06% Gel 35g DualPack 2s	Brand	FDA	01/03/2023	16.35	249.99	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	49502090230	EMSAM TDS Patch 12mg/day 30s	Brand	FDA	01/03/2023	133.64	2042.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	49502090030	EMSAM TDS Patch 6mg/day 30s	Brand	FDA	01/03/2023	133.64	2042.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	49502090130	EMSAM TDS Patch 9mg/day 30s	Brand	FDA	01/03/2023	133.64	2042.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	00037044217	Felbatol 600mg/5mL Oral Suspension 32oz 1s	Brand	FDA	01/03/2023	455.72	6966.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	00037044267	Felbatol 600mg/5mL Oral Suspension 8oz 1s	Brand	FDA	01/03/2023	118.19	1806.59	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	00037043001	Felbatol Tabs 400mg 100s	Brand	FDA	01/03/2023	96.16	1469.94	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	00037043101	Felbatol Tabs 600mg 100s	Brand	FDA	01/03/2023	110.21	1684.64	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	00037682210	Proctofoam HC 1% 10g Foam 1s	Generic	FDA	01/03/2023	11.53	176.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000046	Mylan Specialty LP	03/31/2023	49502080693	YUPELRI Inhalation Solution 175mcg/3mL 30s	Brand	FDA	01/03/2023	85.12	1301.13	10/23/2039	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165002030	ADZENYS XR-ODT 12.5MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165002530	ADZENYS XR-ODT 15.7MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165003030	ADZENYS XR-ODT 18.8MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165000530	ADZENYS XR-ODT 3.1MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165001030	ADZENYS XR-ODT 6.3MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165001530	ADZENYS XR-ODT 9.4MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.34	478.72	06/28/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165020030	COTEMPLA XR-ODT 17.3MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.81	489.27	01/25/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165030030	COTEMPLA XR-ODT 25.9MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.81	489.27	01/25/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000106	Neos Therapeutics, Inc.	06/30/2023	70165010030	COTEMPLA XR-ODT 8.6MG, 30 CT Tablets	Brand	FDA	04/01/2023	21.81	489.27	01/25/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	03/31/2023	72252051002	1 VALTOCO CARTON with 1 10 mg/.1mL VIAL	Brand	FDA	01/01/2023	37.40	660.68	03/27/2029	Single Source Drug	None	1	Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or “list prices” are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential.	None	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	03/31/2023	72252050502	1 VALTOCO CARTON with 1 5 mg/.1mL VIAL	Brand	FDA	01/01/2023	37.40	660.68	03/27/2029	Single Source Drug	None	1	Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or “list prices” are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential.	None	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	03/31/2023	72252052004	1 VALTOCO CARTON with 2 10 mg/.1mL VIALS	Brand	FDA	01/01/2023	37.40	660.68	03/27/2029	Single Source Drug	None	1	Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or “list prices” are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential.	None	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	03/31/2023	72252051504	1 VALTOCO CARTON with 2 7.5 mg/.1mL VIALS	Brand	FDA	01/01/2023	37.40	660.68	03/27/2029	Single Source Drug	None	1	Price actions taken by Neurelis, Inc. reflect evolving market conditions and industry dynamics. A range of financial and nonfinancial factors are considered for price determinations, including but not limited to: research and development costs, manufacturing costs, regulatory costs, wholesaler distribution fees, payer/PBM rebates & fees, patient affordability programs and rising inflation costs. Wholesale Acquisition Cost (WAC) or “list prices” are generally not reflective of the actual cost to patients, health plans, PBMs or government payers, nor are they reflective of the net price or profits realized by the drug manufacturer. Neurelis analyzes the increasing costs associated with providing our products to patients, including the impact of managed care rebate agreements, distribution costs, costs of our patient affordability and access programs, GMP manufacturing costs, costs associated with regulatory obligations and post-marketing commitments, and other costs associated with commercializing a pharmaceutical product in the U.S. For these reasons, the net price received by Neurelis may be quite variable in nature. New and/or increasing discounts, rebates, and service fees continue to be placed on drug manufacturers each year. Neurelis, Inc. does not disclose pricing strategy within the public domain and considers the information to be confidential.	None	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2023	70370204001	INGREZZA ORAL CAPSULE 40 MG, BOTTLE OF 30 CAPSULES	Brand	FDA	12/09/2023	212.00	7514.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2023	70370106001	INGREZZA ORAL CAPSULE 60 MG, BOTTLE OF 30 CAPSULES	Brand	FDA	12/09/2023	233.00	8255.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2023	70370108001	INGREZZA ORAL CAPSULE 80 MG, BOTTLE OF 30 CAPSULES	Brand	FDA	12/09/2023	233.00	8255.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000366	Neurocrine Biosciences, Inc.	12/31/2023	70370204806	INGREZZA ORAL CAPSULE INITIATION PACK 40 MG (7) AND 80 MG (21), BLISTER PACK OF 28 CAPSULES	Brand	FDA	12/09/2023	233.00	8255.00	08/10/2040	Single Source Drug	None	1	Patient access is a priority because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles: -Improving the lives and well-being of patients -Maximizing access and reducing out-of-pocket costs for eligible patients -Striving to reduce obstacles for patients to fill a prescription or undergo treatment -Fueling the discovery and development of life-changing medicines	None	The price increase was not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000204	Noden Pharma USA, Inc.	03/31/2023	70839015030	TEKTURNA 150MG TAB 30/EA	Brand	FDA	01/09/2023	24.00	290.64	08/19/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This report was generated in conjunction with the Registered Prescriber notification (which was distributed via email in the required time period). While conducting internal year-end audit, unclear if this report was filed with California, so re-submitting due to possible oversight of submission.
Rx0000204	Noden Pharma USA, Inc.	03/31/2023	70839030030	TEKTURNA 300MG TAB 30/EA	Brand	FDA	01/09/2023	30.28	366.67	08/19/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This report was generated in conjunction with the Registered Prescriber notification (which was distributed via email in the required time period). While conducting internal year-end audit, unclear if this report was filed with California, so re-submitting due to possible oversight of submission.
Rx0000073	Novartis	03/31/2023	00078063968	COSENTYX® 150mg/ml Sensoready pen 150mg Dose 1 Sensoready pen	Brand	FDA	01/04/2023	452.99	6924.26	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078063941	COSENTYX® 150mg/ml Sensoready pen 300mg Dose 2 Sensoready pens	Brand	FDA	01/04/2023	452.99	6924.26	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078063997	COSENTYX® 150mg/ml Syringe 150mg Dose 1 prefilled syringe	Brand	FDA	01/04/2023	452.99	6924.26	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078063998	COSENTYX® 150mg/ml Syringe 300mg Dose 2 prefilled syringes	Brand	FDA	01/04/2023	452.99	6924.26	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078105697	COSENTYX® 75mg/0.5mL singledose prefilled syringe	Brand	FDA	01/04/2023	226.49	3462.13	05/05/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078065967	ENTRESTO® tablets 24mg/26mg 180s	Brand	FDA	01/04/2023	95.43	2003.94	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078077767	ENTRESTO® tablets 49mg/51mg 180s	Brand	FDA	01/04/2023	95.43	2003.94	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078077720	ENTRESTO® tablets 49mg/51mg 60s	Brand	FDA	01/04/2023	31.81	667.97	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078069667	ENTRESTO® tablets 97mg/103mg 180s	Brand	FDA	01/04/2023	95.43	2003.94	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078069620	ENTRESTO® tablets 97mg/103mg 60s	Brand	FDA	01/04/2023	31.81	667.97	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078065920	ENTRESTO® tablets 24mg/26mg 60s	Brand	FDA	01/04/2023	31.81	667.97	05/09/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078060715	GILENYA® capsules 0.5mg 30s	Brand	FDA	01/04/2023	681.88	10422.99	09/30/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078074303	ILEVRO® 0.3% 3 mL	Brand	FDA	01/04/2023	32.62	362.09	03/31/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from Alcon as portfolio. Acquisition of portfolio was finalized 8/27/2010. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078100768	KESIMPTA® 20 mg/0.4 mL singleuse Sensoready® pen (injection)	Brand	FDA	01/04/2023	534.10	8164.09	12/30/2027	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078090961	KISQALI® FEMARA® COPACK, Kisqali 1 blister pack, containing 21 tablets (200mg per tablet) (200mg daily dose), Femara 2.5mg 28s	Brand	FDA	01/04/2023	485.19	6550.11	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078091661	KISQALI® FEMARA® COPACK, Kisqali 3 blister packs, containing 14 tablets (200mg per tablet) (400mg daily dose), Femara 2.5mg 28s	Brand	FDA	01/04/2023	970.39	13100.27	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078092361	KISQALI® FEMARA® COPACK, Kisqali 3 blister packs, containing 21 tablets (200mg per tablet) (600mg daily dose), Femara 2.5mg 28s	Brand	FDA	01/04/2023	1212.99	16375.34	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078086001	KISQALI® tablets 200mg (200mg daily dose) 1 blister pack x 21 tablets (21 tablets per carton)	Brand	FDA	01/04/2023	485.19	6550.11	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078086742	KISQALI® tablets 200mg (400mg daily dose) 3 blister packs x 14 tablets (42 tablets per carton)	Brand	FDA	01/04/2023	970.39	13100.27	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078087463	KISQALI® tablets 200mg (600mg daily dose) 3 blister packs x 21 tablets (63 tablets per carton)	Brand	FDA	01/04/2023	1212.99	16375.34	04/14/2036	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078097950	MAYZENT® tablets .25mg 28s	Brand	FDA	01/04/2023	140.95	2154.58	11/30/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078098615	MAYZENT® tablets 2mg 30s	Brand	FDA	01/04/2023	604.09	9233.93	11/30/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078070184	PIQRAY® tablets 200mg 28s	Brand	FDA	01/04/2023	1684.98	20406.96	09/28/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078071502	PIQRAY® tablets 250mg 56s	Brand	FDA	01/04/2023	1684.98	20406.96	09/28/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078070802	PIQRAY® tablets 300mg 56s	Brand	FDA	01/04/2023	1684.98	20406.96	09/28/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078097261	PROMACTA powder for oral suspension 12.5mg 30s Kit	Brand	FDA	01/04/2023	554.02	6709.85	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078069761	PROMACTA® powder for oral suspension 25mg 30s Kit	Brand	FDA	01/04/2023	554.05	6710.21	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068415	PROMACTA® tablets 12.5mg 30s	Brand	FDA	01/04/2023	554.02	6709.85	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068515	PROMACTA® tablets 25mg 30s	Brand	FDA	01/04/2023	554.02	6709.85	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068655	PROMACTA® tablets 50mg 14s	Brand	FDA	01/04/2023	467.88	5666.59	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068615	PROMACTA® tablets 50mg 30s	Brand	FDA	01/04/2023	1002.61	12142.71	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068715	PROMACTA® tablets 75mg 30s	Brand	FDA	01/04/2023	1503.91	18214.07	02/01/2028	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078069819	RYDAPT® capsules for oral use 25mg 112s	Brand	FDA	01/04/2023	1597.12	21561.17	12/02/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078069899	RYDAPT® capsules for oral use 25mg 56s	Brand	FDA	01/04/2023	798.56	10780.59	12/02/2030	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	NDC 00078-0698-02 and 00078-0698-51 are not commercially available. The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078070956	TABRECTATM tablets 150mg 56s	Brand	FDA	01/04/2023	799.15	10788.55	07/22/2035	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078071656	TABRECTATM tablets 200mg 56s	Brand	FDA	01/04/2023	799.15	10788.55	07/22/2035	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078068266	TAFINLAR® capsules 50mg 120s	Brand	FDA	01/04/2023	775.27	10466.12	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078068166	TAFINLAR® capsules 75mg 120s	Brand	FDA	01/04/2023	999.13	13488.21	08/30/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Products were acquired from GSK as portfolio. Product was on the market at the time of the acquisition; this NDC was not. Acquisition of portfolio was finalized 3/2/2015. This is prior to the 5 year reporting period.
Rx0000073	Novartis	03/31/2023	00078059287	TASIGNA® 150mg 112 capsules (4 Blister Packs of 28 capsules)	Brand	FDA	01/04/2023	1532.23	18556.96	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078052687	TASIGNA® 200mg 112 capsules (4 Blister Packs of 28 capsules)	Brand	FDA	01/04/2023	1532.23	18556.96	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078095166	TASIGNA® 50 mg capsules 120s	Brand	FDA	01/04/2023	1641.66	19882.38	10/07/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	03/31/2023	00078091112	XIIDRA® 5% 50 mg/mL 60count carton, 12 pouches of 5 singleuse containers (0.2mL each)	Brand	FDA	01/04/2023	50.70	684.45	12/18/2033	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	05/09/2019	Takeda Pharmaceutical Company	3400000000	None	Novartis paid $3.4 billion upfront, plus potential milestone payments of up to $1.9 billion.	553.54	507.00	2016	426.73	None	All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reservesAll such rights. We believe that this submission and ofAll Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and ofAll Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. Product was acquired from Takeda. Acquisition of product was finalized 10/1/2019.
Rx0000073	Novartis	03/31/2023	00078069484	ZYKADIA® 150mg 84s tablets	Brand	FDA	01/04/2023	1096.91	12176.79	02/02/2032	Single Source Drug	None	1	Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000017	Noven Therapeutics, LLC	03/31/2023	68968555203	Daytrana Transdermal Patch 10 MG/9HR - 30 each	Brand	FDA	01/01/2023	22.04	463.01	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2023	68968555303	Daytrana Transdermal Patch 15 MG/9HR - 30 each	Brand	FDA	01/01/2023	22.04	463.01	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2023	68968555403	Daytrana Transdermal Patch 20 MG/9HR - 30 each	Brand	FDA	01/01/2023	22.04	463.01	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000017	Noven Therapeutics, LLC	03/31/2023	68968555503	Daytrana Transdermal Patch 30 MG/9HR - 30 each	Brand	FDA	01/01/2023	22.04	463.01	10/07/2025	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000234	Optinose US, Inc.	03/31/2023	71143037501	XHANCE (fluticasone propionate) (Nasal) 93 MCG/ACT Exhaler Suspension, 1 Exhaler of 16 ML	Brand	FDA	01/01/2023	28.43	596.97	02/23/2036	Single Source Drug	395476	None	Optinose took a 5% price increase on 1/1/2023 as a result of increases in PBM rebates, increases in distribution costs and inflationary factors.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000375	Organon	12/31/2023	78206015001	Pregnyl for Injection 10,000 units/1 vial in package	Brand	FDA	10/02/2023	53.74	170.00	None	Single Source Drug	None	1	This new price represents a market adjustment to align PREGNYL’s WAC pricing more closely with that of the other therapies. PREGNYL’S pricing has remained flat relative to the market for years, where other products in this therapeutic space have taken consistent price increases. PREGNYL’s previous WAC of $116.26 was approximately 63% lower than Novarel and the Fresenius generic, and 47% lower than Ovidrel, and the current price of $170 still represents a 46% discount to the generic.	None	Not applicable	None	06/02/2023	Merck Sharp & Dohme	None	1	Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products. For clarity, this product being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label.	116.26	106.56	1993	25.00	None	Pregnyl no longer under patent, no date to report.
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148004580	Abilify Maintena 300mg Dual Chamber Syringe	Brand	FDA	01/15/2023	124.47	2039.42	09/24/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148001871	Abilify Maintena 300mg Kit	Brand	FDA	01/15/2023	124.47	2039.42	09/24/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148007280	Abilify Maintena 400mg Dual Chamber Syringe	Brand	FDA	01/15/2023	165.96	2719.23	09/24/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148001971	Abilify Maintena 400mg Kit	Brand	FDA	01/15/2023	165.96	2719.23	09/24/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148008213	Jynarque 15mg tablets, 30 count bottle	Brand	FDA	01/15/2023	598.44	9805.14	04/07/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148007928	Jynarque 15mg/15mg 4x weekly blister cards	Brand	FDA	01/15/2023	1117.08	18302.92	04/07/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148008313	Jynarque 30mg tablets, 30 count bottle	Brand	FDA	01/15/2023	598.44	9805.14	04/07/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148008028	Jynarque 30mg/15mg 4x weekly blister cards	Brand	FDA	01/15/2023	1117.08	18302.92	04/07/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148008728	Jynarque 45mg/15mg 4x weekly blister cards	Brand	FDA	01/15/2023	1117.08	18302.92	04/07/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148008828	Jynarque 60mg/30mg 4x weekly blister cards	Brand	FDA	01/15/2023	1117.08	18302.92	04/07/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148008928	Jynarque 90mg/30mg 4x weekly blister cards	Brand	FDA	01/15/2023	1117.08	18302.92	04/07/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148003513	Rexulti 0.25mg tablets, 30 count bottle	Brand	FDA	01/15/2023	86.61	1419.04	10/12/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148003613	Rexulti 0.5mg tablets, 30 count bottle	Brand	FDA	01/15/2023	86.61	1419.04	10/12/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148003713	Rexulti 1mg tablets, 30 count bottle	Brand	FDA	01/15/2023	86.61	1419.04	10/12/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148003813	Rexulti 2mg tablets, 30 count bottle	Brand	FDA	01/15/2023	86.61	1419.04	10/12/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148003913	Rexulti 3mg tablets, 30 count bottle	Brand	FDA	01/15/2023	86.61	1419.04	10/12/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/31/2023	59148004013	Rexulti 4mg tablets, 30 count bottle	Brand	FDA	01/15/2023	86.61	1419.04	12/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000495	Otter Pharmaceuticals LLC	03/31/2023	10094021001	Sympazan (clobazam) oral film 10mg (1ct)	Brand	FDA	01/01/2023	1.48	31.76	09/05/2039	Single Source Drug	None	1	Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.	None	No Change	None	10/26/2022	Acquestive Therapeutics, Inc.	15000000	None	None	30.28	28.70	2018	26.00	None	None
Rx0000495	Otter Pharmaceuticals LLC	03/31/2023	10094021060	Sympazan (clobazam) oral film 10mg (60ct)	Brand	FDA	01/01/2023	88.80	1905.60	09/05/2039	Single Source Drug	None	1	Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.	None	No Change	None	10/26/2022	Acquestive Therapeutics, Inc.	15000000	None	None	1816.80	1722.00	2018	1560.00	None	None
Rx0000495	Otter Pharmaceuticals LLC	03/31/2023	10094022001	Sympazan (clobazam) oral film 20mg (1ct)	Brand	FDA	01/01/2023	2.97	63.53	09/05/2039	Single Source Drug	None	1	Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.	None	No Change	None	10/26/2022	Acquestive Therapeutics, Inc.	15000000	None	None	60.56	57.40	2018	52.00	None	None
Rx0000495	Otter Pharmaceuticals LLC	03/31/2023	10094022060	Sympazan (clobazam) oral film 20mg (60ct)	Brand	FDA	01/01/2023	178.20	3811.80	09/05/2039	Single Source Drug	None	1	Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.	None	No Change	None	10/26/2022	Acquestive Therapeutics, Inc.	15000000	None	None	3633.60	3444.00	2018	3120.00	None	None
Rx0000495	Otter Pharmaceuticals LLC	03/31/2023	10094020501	Sympazan (clobazam) oral film 5mg (1ct)	Brand	FDA	01/01/2023	0.74	15.88	09/05/2039	Single Source Drug	None	1	Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.	None	No Change	None	10/26/2022	Acquestive Therapeutics, Inc.	15000000	None	None	15.14	14.35	2018	13.00	None	None
Rx0000495	Otter Pharmaceuticals LLC	03/31/2023	10094020560	Sympazan (clobazam) oral film 5mg (60ct)	Brand	FDA	01/01/2023	44.40	952.80	09/05/2039	Single Source Drug	None	1	Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.	None	No Change	None	10/26/2022	Acquestive Therapeutics, Inc.	15000000	None	None	908.40	861.00	2018	780.00	None	None
Rx0000192	OWP Pharmaceuticals, Inc.	03/31/2023	69102063909	Lamotrigine USP Blue Starter Kit (35 25mg Tablets)	Generic	FDA	02/01/2023	37.00	505.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000192	OWP Pharmaceuticals, Inc.	03/31/2023	69102035911	Lamotrigine USP Green Starter Kit 98 Tablets (84 25mg, 14 100mg)	Generic	FDA	02/01/2023	105.00	1414.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000192	OWP Pharmaceuticals, Inc.	03/31/2023	69102013710	Lamotrigine USP Orange Starter Kit 49 Tablets (42 25mg, 7 100mg)	Generic	FDA	02/01/2023	55.00	735.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000192	OWP Pharmaceuticals, Inc.	03/31/2023	69102030601	Subvenite (lamotrigine USP) Blue Starter Kit (35 25mg Tablets)	Generic	FDA	02/01/2023	37.00	505.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000192	OWP Pharmaceuticals, Inc.	03/31/2023	69102031201	Subvenite (lamotrigine USP) Green Starter Kit 98 Tablets (84 25mg, 14 100mg)	Generic	FDA	02/01/2023	105.00	1414.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000192	OWP Pharmaceuticals, Inc.	03/31/2023	69102030001	Subvenite (lamotrigine USP) Orange Starter Kit, 49 Tablets (42 25mg, 7 100mg)	Generic	FDA	02/01/2023	55.00	735.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000101	Par Pharmaceutical	09/30/2023	42023010501	BREVITAL SODIUM METHOHEXITAL SODIUM INJECTABLE 500MG/VIAL	Brand	FDA	07/10/2023	6.44	92.36	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/24/2023, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000101	Par Pharmaceutical	09/30/2023	42023011925	TIGAN TRIMETHOBENZAMIDE HYDROCHLORIDE INJECTABLE 100MG/ML, 25vl	Brand	FDA	07/10/2023	87.57	1255.18	None	Single Source Drug	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 10/24/2023, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product.
Rx0000053	Paratek Pharmaceuticals, Inc.	09/30/2023	71715000102	Nuzyra 100mg Vial 10 Vials	Brand	FDA	07/01/2023	123.59	4243.06	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	09/30/2023	71715000227	Nuzyra 150mg Oral Tablet 30 ct/ Carton	Brand	FDA	07/01/2023	223.25	7664.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	09/30/2023	71715000221	Nuzyra 150mg Oral Tablet 6 ct/ Carton	Brand	FDA	07/01/2023	44.65	1532.94	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	03/31/2023	71715000227	Nuzyra Oral Tablet 150 MG 30 pack	Brand	FDA	01/01/2023	216.75	7441.59	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000053	Paratek Pharmaceuticals, Inc.	03/31/2023	71715000221	Nuzyra Oral Tablet 150 MG 6 pack	Brand	FDA	01/01/2023	43.34	1488.29	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000006	Pfizer	09/30/2023	00409005101	ADD-Vantage, ADDapter Connector, 1	Brand	Medispan	07/01/2023	3.67	40.36	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00008042303	Antivenin (micrurus fulvius equine origin), 10mL, 1 VIAL	Brand	FDA	01/01/2023	313.55	6584.74	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00008042303	Antivenin (micrurus fulvius equine origin), 10mL, VIAL (ML), 1	Brand	FDA	07/01/2023	329.24	6913.98	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00009722402	ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, 5 AMPULS (ML)	Brand	FDA	01/01/2023	1431.45	15745.91	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009722402	ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, Ampul(ML), 5	Brand	FDA	07/01/2023	1574.59	17320.50	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409963005	ATROPINE SULFATE (atropine sulfate), 0.05 mg/mL, SYRINGE (ML), 1	Brand	FDA	07/01/2023	18.52	203.75	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793060010	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), 10 SYRINGES (ML)	Brand	FDA	01/01/2023	166.05	1826.58	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793060110	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1	Brand	FDA	07/01/2023	182.66	2009.24	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793060010	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1	Brand	FDA	07/01/2023	182.66	2009.24	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793060210	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (900,000/300,000), 10 SYRINGES (ML)	Brand	FDA	01/01/2023	166.05	1826.58	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793060210	BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (900,000/300,000), SYRINGE (ML), 1	Brand	FDA	07/01/2023	182.66	2009.24	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793060110	BICILLIN C-R (penicillin G benzathine/penicillin Gprocaine), 1,200,000 unit/2 mL (600,000/600,000), 10 SYRINGES (ML)	Brand	FDA	01/01/2023	166.05	1826.58	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793070110	BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	208.31	2291.42	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793070110	BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, SYRINGE (ML), 1	Brand	FDA	07/01/2023	229.14	2520.56	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793070210	BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	426.86	4695.50	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793070210	BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, SYRINGE (ML), 1	Brand	FDA	07/01/2023	469.55	5165.05	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793070010	BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	120.28	1323.03	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	60793070010	BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, SYRINGE (ML), 1	Brand	FDA	07/01/2023	132.30	1455.33	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069013501	BOSULIF (bosutinib), 100 mg, 120 TABLETS	Brand	FDA	01/01/2023	1371.57	18733.27	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069013501	BOSULIF (bosutinib), 100 mg, TABLET, 1	Brand	FDA	07/01/2023	749.33	19482.60	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069019301	BOSULIF (bosutinib), 400 mg, 1x30 BT TABLETS	Brand	FDA	01/01/2023	1371.57	18733.27	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069019301	BOSULIF (bosutinib), 400 mg, TABLET, 1	Brand	FDA	07/01/2023	749.33	19482.60	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069013601	BOSULIF (bosutinib), 500 mg, 30 TABLETS	Brand	FDA	01/01/2023	1371.57	18733.27	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069013601	BOSULIF (bosutinib), 500 mg, TABLET, 1	Brand	FDA	07/01/2023	749.33	19482.60	04/13/2024	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	70255002503	BRAFTOVI (encorafenib), 75 mg, 2X60 BTL CAPSULES	Brand	FDA	01/01/2023	1056.52	14430.23	08/27/2030	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	70255002501	BRAFTOVI (encorafenib), 75 mg, 2X90 BTL CAPSULES	Brand	FDA	01/01/2023	1056.52	14430.23	08/27/2030	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	70255002503	BRAFTOVI (encorafenib), 75 mg, CAPSULE, 120	Brand	FDA	07/01/2023	577.21	15007.44	08/27/2030	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs. The acquisition price is $11,200,000,000. The system would not allow us to enter the full acquisition price.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	70255002501	BRAFTOVI (encorafenib), 75 mg, CAPSULE, 180	Brand	FDA	07/01/2023	577.21	15007.44	08/27/2030	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs. The acquisition price is $11,200,000,000. The system would not allow us to enter the full acquisition price.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409162301	BUTORPHANOL TARTRATE (butorphanol tartrate), 1 mg/mL, 10 VIALs (ML)	Generic	FDA	01/01/2023	5.07	55.74	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409162601	BUTORPHANOL TARTRATE (butorphanol tartrate), 2 mg/mL, 10 VIALS	Generic	FDA	01/01/2023	6.20	68.17	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409162602	BUTORPHANOL TARTRATE (butorphanol tartrate), 2 mg/mL, 10 VIALS (ML)	Generic	FDA	01/01/2023	8.73	95.98	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409162301	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 1 mg/mL (1 mg/mL) Single Dose Glass Fliptop Vial, 10	Generic	FDA	07/01/2023	5.57	61.31	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409162601	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (2 mg/mL) Single Dose Glass Fliptop Vial, 10	Generic	FDA	07/01/2023	6.82	74.99	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409162602	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial, 10	Generic	FDA	07/01/2023	9.60	105.58	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069600125	CEREBYX (fosphenytoin sodium), 100 mg PE/2 mL, 25 VIALS (ML)	Brand	FDA	01/01/2023	45.84	962.66	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069600121	CEREBYX (fosphenytoin sodium), 500 mg PE/10 mL, 10 VIALS (ML)	Brand	FDA	01/01/2023	55.01	1155.19	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409477723	CIPROFLOXACIN-D5W, 200 mg/100 mL, INTRAVENOUS SOLUTION (ML), 100	Generic	Medispan	07/01/2023	8.73	66.96	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409477702	CIPROFLOXACIN-D5W, 400 mg/200 mL, INTRAVENOUS SOLUTION (ML), 200	Generic	Medispan	07/01/2023	10.78	82.64	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409409201	COPPER CHLORIDE (cupric chloride), 0.4 mg/mL, 25 VIALS	Brand	FDA	01/01/2023	54.15	595.65	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409409201	COPPER CHLORIDE (cupric chloride), 0.4 mg/mL, VIAL (ML), 25	Brand	FDA	07/01/2023	59.57	655.22	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409337301	CORLOPAM (fenoldopam mesylate), 10 mg/mL, 1 VIAL (ML)	Brand	Medispan	01/01/2023	42.95	497.90	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409337302	CORLOPAM (fenoldopam mesylate), 20 mg/mL, 1 VIAL (ML)	Brand	Medispan	01/01/2023	85.90	995.81	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009379422	CORVERT (ibutilide fumarate), 0.1 mg/mL, VIAL (ML), 10	Brand	FDA	07/01/2023	26.14	548.85	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009379401	CORVERT (ibutilide fumarate), 1 mg/10 mL, VIAL (ML), 10	Brand	FDA	07/01/2023	26.14	548.85	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069153130	DAURISMO (glasdegib maleate), 100 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1181.16	20867.27	01/30/2031	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069029860	DAURISMO (glasdegib maleate), 25 mg, 1X60 BTL TABLETS	Brand	FDA	01/01/2023	1181.16	20867.27	01/30/2031	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409118130	DEMEROL (meperidine HCl), 50 mg/mL, 1 VIAL (ML)	Brand	FDA	01/01/2023	8.53	93.85	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409136201	DEMEROL (meperidine HCl/PF), 25 mg/mL, 1X10 NEXJECT SYRINGE (ML)	Brand	FDA	01/01/2023	8.05	88.51	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409136201	DEMEROL (meperidine HCl/PF), 25 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	8.85	97.36	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409141801	DEMEROL (meperidine HCl/PF), 50 mg/mL, 1X10 NEXJECT SYRINGE (ML)	Brand	FDA	01/01/2023	8.92	98.15	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409117830	DEMEROL (meperidine HCl/PF), 50 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	6.87	75.54	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409141801	DEMEROL (meperidine HCl/PF), 50 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	9.82	107.97	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409118130	Demerol™ (meperidine hydrochloride) Injection - Controlled Substance - SCHEDULE II Rx, 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial, 1	Brand	FDA	07/01/2023	9.39	103.24	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00009027101	DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, 1 VIAL (ML)	Generic	FDA	01/01/2023	14.01	154.10	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009027101	DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, VIAL (ML), 1	Generic	FDA	07/01/2023	14.55	168.65	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409741903	Dextran (dextran) Injection Rx, 500 mL (10% LMD in 0.9% Sodium Chloride), Intravenous solution, 12	Generic	FDA	07/01/2023	39.85	438.38	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409741803	Dextran (dextran) Injection Rx, 500 mL (10% LMD in 5% Dextrose), Intravenous solution, 12	Generic	FDA	07/01/2023	38.72	425.87	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409741903	Dextran (dextran), LMD 10% WITH 0.9% SOD CHLORIDE (dextran 40 in 0.9 % sodium chloride), 10 % (100 mg/mL), 12 VIALS	Generic	FDA	01/01/2023	36.23	398.53	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409741803	Dextran (dextran), LMD 10% WITH 5% DEXTROSE (dextran 40 in dextrose 5 % in water), 10 %, 12 VIALS	Generic	FDA	01/01/2023	35.20	387.15	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409582001	DOPAMINE HCL (dopamine HCl), 200 mg/5 mL (40 mg/mL), 25 VIALS	Brand	FDA	01/01/2023	11.07	84.89	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409582001	DOPAMINE HCL (dopamine HCl), 200 mg/5 mL (40 mg/mL), VIAL (ML), 25	Brand	FDA	07/01/2023	4.24	89.13	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409493301	EPINEPHRINE (epinephrine), 0.1 mg/mL, 1X10 ABBJ SYRINGE (ML)	Brand	FDA	01/01/2023	6.34	69.72	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409493301	Epinephrine Injection Rx, 1mg/10mL (0.1 mg/mL) ABBOJECT Single-dose syringe, 10	Brand	FDA	07/01/2023	6.97	76.69	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409127632	FENTANYL CITRATE (fentanyl citrate), 100 mcg/2 mL (50 mcg/mL), CARTRIDGE (ML), 2	Generic	Medispan	07/01/2023	2.31	25.44	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909311	FENTANYL CITRATE (fentanyl citrate), 100 mcg/2 mL, CARTRIDGE (ML), 2	Brand	FDA	07/01/2023	0.75	8.20	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909332	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, AMPUL (ML), 2	Brand	FDA	07/01/2023	1.62	17.85	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909335	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, AMPUL (ML), 5	Brand	FDA	07/01/2023	2.17	23.84	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909428	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 10	Brand	FDA	07/01/2023	8.49	93.40	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909422	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 2	Brand	FDA	07/01/2023	3.50	38.50	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909431	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 20	Brand	FDA	07/01/2023	17.64	194.01	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909425	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 5	Brand	FDA	07/01/2023	5.25	57.74	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409909461	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 50	Brand	FDA	07/01/2023	49.47	544.14	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069021702	FRAGMIN (dalteparin sodium,porcine), 10,000 unit/mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	99.81	1097.88	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069022002	FRAGMIN (dalteparin sodium,porcine), 12,500 unit/0.5 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	124.77	1372.45	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069022302	FRAGMIN (dalteparin sodium,porcine), 15,000 unit/0.6 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	149.71	1646.84	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069022802	FRAGMIN (dalteparin sodium,porcine), 18,000 unit/0.72 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	179.66	1976.21	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069019502	FRAGMIN (dalteparin sodium,porcine), 2,500 unit/0.2 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	30.76	338.35	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069023201	FRAGMIN (dalteparin sodium,porcine), 25,000 unit/mL, 1 VIAL (ML)	Brand	FDA	01/01/2023	85.79	943.68	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069019602	FRAGMIN (dalteparin sodium,porcine), 5,000 unit/0.2 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	49.90	548.94	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069020602	FRAGMIN (dalteparin sodium,porcine), 7,500 unit/0.3 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	74.86	823.50	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069021702	Fragmin® (dalteparin sodium) Injection Rx, 10,000 IU/1 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	109.79	1207.67	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069022002	Fragmin® (dalteparin sodium) Injection Rx, 12,500 IU/0.5 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	137.25	1509.70	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069022302	Fragmin® (dalteparin sodium) Injection Rx, 15,000 IU/0.6 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	164.68	1811.52	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069022802	Fragmin® (dalteparin sodium) Injection Rx, 18,000 IU/0.72 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards test potency, 10	Brand	FDA	07/01/2023	197.62	2173.83	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069019502	Fragmin® (dalteparin sodium) Injection Rx, 2,500 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	33.84	372.19	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069019602	Fragmin® (dalteparin sodium) Injection Rx, 5,000 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	54.89	603.83	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069020602	Fragmin® (dalteparin sodium) Injection Rx, 7,500 IU/0.3 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	Brand	FDA	07/01/2023	82.35	905.85	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069023201	Fragmin® (dalteparin sodium) Injection Rx, 95,000 IU/3.8 mL Multidose Vial, 1	Brand	FDA	07/01/2023	94.37	1038.05	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409163910	FUROSEMIDE (furosemide), 10 mg/mL, 10 SYRINGES (ML)	Generic	Medispan	01/01/2023	22.43	246.76	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409120703	GENTAMICIN SULFATE (gentamicin sulfate), 40 mg/mL, 25 VIALS (ML)	Generic	FDA	01/01/2023	8.80	44.01	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409120703	Gentamicin Sulfate Injection Rx, 40 mg/mL (80 mg/2 mL) Single Dose Glass Fliptop Vial, 25	Generic	FDA	07/01/2023	11.00	55.01	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409765062	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 100 Units/mL (25,000 Units/250 mL) Flexible Container, 24	Brand	FDA	07/01/2023	28.22	310.38	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409765062	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 100 Units/mL (25,000 Units/250 mL) Flexible Container, 24 VIALS	Brand	FDA	01/01/2023	25.65	282.16	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409765162	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 50 Units/mL (12,500 Units/250 mL) Flexible Container, 24	Generic	Medispan	07/01/2023	24.41	268.47	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409765162	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 50 Units/mL (12,500 Units/250 mL) Flexible Container, 24 VIALS	Generic	Medispan	01/01/2023	22.19	244.06	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409131632	HEPARIN SODIUM (heparin sodium, porcine), 5000 unit/0.5 mL, CARTRIDGE (ML), 0.5	Generic	FDA	07/01/2023	18.79	206.71	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409140212	HEPARIN SODIUM (heparin sodium, porcine), 5000 unit/mL (1 mL), CARTRIDGE (ML), 1	Generic	FDA	07/01/2023	15.92	175.13	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409765103	HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride), 25,000 unit/500 mL (50 unit/mL), 24 VIALS	Generic	Medispan	01/01/2023	19.33	212.66	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409724803	HETASTARCH-0.9% NACL (hetastarch in 0.9 % sodium chloride), 6 %-0.9 %, 12 VIALS (ML)	Generic	FDA	01/01/2023	45.71	228.54	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409155554	HEXTEND LACTATED ELECTROLYTE (hetastarch/electrolyte solution,lactated), 500mL, Vial, 12	Brand	FDA	07/01/2023	95.07	1045.78	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409155554	HEXTEND LACTATED ELECTROLYTE (hetastarch/electrolyte solution,lactated), 6 %, 12 VIALS (ML)	Brand	FDA	01/01/2023	86.43	950.71	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409128305	HYDROMORPHONE HCL (hydromorphone HCl), 0.5 mg/0.5 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	3.14	34.49	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409255201	HYDROMORPHONE HCL (hydromorphone HCl), 1 mg/mL, 10 AMPULS (ML)	Brand	FDA	01/01/2023	2.24	24.61	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409128337	HYDROMORPHONE HCL (hydromorphone HCl), 1 mg/mL, 1X10 NEXTJECT SYRINGES (ML)	Brand	FDA	01/01/2023	4.05	44.57	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409128337	HYDROMORPHONE HCL (hydromorphone HCl), 1 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	4.46	49.03	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409263401	HYDROMORPHONE HCL (hydromorphone HCl), 10 mg/mL, VIAL (ML), 1	Generic	FDA	07/01/2023	3.90	42.86	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409131236	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, 1X10 NEXJECT SYRINGES (ML)	Brand	FDA	01/01/2023	5.43	59.73	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409131230	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	3.06	33.66	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409131236	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	5.97	65.70	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409336510	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, VIAL (ML), 1	Brand	FDA	07/01/2023	1.74	19.16	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409130431	HYDROMORPHONE HCL (hydromorphone HCl), 4 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	2.86	31.45	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409255201	Hydromorphone Hydrochloride Injection - Controlled Substance - SCHEDULE II Rx, 1 mg/mL (1 mg/1 mL) Glass Ampul, 10	Brand	FDA	07/01/2023	2.46	27.07	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069018821	IBRANCE (palbociclib), 100 mg, 21 CAPSULES	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069048603	IBRANCE (palbociclib), 100 mg, 3X7 BLST TABLETS	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069018921	IBRANCE (palbociclib), 125 mg, 21 CAPSULES	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069068803	IBRANCE (palbociclib), 125 mg, 3X7 BLST TABLETS	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069018721	IBRANCE (palbociclib), 75 mg, 21 CAPSULES	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069028403	IBRANCE (palbociclib), 75 mg, 3X7 BLST TABLETS	Brand	FDA	01/01/2023	1103.93	15077.73	03/05/2027	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069014501	INLYTA (axitinib), 1 mg, 180 TABLETS	Brand	FDA	01/01/2023	1404.28	19180.05	04/29/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069014501	INLYTA (axitinib), 1 mg, TABLET, 1	Brand	FDA	07/01/2023	767.20	19947.25	04/29/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069015111	INLYTA (axitinib), 5 mg, 60 TABLETS	Brand	FDA	01/01/2023	1404.28	19180.05	04/29/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069015111	INLYTA (axitinib), 5 mg, TABLET, 1	Brand	FDA	07/01/2023	767.20	19947.25	04/29/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409233934	LABETALOL HCL (labetalol HCI), 20 mg/4 mL (5 mg/mL), CARTRIDGE (ML), 4	Generic	FDA	07/01/2023	8.26	90.83	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069023101	LORBRENA (lorlatinib), 100 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1475.33	20150.44	03/05/2033	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069022701	LORBRENA (lorlatinib), 25 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	491.77	6716.83	03/05/2033	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409175410	MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), 10 SYRINGES (ML)	Generic	FDA	01/01/2023	23.00	253.03	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409175410	MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), SYRINGE (ML), 1	Generic	FDA	07/01/2023	25.30	278.33	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409409101	MANGANESE CHLORIDE (manganese chloride), 0.1 mg/mL, 25 VIALS	Brand	FDA	01/01/2023	63.66	700.21	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409409101	MANGANESE CHLORIDE (manganese chloride), 0.1 mg/mL, VIAL (ML), 25	Brand	FDA	07/01/2023	70.02	770.23	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	70255001002	MEKTOVI (binimetinib), 15 mg, 1X180 BTL TABLETS	Brand	FDA	01/01/2023	1036.58	14157.96	07/04/2031	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	70255001002	MEKTOVI (binimetinib), 15 mg, TABLET, 180	Brand	FDA	07/01/2023	566.32	14724.28	07/04/2031	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	07/30/2019	Array BioPharma Inc.	1120000000	None	On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in Restructuring charges and certain acquisition-related costs. The acquisition price is $11,200,000,000. The system would not allow us to enter the full acquisition price.	11499.00	10977.00	2018	10977.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409189323	MORPHINE SULFATE (morphine sulfate), 10 mg/mL, 1X10 NEXJECT SYRINGES (ML)	Brand	FDA	01/01/2023	4.20	46.16	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189301	MORPHINE SULFATE (morphine sulfate), 10 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	2.10	23.09	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189323	MORPHINE SULFATE (morphine sulfate), 10 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	4.62	50.78	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409189023	MORPHINE SULFATE (morphine sulfate), 2 mg/mL, 1X10 NEXTJECT SYRINGES (ML)	Brand	FDA	01/01/2023	3.54	38.96	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189023	MORPHINE SULFATE (morphine sulfate), 2 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	3.90	42.86	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409189123	MORPHINE SULFATE (morphine sulfate), 4 mg/mL, 1X10 NEXTJECT SYRINGES (ML)	Brand	FDA	01/01/2023	3.57	39.27	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189123	MORPHINE SULFATE (morphine sulfate), 4 mg/mL, SYRINGE (ML), 10	Brand	FDA	07/01/2023	3.93	43.20	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409189201	MORPHINE SULFATE (morphine sulfate), 8 mg/mL, CARTRIDGE (ML), 1	Brand	FDA	07/01/2023	2.10	23.09	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069131202	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1	Brand	FDA	07/01/2023	59.80	2048.20	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069110902	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1	Brand	FDA	07/01/2023	14.95	512.05	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069141502	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1	Brand	FDA	07/01/2023	119.60	4096.40	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069155802	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1	Brand	FDA	07/01/2023	178.96	6144.16	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00069122402	Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1	Brand	FDA	07/01/2023	29.90	1024.10	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793013110	PENICILLIN G PROCAINE (penicillin G procaine), 1.2 million unit/2 mL, 10 SYRINGES (ML)	Generic	Medispan	01/01/2023	70.23	772.48	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe factors for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	60793013010	PENICILLIN G PROCAINE (penicillin G procaine), 600,000 unit/mL, 10 SYRINGES (ML)	Generic	Medispan	01/01/2023	41.77	459.51	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409299914	PIPERACILLIN-TAZOBACTAM (piperacillin sodium/tazobactam sodium), 13.5 gram, VIAL (EA), 1	Generic	FDA	07/01/2023	5.43	59.69	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409796905	PLEGISOL (cardioplegic solution no.1), 16 mEq/L (potassium), 12 PLASTIC BAG, PERFUSION (ML)	Brand	FDA	01/01/2023	69.89	768.80	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409796905	PLEGISOL (cardioplegic solution), 1000mL, PLASTIC BAG, PERFUSION (ML), 12	Brand	FDA	07/01/2023	76.88	845.68	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00009335901	PREPIDIL (dinoprostone), 0.5 mg/3 gram, 1X3G PLST GEL WITH PREFILLED APPLICATOR (GRAM)	Brand	FDA	01/01/2023	32.74	687.52	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009335901	PREPIDIL (dinoprostone), 0.5 mg/3 gram, GEL WITH PREFILLED APPLICATOR (GRAM), 1	Brand	FDA	07/01/2023	34.38	721.90	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409553414	SODIUM BICARBONATE (sodium bicarbonate), 0.5 mEq/mL, 1X10 ABBJ SYR SYRINGES (ML)	Generic	FDA	01/01/2023	13.74	151.09	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409491614	SODIUM BICARBONATE (sodium bicarbonate), 0.9 mEq/mL, 1X10 ABBJ SYR SYRINGES (ML)	Generic	FDA	01/01/2023	17.79	195.69	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409663714	SODIUM BICARBONATE (sodium bicarbonate), 1 mEq/mL (8.4 %), 1X10 ABBJ SYR SYRINGES (ML)	Generic	FDA	01/01/2023	13.10	144.11	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409490014	SODIUM BICARBONATE (sodium bicarbonate), 10 mEq/10 mL (8.4 %), 1X10 ABBJ SYR SYRINGES (ML)	Generic	FDA	01/01/2023	17.74	195.13	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409553414	Sodium Bicarbonate Injection Rx, 4.2% (5mEq/10mL) per glass Abboject® syringe, 10	Generic	FDA	07/01/2023	15.11	166.20	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409491614	Sodium Bicarbonate Injection Rx, 7.5% (44/6 mEq/50mL) per glass Abboject® syringe, 10	Generic	FDA	07/01/2023	19.57	215.26	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409490014	Sodium Bicarbonate Injection Rx, 8.4% (10mEq/10mL) per glass vial Abboject® syringe, 10	Generic	FDA	07/01/2023	19.51	214.64	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409663714	Sodium Bicarbonate Injection Rx, 8.4% (50mEq/50mL) per glass Abbotject® syringe, 10	Generic	FDA	07/01/2023	14.41	158.52	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409739172	SODIUM PHOSPHATE (sodium phosphate,monobasic-dibasic), 3 mmol/mL, 25 VIALS	Brand	FDA	01/01/2023	76.15	456.92	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009082501	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg, VIAL (EA) 1	Brand	FDA	07/01/2023	0.69	14.38	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001103	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL (EA) 1	Brand	FDA	07/01/2023	0.93	19.43	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001104	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL (EA), 1	Brand	FDA	07/01/2023	23.14	485.90	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001305	SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL, VIAL (EA) 1	Brand	FDA	07/01/2023	1.71	35.95	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001306	SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL, VIAL (EA), 1	Brand	FDA	07/01/2023	42.80	898.76	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009001612	SOLU-CORTEF (hydrocortisone sodium succinate), 500 mg/4 mL, VIAL (EA), 1	Brand	FDA	07/01/2023	3.43	71.93	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00009000501	SOLU-CORTEF(hydrocortisone sodium succinate), 1000 mg/8 mL, VIAL (EA), 1	Brand	FDA	07/01/2023	6.85	143.83	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409338221	SUFENTANIL CITRATE (sufentanil citrate), 50 mcg/mL, VIAL (ML), 1	Generic	FDA	07/01/2023	6.50	71.48	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069055038	SUTENT (sunitinib malate), 12.5 mg, 28 CAPSULES	Brand	FDA	01/01/2023	298.49	6268.37	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069077038	SUTENT (sunitinib malate), 25 mg, 28 CAPSULES	Brand	FDA	01/01/2023	596.98	12536.76	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069083038	SUTENT (sunitinib malate), 37.5 mg, 28 CAPSULES	Brand	FDA	01/01/2023	895.48	18805.14	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069098038	SUTENT (sunitinib malate), 50 mg, 28 CAPSULES	Brand	FDA	01/01/2023	1039.27	21824.72	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409159304	THAM (tromethamine), 36 mg/mL (0.3 M), INTRAVENOUS SOLUTION, 6	Brand	FDA	07/01/2023	176.97	1946.69	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409159304	THAM (tromethamine), 36 mg/mL (0.3 M), Tham (Tromethamine) Inj Solution 500ml, 1 VIAL	Brand	FDA	01/01/2023	160.88	1769.72	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409357801	TOBRAMYCIN SULFATE (tobramycin sulfate), 40 mg/mL, VIAL (ML), 2	Generic	FDA	07/01/2023	6.78	74.61	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409577901	TPN ELECTROLYTES (multiple electrolyte additive) Solution Rx, 20 mL, 25 VIALS	Brand	FDA	01/01/2023	17.62	193.80	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409577901	TPN ELECTROLYTES (multiple electrolyte additive) Solution Rx, 20 mL, VIAL (ML), 25	Brand	FDA	07/01/2023	19.38	213.18	None	Innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00005010010	TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg/0.5 mL, 10 SYRINGES (ML)	Brand	FDA	01/01/2023	115.51	1789.55	10/01/2026	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00005010005	TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg/0.5 mL, 5 SYRINGES (ML)	Brand	FDA	01/01/2023	57.75	894.77	10/01/2026	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409963305	VERAPAMIL HCL (verapamil HCl), 2.5 mg/mL, 10 SYRINGES (ML)	Generic	FDA	01/01/2023	61.05	671.53	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	09/30/2023	00409963305	Verapamil Hydrochloride Injection Rx, 2.5 mg/mL (10 mg/4 mL) Ansyr™ Plastic Syringe, 10	Generic	FDA	07/01/2023	67.15	738.68	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	61703030906	VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, 1 VIAL	Generic	FDA	01/01/2023	10.30	16.14	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	61703030926	VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, 1 VIAL (ML)	Generic	FDA	01/01/2023	8.36	14.11	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	61703030925	VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL, 1 VIAL	Generic	FDA	01/01/2023	4.76	15.45	None	Non-innovator Multiple Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	61703030916	VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL, 1 VIAL (ML)	Generic	FDA	01/01/2023	3.16	14.00	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069019730	VIZIMPRO (dacomitinib), 15 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1139.40	15562.32	08/26/2028	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069119830	VIZIMPRO (dacomitinib), 30 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1139.40	15562.32	08/26/2028	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069229930	VIZIMPRO (dacomitinib), 45 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	1139.40	15562.32	08/26/2028	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069814120	XALKORI (crizotinib), 200 mg, 60 CAPSULES	Brand	FDA	01/01/2023	1549.10	21157.97	10/08/2029	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069814020	XALKORI (crizotinib), 250 mg, 60 CAPSULES	Brand	FDA	01/01/2023	1549.10	21157.97	10/08/2029	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069100201	XELJANZ (tofacitinib citrate), 10 mg, XELJANZ 10mg FCT 1x60 BTL TABLETS	Brand	FDA	01/01/2023	312.10	5513.77	12/08/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069100101	XELJANZ (tofacitinib citrate), 5 mg, 60 TABLETS	Brand	FDA	01/01/2023	312.10	5513.77	12/08/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069050130	XELJANZ XR (tofacitinib citrate), 11 mg, 1x30 TABLETS	Brand	FDA	01/01/2023	312.10	5513.77	12/08/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00069050230	XELJANZ XR (tofacitinib citrate), 22 mg, 1X30 BTL TABLETS	Brand	FDA	01/01/2023	312.10	5513.77	12/08/2025	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	03/31/2023	00409409001	ZINC CHLORIDE (zinc chloride), 1 mg/mL, 25 VIALS	Brand	FDA	01/01/2023	53.84	592.30	None	Single Source Drug	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-21, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121064610	Amantadine HCl Oral Solution 50 MG/5ML, 10mL, 100ct, oral solution in one unit dose cup	Generic	FDA	12/11/2023	38.50	359.35	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121154410	HYDROcodone-Acetaminophen Oral Solution 2.5-108 MG/5ML, 10mL single count unit dose cup	Generic	FDA	12/11/2023	1.23	9.41	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121477205	HYDROcodone-Acetaminophen Oral Solution 2.5-108 MG/5ML, 5mL single count unit dose cup	Generic	FDA	12/11/2023	1.11	8.45	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121154440	HYDROcodone-Acetaminophen Oral Solution 2.5-108 MG/5ML, 5mL, 40 count unit dose cup	Generic	FDA	12/11/2023	49.08	376.29	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121477240	HYDROcodone-Acetaminophen Oral Solution 2.5-108 MG/5ML, 5mL, 40 count unit dose cups	Generic	FDA	12/11/2023	44.06	337.81	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121202410	Lacosamide Oral Solution 10 MG/ML, 10mL single unit dose cup	Generic	FDA	12/11/2023	9.81	49.03	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121202495	Lacosamide Oral Solution 10 MG/ML, 10mL, 10ct unit dose cups	Generic	FDA	12/11/2023	98.05	490.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121303615	Lacosamide Oral Solution 10 MG/ML, 15mL single unit dose cup	Generic	FDA	12/11/2023	14.71	73.54	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121303695	Lacosamide Oral Solution 10 MG/ML, 15mL, 10 count unit dose cups	Generic	FDA	12/11/2023	147.08	735.38	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121404895	Lacosamide Oral Solution 10 MG/ML, 20mL, 10ct unit dose cups	Generic	FDA	12/11/2023	196.10	980.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121404874	Lacosamide Oral Solution 10 MG/ML, 20mL, one single dose cup	Generic	FDA	12/11/2023	19.61	98.05	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121101295	Lacosamide Oral Solution 10 MG/ML, 5mL 10count unit dos cups	Generic	FDA	12/11/2023	49.03	245.13	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121101205	Lacosamide Oral Solution 10 MG/ML, 5mL single unit dos cup	Generic	FDA	12/11/2023	4.90	24.51	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121115400	Lactulose Oral Solution 10 GM/15ML, 100ct 30mL unit dose cups	Generic	FDA	04/01/2023	44.14	112.04	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121457715	Lactulose Oral Solution 10 GM/15ML, 15mL UDC, 15ct	Generic	FDA	12/11/2023	0.38	1.46	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121457740	Lactulose Oral Solution 10 GM/15ML, 15mL Unit dose cups, 100 count	Generic	FDA	12/11/2023	15.12	58.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121115430	Lactulose Oral Solution 10 GM/15ML, 30mL single UDC	Generic	FDA	12/11/2023	0.38	1.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121115400	Lactulose Oral Solution 10 GM/15ML, 30mL UDC, 100ct	Generic	FDA	12/11/2023	39.21	151.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121115440	Lactulose Oral Solution 10 GM/15ML, 30mL UDC, 40ct	Generic	FDA	12/11/2023	15.12	65.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121115440	Lactulose Oral Solution 10 GM/15ML, 40ct 30mL unit dose cups, 10 UDCs per tray, 4 trays in one carton	Generic	FDA	04/01/2023	18.90	50.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121457740	Lactulose Oral Solution 10 GM/15ML, one single 15mL unit dose cup	Generic	FDA	04/01/2023	16.20	43.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121457715	Lactulose Oral Solution 10 GM/15ML, single 15mL unit dose cup	Generic	FDA	04/01/2023	0.40	1.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121115430	Lactulose Oral Solution 10 GM/15ML, single 30mL unit dose cup	Generic	FDA	04/01/2023	0.47	1.26	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121090315	Lidocaine Viscous HCl Mouth/Throat Solution 2 % 15mL, 1 unit dose cup	Generic	FDA	06/01/2023	1.78	3.74	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121090340	Lidocaine Viscous HCl Mouth/Throat Solution 2 % 15mL, 40CT Unit Dose Cups 10 cups in 4 trays.	Generic	FDA	06/01/2023	71.00	149.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	0.00	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121157610	Metoclopramide HCl Oral Solution 10 MG/10ML, 10mL 100ct Unit Dose Cups	Generic	FDA	12/11/2023	52.85	405.21	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121086805	Nystatin Mouth/Throat Suspension 100000 UNIT/ML, 20mL Unit Dose Cup	Generic	FDA	12/11/2023	0.56	1.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121086850	Nystatin Mouth/Throat Suspension 100000 UNIT/ML, 20mL, 40ct Unit Dose cups	Generic	FDA	12/11/2023	28.00	98.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121086800	Nystatin Mouth/Throat Suspension 100000 UNIT/ML, 5mL, 100ct Unit Dose Cups	Generic	FDA	12/11/2023	51.00	188.85	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121085320	Sulfamethoxazole-Trimethoprim Oral Suspension 200-40 MG/5ML 20 mL Unit dose cup Oral Suspension	Generic	Medispan	12/11/2023	4.97	14.91	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121085340	Sulfamethoxazole-Trimethoprim Oral Suspension 200-40 MG/5ML 20mL, 40ct Unit Dose Cups, Oral Suspension	Generic	Medispan	12/11/2023	198.84	596.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	06/30/2023	00121067585	VALPROIC ACID ORAL SOLN - 16oz Rx 12/cs 250 MG/5ML	Generic	FDA	06/01/2023	6.25	18.75	12/15/2020	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121135010	Valproic Acid Oral Solution 250 MG/5ML, 10mL 1 single unit dose	Generic	FDA	12/11/2023	0.64	2.24	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121135000	Valproic Acid Oral Solution 250 MG/5ML, 10mL, 100ct unit dose cups	Generic	FDA	12/11/2023	64.14	224.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121467505	Valproic Acid Oral Solution 250 MG/5ML, 5mL single unit dose cup	Generic	FDA	12/11/2023	0.37	1.25	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121467500	Valproic Acid Oral Solution 250 MG/5ML, 5mL, 100ct unit dose cups	Generic	FDA	12/11/2023	36.90	124.79	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	12/31/2023	00121467540	Valproic Acid Oral Solution 250 MG/5ML, 5mL, 40ct unit dose cups	Generic	FDA	12/11/2023	22.47	78.65	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000319	Pharmacosmos Therapeutics	12/31/2023	73594931001	Monoferric (ferric derisomaltose), Injection 1000mg/10mL 1 unit vial	Brand	FDA	10/01/2023	214.41	3006.27	06/22/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962014012	Imbruvica 120 Oral Capsule 140 MG	Brand	FDA	01/01/2023	1324.68	22690.52	04/24/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962007028	Imbruvica 28 Oral Capsule 70 MG	Brand	FDA	01/01/2023	927.28	15883.36	04/24/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962001428	Imbruvica 28 Oral Tablet 140 MG	Brand	FDA	01/01/2023	927.28	15883.36	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962028028	Imbruvica 28 Oral Tablet 280 MG	Brand	FDA	01/01/2023	927.28	15883.36	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962042028	Imbruvica 28 Oral Tablet 420 MG	Brand	FDA	01/01/2023	927.28	15883.36	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962056028	Imbruvica 28 Oral Tablet 560 MG	Brand	FDA	01/01/2023	927.28	15883.36	03/03/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000237	Pharmacyclics an AbbVie Company	03/31/2023	57962014009	Imbruvica 90 Oral Capsule 140 MG	Brand	FDA	01/01/2023	993.51	17017.89	04/24/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000469	Pharming Healthcare Inc	03/31/2023	71274035002	Ruconest 2100 U; Injection; Powder for Solution; 1 Carton	Brand	FDA	01/13/2023	410.00	7270.00	10/07/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	03/29/2024	81140010210	RoxyBond Oral Tablet Abuse-Deterrent 15 MG sold to pharmacists in bottles of 100 tablets	Brand	FDA	04/01/2023	141.46	1570.30	08/12/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	03/29/2024	81140010310	RoxyBond Oral Tablet Abuse-Deterrent 30 MG sold to pharmacists in bottles of 100 tablets	Brand	FDA	04/01/2023	190.64	2116.28	08/12/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	03/29/2024	81140010110	RoxyBond Oral Tablet Abuse-Deterrent 5 MG sold to pharmacists in bottles of 100 tablets	Brand	FDA	04/01/2023	114.70	1273.28	08/12/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050203	EMFLAZA (deflazacort) 18mg tabs/30 ct	Brand	FDA	01/16/2023	664.94	7738.67	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	3925.00	0.00	2017	3925.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050203	EMFLAZA (deflazacort) 18mg tabs/30 ct	Brand	FDA	05/01/2023	1470.34	9209.01	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	3925.00	0.00	2017	3925.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050522	EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE	Brand	FDA	01/16/2023	486.72	5664.51	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	2873.00	0.00	2017	2873.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050522	EMFLAZA (deflazacort) 22.75 mg/ml susp/13 mL in 1 BOTTLE	Brand	FDA	05/01/2023	1076.25	6740.76	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	2873.00	0.00	2017	2873.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050303	EMFLAZA (deflazacort) 30mg tabs/30 ct	Brand	FDA	01/16/2023	1108.27	12898.43	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	6542.00	0.00	2017	6542.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050303	EMFLAZA (deflazacort) 30mg tabs/30 ct	Brand	FDA	05/01/2023	2450.71	15349.14	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	6542.00	0.00	2017	6542.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050403	EMFLAZA (deflazacort) 36mg tabs/30 ct	Brand	FDA	01/16/2023	1282.95	14931.40	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	7290.00	0.00	2017	7290.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050403	EMFLAZA (deflazacort) 36mg tabs/30 ct	Brand	FDA	05/01/2023	2836.96	17768.36	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	7290.00	0.00	2017	7290.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	03/31/2023	52856050101	EMFLAZA (deflazacort) 6mg tabs/100 ct	Brand	FDA	01/16/2023	738.80	8598.30	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	4361.00	0.00	2017	4361.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000236	PTC Therapeutics, Inc	06/30/2023	52856050101	EMFLAZA (deflazacort) 6mg tabs/100 ct	Brand	FDA	05/01/2023	1633.68	10231.98	None	Single Source Drug	None	1	None	1	None	1	04/01/2017	Marathon Pharmaceuticals	140000000	None	None	4361.00	0.00	2017	4361.00	None	Price increase for all strengths only includes PTC NDC related products. The product was launched in 2017 under Marathon's NDC, 42998, and has since been removed from the market.
Rx0000220	Puma Biotechnology, Inc.	03/31/2023	70437024033	Nerlynx Oral Tablet 40 mg, 133 tablet package	Brand	FDA	01/13/2023	1055.00	15295.00	07/18/2031	Single Source Drug	619	None	Inflation has driven up costs in almost all areas of operations.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000220	Puma Biotechnology, Inc.	03/31/2023	70437024018	Nerlynx Oral Tablet 40 mg, 180 tablet package	Brand	FDA	01/13/2023	1425.00	20700.00	07/18/2031	Single Source Drug	11943	None	Inflation has driven up costs in almost all areas of operations.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000462	QOL Medical LLC	03/31/2023	67871011101	Sacrosidase Solution 8500 Unit/ML, 118 ML, Bottle	Brand	FDA	01/01/2023	165.67	4309.36	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000462	QOL Medical LLC	03/31/2023	67871011104	Sacrosidase Solution 8500 Unit/ML, 118 ML, Bottle Qty 2	Brand	FDA	01/01/2023	331.34	8618.72	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000356	Radius Health, Inc.	03/31/2023	70539000101	TYMLOS 80 MCG Pen	Brand	FDA	01/01/2023	226.64	2515.98	01/10/2040	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 03/16/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000356	Radius Health, Inc.	03/31/2023	70539000102	TYMLOS 80 MCG Pen / Carton	Brand	FDA	01/01/2023	226.64	2515.98	01/10/2040	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 03/16/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292020111	Chemet Oral Capsule 100 MG Package Size 100 Quantity 1	Brand	FDA	01/05/2023	178.08	2404.02	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292081155	Cosmegen Intravenous Solution Reconstituted 0.5 MG Package Size 1 Quantity 1	Brand	FDA	01/05/2023	234.99	2708.54	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292041005	Cystadrops Ophthalmic Solution 0.37 % Package Size 5 Quantity 1	Brand	FDA	01/05/2023	59.62	2046.88	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292032020	Isturisa Oral Tablet 1 MG 20 EA	Brand	FDA	05/01/2023	275.02	3169.98	10/12/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292032060	Isturisa Oral Tablet 1 MG 60 EA	Brand	FDA	05/01/2023	825.06	9509.93	10/12/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292032220	Isturisa Oral Tablet 10 MG 20 EA	Brand	Medispan	05/01/2023	1100.84	12688.66	10/12/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292032260	Isturisa Oral Tablet 10 MG 60 EA	Brand	Medispan	05/01/2023	3302.25	38065.96	10/12/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292032120	Isturisa Oral Tablet 5 MG 20 EA	Brand	FDA	06/16/2023	6091.72	15849.88	10/12/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292032160	Isturisa Oral Tablet 5 MG 60 EA	Brand	FDA	06/16/2023	18275.18	47549.65	10/12/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292012252	NeoProfen Intravenous Solution 10 MG/ML Package Size 2 Package Quantity 3	Brand	FDA	01/05/2023	280.32	3231.09	03/02/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292070255	Panhematin Intravenous Solution Reconstituted 350 MG Package Size 1 Quantity 1	Brand	FDA	01/05/2023	751.08	10139.59	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292013901	Signifor LAR Intramuscular Suspension Reconstituted ER 10 MG	Brand	FDA	06/23/2023	717.57	16663.56	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	00078074881	Signifor LAR Intramuscular Suspension Reconstituted ER 10 MG Package Size 1 Quantity 1	Brand	Medispan	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292013901	Signifor LAR Intramuscular Suspension Reconstituted ER 10mg Package Size 1 Quantity 1	Brand	FDA	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292014001	Signifor LAR Intramuscular Suspension Reconstituted ER 20 MG	Brand	FDA	06/23/2023	717.57	16663.56	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	00078064181	Signifor LAR Intramuscular Suspension Reconstituted ER 20 MG Package Size 1 Package Quantity 1	Brand	Medispan	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292014001	Signifor LAR Intramuscular Suspension Reconstituted ER 20mg Package Size 1 Quantity 1	Brand	FDA	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292014101	Signifor LAR Intramuscular Suspension Reconstituted ER 30 MG	Brand	FDA	06/23/2023	717.57	16663.56	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	00078074181	Signifor LAR Intramuscular Suspension Reconstituted ER 30 MG Size 1 Package Quantity 1	Brand	Medispan	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292014101	Signifor LAR Intramuscular Suspension Reconstituted ER 30mg Package Size 1 Quantity 1	Brand	FDA	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292014201	Signifor LAR Intramuscular Suspension Reconstituted ER 40 MG	Brand	FDA	06/23/2023	717.57	16663.56	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	00078064281	Signifor LAR Intramuscular Suspension Reconstituted ER 40 MG Size 1 Package Quantity 1	Brand	Medispan	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292014201	Signifor LAR Intramuscular Suspension Reconstituted ER 40mg Package Size 1 Quantity 1	Brand	FDA	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292014301	Signifor LAR Intramuscular Suspension Reconstituted ER 60 MG	Brand	FDA	06/23/2023	717.57	16663.56	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	00078064381	Signifor LAR Intramuscular Suspension Reconstituted ER 60 MG Size 1 Package Quantity 1	Brand	Medispan	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292014301	Signifor LAR Intramuscular Suspension Reconstituted ER 60mg Package Size 1 Quantity 1	Brand	FDA	01/05/2023	759.33	15945.99	05/23/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292013160	Signifor Subcutaneous Solution 0.3 MG/ML	Brand	FDA	06/23/2023	755.92	17554.12	12/14/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	00078063320	Signifor Subcutaneous Solution 0.3 MG/ML Package size 1 Package Quantity 60	Brand	Medispan	01/05/2023	799.91	16798.20	12/14/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292013160	Signifor Subcutaneous Solution 0.3MG Package Size 1 Package Quantity 60	Brand	FDA	01/05/2023	799.91	16798.20	12/14/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292013260	Signifor Subcutaneous Solution 0.6 MG/ML	Brand	FDA	06/23/2023	755.92	17554.12	12/14/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	00078063420	Signifor Subcutaneous Solution 0.6 MG/ML Package size 1 Package Quantity 60	Brand	Medispan	01/05/2023	799.91	16798.20	12/14/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292013260	Signifor Subcutaneous Solution 0.6MG Package Size 1 Package Quantity 60	Brand	FDA	01/05/2023	799.91	16798.20	12/14/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	06/30/2023	55292013360	Signifor Subcutaneous Solution 0.9 MG/ML	Brand	FDA	06/23/2023	755.92	17554.12	12/14/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	00078063520	Signifor Subcutaneous Solution 0.9 MG/ML Package size 1 Package Quantity 60	Brand	Medispan	01/05/2023	799.91	16798.20	12/14/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	03/31/2023	55292013360	Signifor Subcutaneous Solution 0.9MG Package Size 1 Package Quantity 60	Brand	FDA	01/05/2023	799.91	16798.20	12/14/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000166	Redhill Biopharma, Inc.	03/31/2023	57841115001	Talicia Oral Capsule Delayed Release 250-12.5-10 MG	Brand	FDA	01/01/2023	28.35	382.73	None	Single Source Drug	21552	None	Increased inflation costs and manufacturing agreement costs for product	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000166	Redhill Biopharma, Inc.	03/31/2023	57841115002	Talicia Oral Capsule Delayed Release 250-12.5-10MG	Brand	FDA	01/01/2023	56.70	765.46	None	Single Source Drug	21552	None	Increased inflation costs and manufacturing agreement costs for product	None	None	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000239	Rigel Pharmaceuticals, Inc.	03/31/2023	71332000101	Tavalisse 100 mg oral tablet 60 count	Brand	FDA	01/04/2023	780.00	13800.00	07/27/2032	Single Source Drug	None	1	Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000239	Rigel Pharmaceuticals, Inc.	03/31/2023	71332000201	Tavalisse 150 mg oral tablet 60 count	Brand	FDA	01/04/2023	780.00	13800.00	07/27/2032	Single Source Drug	None	1	Rigel's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Rigel to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000158	RISING PHARMA HOLDINGS, INC.	09/30/2023	70199002611	AQUASOL A PARENTERAL 50,000	Brand	FDA	07/10/2023	143.75	718.75	None	Single Source Drug	16368	None	The last time the WAC was changed on the product was in 12/30/2020 which is approximately 2.5 years ago. This WAC change is 25% above the current WAC of $575. The is not a retail product and has very low usage. Even though the WAC has changed 07/10/2023 Casper has sold enough inventory at the previous WAC to support the trade for 60 days include wholesaler inventory and inventory in the channel. Casper has also implemented a state notification module with a third party vendor for timely filling and responses in the future.	None	The last time the WAC was changed on the product was in 12/30/2020 which is approximately 2.5 years ago. This WAC change is 25% above the current WAC of $575. The is not a retail product and has very low usage.Even though the WAC has changed 07/10/2023 Casper has sold enough inventory at the previous WAC to support the trade for 60 days include wholesaler inventory and inventory in the channel. Casper has also implemented a state notification module with a third party vendor for timely filling and responses in the future.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000158	RISING PHARMA HOLDINGS, INC.	12/31/2023	64980044715	CALCITRIOL ORAL SOL 1MCG/ML 15ML	Generic	FDA	11/14/2023	325.00	400.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000158	RISING PHARMA HOLDINGS, INC.	12/31/2023	64980058206	CHLORZOXAZONE TAB 250 MG 60CT	Generic	FDA	10/27/2023	489.68	1134.68	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000158	RISING PHARMA HOLDINGS, INC.	12/31/2023	16571060096	CROMOLYN SODIUM ORAL SOL CONC 100MG/5ML 96CT	Generic	FDA	11/13/2023	300.00	600.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000158	RISING PHARMA HOLDINGS, INC.	09/30/2023	64980052660	NITAZOXANIDE TABLETS 500MG 6CT	Generic	FDA	08/01/2023	429.30	780.55	None	Non-innovator Multiple Source Drug	None	1	Rising was the first company to receive an FDA approval for the generic equivalent to the brand (Alinia). The methodology used to price the new prescriptions drug was a discount on the brand equivalent. Rising's listed price i.e. WAC is priced 10.23% lower than the brand listed price. The price was decided on the fact that we are the first generic entrant in the market. The 6ct pack size price is in pill parity with the 12ct pack size.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649040001	PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), Kit	Brand	FDA	01/01/2023	7.73	138.74	09/10/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649055102	RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial	Brand	FDA	01/01/2023	8.71	153.85	12/30/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649055103	RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct	Brand	FDA	01/01/2023	60.96	1076.94	12/30/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649055107	RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial	Brand	FDA	01/01/2023	8.71	153.85	12/30/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649055204	RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct	Brand	FDA	01/01/2023	60.96	1076.94	12/30/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649015090	RELISTOR® (methylnaltrexone bromide) Tablets 150mg, 90ct	Brand	FDA	01/01/2023	145.87	2323.02	03/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649000330	Trulance® (plecanatide) 3mg Tablets, 30	Brand	FDA	01/01/2023	30.49	538.67	06/05/2034	Single Source Drug	None	1	None	1	None	1	03/01/2019	Synergy Pharmaceuticals Inc.	None	1	Bausch Health acquired certain assets of Synergy Pharmaceuticals Inc. including Trulance in a transaction valued at approximately $200 million plus certain assumed liabilities. https://ir.bauschhealth.com/news-releases/2018/12-12-2018-113003808	411.78	388.47	2017	353.48	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	70194000330	Trulance® (plecanatide) 3mg Tablets, Blister Pack of 30	Brand	Medispan	01/01/2023	30.49	538.67	06/05/2034	Single Source Drug	None	1	None	1	None	1	03/01/2019	Synergy Pharmaceuticals Inc.	None	1	Bausch Health acquired certain assets of Synergy Pharmaceuticals Inc. including Trulance in a transaction valued at approximately $200 million plus certain assumed liabilities. https://ir.bauschhealth.com/news-releases/2018/12-12-2018-113003809	411.78	388.47	2017	353.48	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649065103	UCERIS® (budesonide) Rectal Aerosol, Foam, two 54 ml Canisters, 2 mg/actuation	Brand	FDA	01/01/2023	52.49	813.29	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649030303	XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card	Brand	FDA	01/01/2023	184.47	3159.79	10/02/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	03/31/2023	65649030302	XIFAXAN® (rifaximin) 550mg Tablets, 60ct	Brand	FDA	01/01/2023	184.47	3159.79	10/02/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000011	Sanofi	03/31/2023	58468021004	AUBAGIO® (teriflunomide) 14 mg tablet - bottle of 30	Brand	FDA	01/03/2023	511.12	9029.72	02/04/2034	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	In the U.S., generics of teriflunomide entered the market mid-March 2023, as per settlements with generic manufacturers in 2017.
Rx0000011	Sanofi	09/30/2023	58468021004	AUBAGIO® (teriflunomide) 14 mg tablet - bottle of 30	Brand	FDA	07/01/2023	316.05	9345.77	08/04/2034	Innovator Multiple Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	In the U.S., generics of teriflunomide entered the market mid-March 2023, as per settlements with generic manufacturers in 2017. The patent expiration date of the last to expire patent was extended by six months of pediatric exclusivity from 4 February 2034 to 4 August 2034.
Rx0000011	Sanofi	03/31/2023	58468021104	AUBAGIO® (teriflunomide) 7 mg tablet - bottle of 30	Brand	FDA	01/03/2023	511.12	9029.72	02/04/2034	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	In the U.S., generics of teriflunomide entered the market mid-March 2023, as per settlements with generic manufacturers in 2017.
Rx0000011	Sanofi	09/30/2023	58468021104	AUBAGIO® (teriflunomide) 7 mg tablet - bottle of 30	Brand	FDA	07/01/2023	316.05	9345.77	08/04/2034	Innovator Multiple Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	In the U.S., generics of teriflunomide entered the market mid-March 2023, as per settlements with generic manufacturers in 2017. The patent expiration date of the last to expire patent was extended by six months of pediatric exclusivity from 4 February 2034 to 4 August 2034.
Rx0000011	Sanofi	09/30/2023	00024515010	ELITEK® (rasburicase) 1.5 mg vial/kit - 3 kits	Brand	FDA	07/01/2023	62.58	3191.63	None	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	09/30/2023	00024515175	ELITEK® (rasburicase) 7.5 mg vial/kit - 1 kit	Brand	FDA	07/01/2023	104.30	5319.38	None	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	09/30/2023	00024582411	JEVTANA® (cabazitaxel) 60 mg/1.5 mL vial kit - 1 kit	Brand	FDA	07/01/2023	264.02	13465.19	04/27/2031	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	As per patent litigation settlements with generic manufacturers, Sanofi expects generic competition in Q2/Q3 2029. In addition to the method of treating patent referenced in the Patent Expiration Date field (US Patent No. 8,927,592), there are three other extant U.S. patents for this product (US Patent Nos. 7,241,907 expiring 10 June 2026, and 10,583,110 and 10,716,777 both having expiration dates of 27 October 2030.
Rx0000011	Sanofi	03/31/2023	00024592001	KEVZARA® (sarilumab) 150 mg/1.14 mL pen - carton of 2 pens	Brand	FDA	01/03/2023	231.93	4097.28	09/19/2031	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2023	00024590801	KEVZARA® (sarilumab) 150 mg/1.14 mL syringe - carton of 2 syringes	Brand	FDA	01/03/2023	231.93	4097.28	09/19/2031	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2023	00024592201	KEVZARA® (sarilumab) 200 mg/1.14 mL pen - carton of 2 pens	Brand	FDA	01/03/2023	231.93	4097.28	09/19/2031	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2023	00024591001	KEVZARA® (sarilumab) 200 mg/1.14 mL syringe - carton of 2 syringes	Brand	FDA	01/03/2023	231.93	4097.28	09/19/2031	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	03/31/2023	00024586201	Mozobil® (plerixafor) 24 mg/1.2 mL (20mg/mL)	Brand	FDA	01/03/2023	652.12	9968.07	07/22/2023	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	There are there are two extant U.S. patents for this product (US Patent Nos. 6,987,102 and 7,897,590), which both are directed to methods of using Mozobil® and both have expiration dates of July 22, 2023, which is the date reported in the Patent Expiration Date field.
Rx0000011	Sanofi	03/31/2023	58468008001	Thymoglobulin® (anti-thymocyte globulin [rabbit]) - 25mg inj 1 Vial	Brand	FDA	01/03/2023	48.61	1020.74	None	Single Source Drug	None	1	Sanofi acknowledges its role in preserving a sustainable health care system and in limiting our contribution to U.S. health care spending growth. Our approach to pricing our medicines responsibly balances: • Our ambition to chase the miracles of science to improve people’s lives and ensure patients have access to the medicines they need now and in the future; • Government policies; and • Evolving trends in the marketplace. Should Sanofi take list price actions during the fiscal year (Jan. 1 to Dec. 31) on any of our medicines, the guiding principle is to adhere to a level that is consistent with our approach on responsible pricing. Sanofi will annually disclose additional background if price actions trigger a prescription drug inflation rebate under the Inflation Reduction Act of 2022. The revised “Limited U.S. Price Increases” policy is effective as of January 1, 2023. Previous price increases were evaluated based on our policy originally established in 2016. More about our updated pricing policies can be found at: https://www.sanofi.us/en/corporate-responsibility/pricing-principles/limited-us-price-increases	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000092	Santarus, Inc.	03/31/2023	68012025820	CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct	Brand	FDA	01/01/2023	75.56	1110.65	04/30/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000086	Seagen, Inc.	06/30/2023	51144005001	ADCETRIS, 50mg, single-dose vial, packaged singly	Brand	FDA	06/29/2023	408.00	10878.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000086	Seagen, Inc.	12/31/2023	51144005001	ADCETRIS, 50mg, single-dose vial, packaged singly	Brand	FDA	12/28/2023	424.00	11302.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Healthcare Access and Information ("HCAI") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product.
Rx0000086	Seagen, Inc.	03/31/2023	51144002001	PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution	Brand	FDA	03/30/2023	99.00	2651.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000086	Seagen, Inc.	09/30/2023	51144002001	PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution	Brand	FDA	09/28/2023	103.00	2754.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000086	Seagen, Inc.	03/31/2023	51144003001	PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution	Brand	FDA	03/30/2023	148.50	3976.50	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000086	Seagen, Inc.	09/30/2023	51144003001	PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution	Brand	FDA	09/28/2023	154.50	4131.00	12/31/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
Rx0000086	Seagen, Inc.	12/31/2023	51144000212	TUKYSA, 150mg, 120 Count Oral Tablet per Bottle	Brand	FDA	12/28/2023	2116.00	25630.00	03/25/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000086	Seagen, Inc.	12/31/2023	51144000260	TUKYSA, 150mg, 60 Count Oral Tablet per Bottle	Brand	FDA	12/28/2023	1058.00	12815.00	03/25/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000086	Seagen, Inc.	12/31/2023	51144000160	TUKYSA, 50mg, 60 Count Oral Tablet per Bottle	Brand	FDA	12/28/2023	526.00	6373.00	03/25/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000121	Secura Bio, Inc.	12/31/2023	73116021556	Copiktra Duvelisib Oral Capsule 15 MG, 56ct	Brand	FDA	12/15/2023	2402.08	26422.84	05/17/2032	Single Source Drug	None	1	None	1	Price increase is to help offset the costs of mandatory clinical trials and other regulatory costs. In addition, the company is still selling this product as a loss as well as not producing net income on a company basis at this time. Price increase is being taken to better position the product with its competitors.	None	09/30/2020	Verastem, Inc.	35000000	None	None	12390.00	11800.00	2018	11800.00	None	None
Rx0000121	Secura Bio, Inc.	12/31/2023	73116022556	Copiktra Duvelisib Oral Capsule 25 MG, 56ct	Brand	FDA	12/15/2023	2402.08	26422.84	05/17/2032	Single Source Drug	None	1	None	1	Price increase is to help offset the costs of mandatory clinical trials and other regulatory costs. In addition, the company is still selling this product as a loss as well as not producing net income on a company basis at this time. Price increase is being taken to better position the product with its competitors.	None	09/30/2020	Verastem, Inc.	35000000	None	None	12390.00	11800.00	2018	11800.00	None	None
Rx0000028	Servier Pharmaceuticals LLC	03/31/2023	72694095401	Oncaspar Injection Solution 750 UNIT/ML, 5 ML, Unit-Dose, Vial	Brand	FDA	01/01/2023	2079.67	24322.13	06/01/2037	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	Not applicable	None	04/16/2018	Shire Oncology	None	1	None	14544.54	13467.17	1994	896.45	None	Patent application pending
Rx0000028	Servier Pharmaceuticals LLC	03/31/2023	72694061760	Tibsovo Oral Tablet 250 MG, 60 Each, Bottle	Brand	FDA	01/01/2023	2105.80	32188.60	06/07/2039	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including, but not limited to, clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, commercial and government rebates, patient support, and overall research and development costs.	None	Not applicable	None	04/06/2021	Agios Pharmaceuticals	None	1	None	28380.00	27420.75	2018	26115.00	None	None
Rx0000542	Singular Dreamer, Ltd	12/31/2023	83035121509	TM-Vite Rx #90 Tablets ASCORBIC ACID 60 mg RIBOFLAVIN 1.7 mg NIACINAMIDE 20 mg PYRIDOXINE 10 mg FOLIC ACID 1 mg CYANOCOBALAMIN 6 ug BIOTIN 300 ug PANTOTHENIC ACID 10 mg THIAMINE MONONITRATE 1.5 mg	Generic	Medispan	11/08/2023	259.20	562.50	None	Innovator Multiple Source Drug	1196	None	Initial market analysis only took account of cost basis. During premarket launch this analysis was redone to take into account competitive products within the marketplace and price was adjust accordly.	None	See column 10	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000175	Sobi Inc	03/31/2023	66658023407	KINERET (anakinra) 100 MG/0.67 ML SYRINGE. 7 syringes in 1 carton (.67 ML in 1 syringe).	Brand	FDA	01/01/2023	95.42	1288.14	None	Single Source Drug	None	1	Sobi, Inc., pricing decisions regarding the Wholesale Acquisition Cost (“WAC”) price of medication are determined after careful consideration of several interdependent factors, including but not limited to the clinical and economic value of the medicine.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000244	Sprout Pharmaceuticals, Inc.	12/31/2023	58604021430	Addyi - FLIBANSERIN 100mg Oral Tablet, 30ct Bottle - [Qty:1]	Brand	FDA	12/18/2023	306.50	829.00	05/09/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000221	Strides Pharma, Inc.	03/31/2023	64380018202	Omeprazole NaHCO3 Powder 20mg/1.68gm, 30	Generic	FDA	03/07/2023	2320.90	2620.90	None	Non-innovator Multiple Source Drug	530	None	The product was recently acquired from Par Pharmaceuticals. Strides began marketing the drug in November 2022 and set a low WAC relative to the rest of the market. In order to remain competitive Strides raise the WAC to the original PAR price of $2620.90. This is the same published WAC for other generic suppliers such as Ajanta and Oceanside. The brand Zegerid sold by Santarus WAC is currently $3306.82	None	No change or improvement. WAC was increased to bring back in line with the rest of the market on this product	None	11/05/2022	Par Pharmaceuticals	6	None	None	300.00	2620.90	2016	2620.90	None	None
Rx0000221	Strides Pharma, Inc.	03/31/2023	64380018302	Omeprazole NaHCO3 Powder 40mg/1.68gm, 30	Generic	FDA	03/07/2023	2320.90	2620.90	None	Non-innovator Multiple Source Drug	852	None	The product was recently acquired from Par Pharmaceuticals. Strides began marketing the drug in November 2022 and set a low WAC relative to the rest of the market. In order to remain competitive Strides raise the WAC to the original PAR price of $2620.90. This is the same published WAC for other generic suppliers such as Ajanta and Oceanside. The brand Zegerid sold by Santarus WAC is currently $3306.82	None	No change or improvement. WAC was increased to bring back in line with the rest of the market on this product	None	11/05/2022	Par Pharmaceuticals	6	None	None	300.00	2620.90	2016	2620.90	None	None
Rx0000005	Sumitomo Pharma America, Inc.	12/31/2023	72974041501	Myfembree (40 mg relugolix, 1mg estradiol, and .5 mg norethindrone acetate) oral tablets 28 per bottle	Brand	FDA	12/30/2023	81.50	1168.21	None	Single Source Drug	None	1	Sumitomo Pharma America, Inc. has made the decision to increase the WAC price of the applicable product effective December 30th 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000005	Sunovion Pharmaceuticals Inc.	03/31/2023	63402020230	Aptiom 30 Tablets 200 MG 30 Pack	Brand	FDA	01/01/2023	78.30	1198.80	05/06/2023	Single Source Drug	None	1	Sunovion has made the decision to increase the WAC price of the applicable product effective January 1st, 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000005	Sunovion Pharmaceuticals Inc.	03/31/2023	63402020430	Aptiom 30 Tablets 400 MG 30 Pack	Brand	FDA	01/01/2023	78.30	1198.80	05/06/2023	Single Source Drug	None	1	Sunovion has made the decision to increase the WAC price of the applicable product effective January 1st, 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000005	Sunovion Pharmaceuticals Inc.	03/31/2023	63402020830	Aptiom 30 Tablets 800 MG 30 Pack	Brand	FDA	01/01/2023	78.30	1198.80	05/06/2023	Single Source Drug	None	1	Sunovion has made the decision to increase the WAC price of the applicable product effective January 1st, 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000005	Sunovion Pharmaceuticals Inc.	03/31/2023	63402020660	Aptiom 60 Tablets 600 MG 60 Pack	Brand	FDA	01/01/2023	156.60	2397.60	05/06/2023	Single Source Drug	None	1	Sunovion has made the decision to increase the WAC price of the applicable product effective January 1st, 2023. This price change is due to increases in the cost of business operations related to the product that are consistent with inflation over the past 12 months.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	27505000401	Apokyn Subcutaneous Solution Cartridge 30 MG/3ML Package Size 3 Package Quantiy 1	Brand	FDA	01/01/2023	157.21	1478.31	None	Innovator Multiple Source Drug	None	1	None	1	No change or improvement to the drug.	None	06/09/2020	US Worldmeds	None	1	Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available.	1100.00	1058.00	2004	995.00	None	NDC 27505000401 is the inner level of a multi-level package. As such it is not listed separately on the FDA NDC Directory, it is instead included in the package description of NDC 2705000405. Supernus only markets the 27505000405 NDC.
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	27505000405	Apokyn Subcutaneous Solution Cartridge 30 MG/3ML Package Size 3 Package Quantiy 5	Brand	FDA	01/01/2023	786.06	7391.57	None	Innovator Multiple Source Drug	None	1	None	1	No change or improvement to the drug.	None	06/10/2020	US Worldmeds	None	1	Information regarding the purchase of the USWM CNS product line can be found in press releases, however, information regarding specific product pricing is not available.	5500.00	5290.00	2004	4975.00	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	09/30/2023	70482007530	Osmolex ER Oral Tablet Extended Release 24 Hour 129 MG Package Size 30 Package Quantity 1	Brand	FDA	07/01/2023	53.81	597.32	02/15/2038	Single Source Drug	None	1	None	1	None	1	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	450.00	450.00	2018	450.00	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	09/30/2023	70482007630	Osmolex ER Oral Tablet Extended Release 24 Hour 193 MG Package Size 30 Package Quantity 1	Brand	FDA	07/01/2023	53.81	597.32	02/15/2038	Single Source Drug	None	1	None	1	None	1	11/24/2021	Adamas Pharmaceuticals	None	1	Information regarding the purchase of Adamas Pharmaceuticals can be found in press releases, however, information regarding specific product pricing is not available.	450.00	450.00	2018	450.00	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772012101	Oxtellar XR Oral Tablet Extended Release 24 Hour 150 MG Size 100 Package Quantity 1	Brand	FDA	01/01/2023	48.22	851.81	04/13/2027	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772012201	Oxtellar XR Oral Tablet Extended Release 24 Hour 300 MG Package Size 100 Package Quantity 1	Brand	FDA	01/01/2023	66.98	1183.38	04/13/2027	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772012301	Oxtellar XR Oral Tablet Extended Release 24 Hour 600 MG Package Size 100 Package Quantity 1	Brand	FDA	01/01/2023	122.64	2166.66	04/13/2027	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772010301	Trokendi XR Oral Capsule Extended Release 24 Hour 100 MG Package Size 100 Package Quantity 1	Brand	FDA	01/01/2023	179.63	3173.52	04/04/2028	Innovator Multiple Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772010330	Trokendi XR Oral Capsule Extended Release 24 Hour 100 MG Package Size 30 Package Quantity 1	Brand	FDA	01/01/2023	53.89	952.05	04/04/2028	Innovator Multiple Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772010401	Trokendi XR Oral Capsule Extended Release 24 Hour 200 MG Package Size 100 Package Quantity 1	Brand	FDA	01/01/2023	245.73	4341.15	04/04/2028	Innovator Multiple Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772010430	Trokendi XR Oral Capsule Extended Release 24 Hour 200 MG Package Size 30 Package Quantity 1	Brand	FDA	01/01/2023	73.72	1302.36	04/04/2028	Innovator Multiple Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772010101	Trokendi XR Oral Capsule Extended Release 24 Hour 25 MG Package Size 100 Package Quantity 1	Brand	FDA	01/01/2023	69.60	1229.64	04/04/2028	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772010130	Trokendi XR Oral Capsule Extended Release 24 Hour 25 MG Package Size 30 Package Quantity 1	Brand	FDA	01/01/2023	20.88	368.89	04/04/2028	Innovator Multiple Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772010201	Trokendi XR Oral Capsule Extended Release 24 Hour 50 MG Package Size 100 Package Quantity 1	Brand	FDA	01/01/2023	90.66	1601.73	04/04/2028	Innovator Multiple Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	17772010230	Trokendi XR Oral Capsule Extended Release 24 Hour 50 MG Package Size 30 Package Quantity 1	Brand	FDA	01/01/2023	27.20	480.51	04/04/2028	Innovator Multiple Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	27505011130	Xadago Oral Tablet 100 MG Size 30 Package Quantity 1	Brand	FDA	01/01/2023	84.41	1139.49	06/08/2027	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	03/31/2023	27505011030	Xadago Oral Tablet 50 MG Package Size 30 Package Quantity 1	Brand	FDA	01/01/2023	84.41	1139.49	06/08/2027	Single Source Drug	None	1	None	1	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020018030	ALUNBRIG 180 MG TABLET * 30 PACK	Brand	FDA	01/04/2023	1251.00	19121.00	11/10/2035	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020011330	ALUNBRIG 30 MG TABLET * 30 PACK	Brand	FDA	01/04/2023	418.00	6377.00	11/10/2035	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020009030	ALUNBRIG 90 MG TABLET * 30 PACK	Brand	FDA	01/04/2023	1251.00	19121.00	11/10/2035	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020009007	ALUNBRIG 90 MG TABLET * 7 PACK	Brand	FDA	01/04/2023	292.00	4463.00	11/10/2035	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020019830	ALUNBRIG INITIATION PACK - 7 CT 90 MG TABLET and 23 CT 180 MG TABLET - PER PACK	Brand	FDA	01/04/2023	1251.00	19121.00	11/10/2035	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	64764030020	Entyvio 300mg 20mL Vial	Brand	FDA	01/01/2023	462.79	8176.02	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020053630	ICLUSIG 10 MG TABLET * 30 PACK	Brand	FDA	01/04/2023	1317.00	20126.00	12/12/2033	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020053530	ICLUSIG 15 MG TABLET * 30 PACK	Brand	FDA	01/04/2023	1317.00	20126.00	12/12/2033	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020053330	ICLUSIG 30 MG TABLET * 30 PACK	Brand	FDA	01/04/2023	1317.00	20126.00	12/12/2033	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020053430	ICLUSIG 45 MG TABLET * 30 PACK	Brand	FDA	01/04/2023	1317.00	20126.00	12/12/2033	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020023002	NINLARO 2.3 MG CAPSULE * 3 PACK	Brand	FDA	01/04/2023	801.00	12240.00	11/20/2029	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020023001	NINLARO 2.3 MG CAPSULE * SINGLE PACK	Brand	FDA	01/04/2023	268.00	4083.00	11/20/2029	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020039002	NINLARO 3.0 MG CAPSULE * 3 PACK	Brand	FDA	01/04/2023	801.00	12240.00	11/20/2029	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020039001	NINLARO 3.0 MG CAPSULE * SINGLE PACK	Brand	FDA	01/04/2023	268.00	4083.00	11/20/2029	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020040002	NINLARO 4.0 MG CAPSULE * 3 PACK	Brand	FDA	01/04/2023	801.00	12240.00	11/20/2029	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2023	63020040001	NINLARO 4.0 MG CAPSULE * SINGLE PACK	Brand	FDA	01/04/2023	268.00	4083.00	11/20/2029	Single Source Drug	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000232	TerSera Therapeutics LLC	03/31/2023	70720012585	Xermelo Oral Tablet 250 MG Package Size 84 Package Quantity 1	Brand	FDA	01/01/2023	785.27	8717.34	None	Single Source Drug	None	1	None	1	None	1	09/08/2020	Lexicon Pharmaceuticals, Inc	159000000	None	Lexicon received approximately $159M in upfront payments and up to $65 million in future milestone payments plus mid-teens royalties on net sales of XERMELO for the treatment of biliary tract cancer.	6559.00	5961.00	2017	5164.00	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	03/31/2023	70720095036	Zoladex Subcutaneous Implant 3.6 MG Package Size 1 Quantity 1	Brand	FDA	01/01/2023	77.58	861.19	None	Single Source Drug	None	1	None	1	None	1	04/06/2018	AztraZeneca	320000000	None	AstraZeneca received a $250m upfront payment for the rights of Zoladex, with double-digit quarterly sales-based payments being recieved on an ongoing basis. A further $70m was also in the sell should Zoladex meet a series of sales-related milestones.	605.00	550.50	1989	265.63	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000302	Tetraphase Pharmaceuticals	03/31/2023	71773005012	XERAVA® (eravacycline) for injection, for intravenous use: 12 VIAL GLASS IN 1 CARTON > 1 INJECTION / POWDER / LYOPHILIZED / FOR SOLUTION IN 1 VIAL GLASS > 50 MG/1 VIAL	Brand	FDA	01/01/2023	48.00	684.00	10/19/2037	Innovator Multiple Source Drug	None	1	The increase of Wholesale Acquisition Cost (WAC) for the product is due to financial and non-financial factors that include, but are not limited to, the rising costs of manufacturing, distribution, and marketing.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000217	Teva Neuroscience, Inc.	03/31/2023	68546017260	AUSTEDO TABLETS 12MG 60	Brand	FDA	01/01/2023	450.80	7080.70	09/15/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	03/31/2023	68546017060	AUSTEDO TABLETS 6MG 60	Brand	FDA	01/01/2023	300.60	4720.50	09/15/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	03/31/2023	68546017160	AUSTEDO TABLETS 9MG 60	Brand	FDA	01/01/2023	338.10	5310.50	09/15/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	03/31/2023	68546014256	AZILECT TABLET 0.5MG 30	Brand	FDA	01/01/2023	48.80	1045.30	08/27/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	03/31/2023	68546022956	AZILECT TABLET 1MG 30	Brand	FDA	01/01/2023	48.80	1045.30	08/27/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844011001	ADDERALL TABLET 10MG 100	Generic	FDA	01/01/2023	84.20	980.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844011201	ADDERALL TABLET 12.5MG 100	Generic	FDA	01/01/2023	84.20	980.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844011501	ADDERALL TABLET 15MG 100	Generic	FDA	01/01/2023	84.20	980.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844012001	ADDERALL TABLET 20MG 100	Generic	FDA	01/01/2023	84.20	980.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844013001	ADDERALL TABLET 30MG 100	Generic	FDA	01/01/2023	84.20	980.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844010501	ADDERALL TABLET 5MG 100	Generic	FDA	01/01/2023	84.20	980.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844011701	ADDERALL TABLET 7.5MG 100	Generic	FDA	01/01/2023	84.20	980.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844001901	ADIPEX-P CAPSULES 100	Brand	Medispan	01/01/2023	21.78	253.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844014001	ADIPEX-P TABLETS 100	Generic	FDA	01/01/2023	21.39	248.96	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844014056	ADIPEX-P TABLETS 30	Generic	FDA	01/01/2023	4.97	57.83	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	63459070060	AMRIX ORAL CAPSULE ER 15 MG 60	Brand	FDA	01/01/2023	148.70	3183.20	02/26/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	63459070160	AMRIX ORAL CAPSULE ER 30 MG 60	Brand	FDA	01/01/2023	148.70	3183.20	02/26/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	63459054128	FENTORA TABLET 100MCG 28	Brand	FDA	01/01/2023	94.00	2012.90	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	63459054228	FENTORA TABLET 200MCG 28	Brand	FDA	01/01/2023	118.80	2543.20	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	63459054428	FENTORA TABLET 400MCG 28	Brand	FDA	01/01/2023	172.40	3690.20	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	63459054628	FENTORA TABLET 600MCG 28	Brand	FDA	01/01/2023	223.80	4790.80	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	63459054828	FENTORA TABLET 800MCG 28	Brand	FDA	01/01/2023	275.70	5902.10	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	52544008001	FIORICET CAPSULE 50/300/40 MG 100	Generic	FDA	01/01/2023	51.50	703.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	52544008201	FIORICET/CODEINE CAPSULE 50/300/40/30MG 100	Generic	FDA	01/01/2023	107.80	1472.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	06/30/2023	00093360882	FLUTIC/SALMET INH PWD 113/14MCG 60 DOSE	Generic	FDA	05/19/2023	5.73	122.73	04/06/2035	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years. This covered drug is an authorized generic (“AG”) version of AirDuo™ RespiClick®, a branded product also sold by Teva. Both the branded AirDuo™ RespiClick® product and the AG version of that same product, on which Teva is reporting here, simultaneously launched under the same NDA #208799 and thus are subject to the same patent expiration dates.
Rx0000019	Teva Pharmaceuticals USA	06/30/2023	00093360982	FLUTIC/SALMET INH PWD 232/14MCG 60 DOSE	Generic	FDA	05/19/2023	5.73	122.73	04/06/2035	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years. This covered drug is an authorized generic (“AG”) version of AirDuo™ RespiClick®, a branded product also sold by Teva. Both the branded AirDuo™ RespiClick® product and the AG version of that same product, on which Teva is reporting here, simultaneously launched under the same NDA #208799 and thus are subject to the same patent expiration dates.
Rx0000019	Teva Pharmaceuticals USA	06/30/2023	00093360782	FLUTICA/SALMET INH PWD 55-14MCG 60 DOSE	Generic	FDA	05/19/2023	5.73	122.73	04/06/2035	Non-innovator Multiple Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years. This covered drug is an authorized generic (“AG”) version of AirDuo™ RespiClick®, a branded product also sold by Teva. Both the branded AirDuo™ RespiClick® product and the AG version of that same product, on which Teva is reporting here, simultaneously launched under the same NDA #208799 and thus are subject to the same patent expiration dates.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844020852	GALZIN CAPSULE 50 MG 250	Brand	FDA	01/01/2023	74.30	864.40	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	57844021552	GALZIN CAPSULE 25 MG 250	Brand	FDA	01/01/2023	44.60	518.70	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	00575620030	PROGLYCEM ORAL SUSPENSION 50MG/ML 30ML/ 1 BOTTLE	Brand	FDA	01/01/2023	29.80	406.60	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	03/31/2023	63459017714	SYNRIBO INJECTIONS 3.5MG VIAL	Brand	Medispan	01/01/2023	114.40	1330.90	10/26/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2023	59310081206	AirDuo RespiClick 113/14 Inhalation Aerosol Powder Breath Activated 113-14 MCG/ACT	Brand	FDA	01/01/2023	18.80	402.10	04/06/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2023	59310082206	AirDuo RespiClick 232/14 Inhalation Aerosol Powder Breath Activated 232-14 MCG/ACT	Brand	FDA	01/01/2023	18.80	402.10	04/06/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2023	59310080506	AirDuo RespiClick 55/14 Inhalation Aerosol Powder Breath Activated 55-14 MCG/ACT	Brand	FDA	01/01/2023	18.80	402.10	04/06/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2023	59310040606	Qnasl Childrens Nasal Aerosol Solution 40 MCG/ACT	Brand	FDA	01/01/2023	13.80	295.53	10/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218	Teva Respiratory, LLC	03/31/2023	59310041012	Qnasl Nasal Aerosol Solution 80 MCG/ACT	Brand	FDA	01/01/2023	13.80	295.53	10/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285013197	LOESTRIN 21 TABLET 1.0MG/20MCG 105	Generic	FDA	01/01/2023	66.50	908.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285012797	LOESTRIN 21 TABLET 1.5MG/30MCG 105	Generic	FDA	01/01/2023	66.50	908.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285012870	LOESTRIN FE TABLET 28 1.5MG/30MCG 140	Generic	FDA	01/01/2023	66.50	908.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285012570	LOESTRIN FE TABLET 28 1MG/20MCG 140	Generic	FDA	01/01/2023	66.50	908.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285012058	MIRCETTE TABLET 28 .15MG/.02MG .01MG	Generic	FDA	01/01/2023	99.20	1154.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285006390	PREFEST TABLET 1/1-0.09 MG 180	Generic	FDA	01/01/2023	84.90	1159.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285043187	QUARTETTE TABLET 42-21-21-7 DAYS 182	Brand	FDA	01/01/2023	110.20	1282.90	03/11/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285036801	TREXALL TABLET 10 MG 30	Generic	FDA	01/01/2023	99.30	1156.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285036901	TREXALL TABLET 15 MG 30	Generic	FDA	01/01/2023	149.00	1734.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285036601	TREXALL TABLET 5 MG 30	Generic	FDA	01/01/2023	49.70	578.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285036701	TREXALL TABLET 7.5 MG 30	Generic	FDA	01/01/2023	74.50	867.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285004001	ZIAC TABLET 10MG/6.25MG 30	Brand	FDA	01/01/2023	23.20	270.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285004702	ZIAC TABLET 2.5MG/6.25MG 100	Brand	FDA	01/01/2023	77.40	900.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	03/31/2023	51285005002	ZIAC TABLET 5MG/6.25MG 100	Brand	FDA	01/01/2023	77.40	900.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000057	Theratechnologies Inc.	03/31/2023	62064024130	EGRIFTA SV 2MG LYO PWD 30/PAC	Brand	FDA	01/01/2023	454.00	6945.00	05/01/2023	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Theratechnologies considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000207	Tolmar Pharmaceuticals, Inc.	12/31/2023	69087015812	Jatenza, 158 mg, 12 BOTTLES in 1 BOX, 120 Liquid Filled Capsules in 1 Bottle	Brand	FDA	12/09/2023	38.50	1001.15	04/12/2039	Single Source Drug	8176	None	Tolmar utilizes a Pricing Committee which uses several factors to determine the price of our prescription medications.?? These include current market pricing competitiveness, existing and predicted future competition, manufacturing and distribution considerations (including distribution channel and payer model), costing including product development expenditures, profitability, and legal considerations, including compliance with rules and regulations governing sales to government and institutional purchasers.? The list price of Tolmar?s products is not reflective of discounts and rebates which may be available to patients and payers, including but not limited to, Medicaid and commercial insurance.	None	none	None	10/27/2022	Clarus	7500000	None	None	962.64	917.67	2020	835.00	None	None
Rx0000207	Tolmar Pharmaceuticals, Inc.	12/31/2023	69087019812	Jatenza, 198 mg, 12 BOTTLES in 1 BOX, 120 Liquid Filled Capsules in 1 Bottle	Brand	FDA	12/09/2023	38.50	1001.15	04/12/2039	Single Source Drug	7527	None	Tolmar utilizes a Pricing Committee which uses several factors to determine the price of our prescription medications.?? These include current market pricing competitiveness, existing and predicted future competition, manufacturing and distribution considerations (including distribution channel and payer model), costing including product development expenditures, profitability, and legal considerations, including compliance with rules and regulations governing sales to government and institutional purchasers.? The list price of Tolmar?s products is not reflective of discounts and rebates which may be available to patients and payers, including but not limited to, Medicaid and commercial insurance.	None	none	None	10/27/2022	Clarus	7500000	None	None	962.64	917.67	2020	835.00	None	None
Rx0000207	Tolmar Pharmaceuticals, Inc.	12/31/2023	69087023712	Jatenza, 237 mg, 12 BOTTLES in 1 BOX, 120 Liquid Filled Capsules in 1 Bottle	Brand	FDA	12/09/2023	77.01	2002.27	04/12/2039	Single Source Drug	16577	None	Tolmar utilizes a Pricing Committee which uses several factors to determine the price of our prescription medications.?? These include current market pricing competitiveness, existing and predicted future competition, manufacturing and distribution considerations (including distribution channel and payer model), costing including product development expenditures, profitability, and legal considerations, including compliance with rules and regulations governing sales to government and institutional purchasers.? The list price of Tolmar?s products is not reflective of discounts and rebates which may be available to patients and payers, including but not limited to, Medicaid and commercial insurance.	None	none	None	10/27/2022	Clarus	7500000	None	None	1925.26	1835.33	2020	1670.00	None	None
Rx0000090	UCB, Inc	03/31/2023	50474077066	BRIVIACT 100MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474077009	BRIVIACT 100MG UNIT DOSE CARTON OF 100 TABLETS	Brand	FDA	01/01/2023	127.70	2291.95	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474037066	BRIVIACT 10MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474087015	BRIVIACT 10MG ORAL SOLUTION-300ML	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474047066	BRIVIACT 25MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474047009	BRIVIACT 25MG UNIT DOSE CARTON OF 100 TABLETS	Brand	FDA	01/01/2023	127.70	2291.95	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474057066	BRIVIACT 50MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474057009	BRIVIACT 50MG UNIT DOSE CARTON OF 100 TABLETS	Brand	FDA	01/01/2023	127.70	2291.95	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474067066	BRIVIACT 75MG 60 TABLETS	Brand	FDA	01/01/2023	76.61	1375.16	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474097075	BRIVIACT IV INJECTION FOR INTRAVENOUS USE 50mg/5mL	Brand	FDA	01/01/2023	32.84	589.36	02/21/2026	Single Source Drug	399380000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474070062	CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS	Brand	FDA	01/01/2023	300.88	5400.56	02/13/2024	Single Source Drug	1451431000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474071079	CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES	Brand	FDA	01/01/2023	300.88	5400.56	02/13/2024	Single Source Drug	1451431000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474071081	CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES	Brand	FDA	01/01/2023	902.65	16201.68	02/13/2024	Single Source Drug	1451431000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059766	KEPPRA 1000MG-60 TABLETS	Brand	FDA	01/01/2023	63.17	1133.76	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059440	KEPPRA 250MG-120 TABLETS	Brand	FDA	01/01/2023	51.68	927.63	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059540	KEPPRA 500 MG-120 TABLETS	Brand	FDA	01/01/2023	63.17	1133.76	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059640	KEPPRA 750MG-120 TABLETS	Brand	FDA	01/01/2023	85.58	1536.02	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474000263	KEPPRA IV-1ML INJECTION FOR INTRAVENOUS USE 500mg5mL 10 VIALS	Brand	FDA	01/01/2023	35.49	636.96	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474000148	KEPPRA ORAL SOLUTION-100MG	Brand	FDA	01/01/2023	48.02	861.85	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059866	KEPPRA XR (LEVETIRACETAM) 500MG-60 TABLETS	Brand	FDA	01/01/2023	28.63	513.89	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	50474059966	KEPPRA XR 750MG (LEVETIRACETAM)-60 TABLETS	Brand	FDA	01/01/2023	42.99	771.63	11/14/2008	Innovator Multiple Source Drug	163956000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247860	VIMPAT 100MG UD-60 TABLETS	Brand	FDA	01/01/2023	64.79	1163.02	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247835	VIMPAT 100MG-60 TABLETS	Brand	FDA	01/01/2023	58.90	1057.21	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247960	VIMPAT 150MG UD-60 TABLETS	Brand	FDA	01/01/2023	68.62	1231.70	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247935	VIMPAT 150MG-60 TABLETS	Brand	FDA	01/01/2023	62.38	1119.67	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131248060	VIMPAT 200MG UD-60 TABLETS	Brand	FDA	01/01/2023	68.64	1232.10	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131248035	VIMPAT 200MG-60 TABLETS	Brand	FDA	01/01/2023	62.40	1119.98	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247760	VIMPAT 50MG UD-60 TABLETS	Brand	FDA	01/01/2023	41.45	743.92	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131247735	VIMPAT 50MG-60 TABLETS	Brand	FDA	01/01/2023	37.67	676.22	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131181067	VIMPAT INJECTION FOR INTRAVENOUS USE 200MG/20ML 10 VIALS	Brand	FDA	01/01/2023	51.54	925.03	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2023	00131541072	VIMPAT ORAL SOLUTION 10MG-200ML	Brand	FDA	01/01/2023	24.37	437.38	03/17/2022	Single Source Drug	742006000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	03/31/2023	69794010201	Crysvita 10 mg/mL Subcutaneous Injection 1 Carton	Brand	FDA	01/02/2023	119.00	4116.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for 2022 calendar year, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	03/31/2023	69794020301	Crysvita 20 mg/mL Subcutaneous Injection 1 Carton	Brand	FDA	01/02/2023	238.00	8232.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for 2022 calendar year, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	03/31/2023	69794030401	Crysvita 30 mg/mL Subcutaneous Injection 1 Carton	Brand	FDA	01/02/2023	357.00	12348.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for 2022 calendar year, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	03/31/2023	69794000101	Mepsevii 10 mg/5mL (2mg/mL) Intravenous Injection 1 Carton	Brand	FDA	01/02/2023	74.00	2560.00	03/05/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for 2022 calendar year, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.
Rx0000036	United Therapeutics	03/31/2023	66302030010	ORENITRAM ER .125 MG Oral Tablet 10 Pack	Brand	FDA	01/01/2023	4.27	66.20	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302030001	ORENITRAM ER .125 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	42.73	661.98	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302030210	ORENITRAM ER .25 MG Oral Tablet 10 Pack	Brand	FDA	01/01/2023	8.54	132.38	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302030201	ORENITRAM ER .25 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	85.45	1323.88	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302031010	ORENITRAM ER 1 MG Oral Tablet 10 Pack	Brand	FDA	01/01/2023	34.18	529.57	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302031001	ORENITRAM ER 1 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	341.81	5295.65	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302032510	ORENITRAM ER 2.5 MG Oral Tablet 10 Pack	Brand	FDA	01/01/2023	85.45	1323.91	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302032501	ORENITRAM ER 2.5 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	854.54	13239.15	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302035001	ORENITRAM ER 5 MG Oral Tablet 100 Pack	Brand	FDA	01/01/2023	1709.07	26478.27	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302035010	ORENITRAM ER 5 MG Pack Oral Tablet 10 Pack	Brand	FDA	01/01/2023	170.91	2647.83	08/11/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000036	United Therapeutics	03/31/2023	66302001401	Unituxin Intravenous Solution 17.5 MG/5ML 1 Vial in 1 Carton	Brand	FDA	01/01/2023	1420.61	15770.21	03/01/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992307501	Envarsus XR .75mg 100 Tab	Brand	FDA	06/23/2023	16.66	492.54	08/30/2028	Single Source Drug	13549780	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992307501	Envarsus XR .75mg 100 Tab	Brand	FDA	12/22/2023	9.85	502.39	08/30/2028	Single Source Drug	31741	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992307503	Envarsus XR .75mg 30 Tab	Brand	FDA	06/23/2023	5.00	147.77	08/30/2028	Single Source Drug	7342461	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992307503	Envarsus XR .75mg 30 Tab	Brand	FDA	12/22/2023	2.96	150.73	08/30/2028	Single Source Drug	54789	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992301001	Envarsus XR 1mg 100 Tab	Brand	FDA	06/23/2023	22.21	656.72	08/30/2028	Single Source Drug	91569047	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992301001	Envarsus XR 1mg 100 Tab	Brand	FDA	12/22/2023	13.13	669.85	08/30/2028	Single Source Drug	159730	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992301003	Envarsus XR 1mg 30 Tab	Brand	FDA	06/23/2023	6.66	197.02	08/30/2028	Single Source Drug	41272566	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992301003	Envarsus XR 1mg 30 Tab	Brand	FDA	12/22/2023	3.94	200.96	08/30/2028	Single Source Drug	231804	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992304001	Envarsus XR 4mg 100 Tab	Brand	FDA	06/23/2023	88.83	2626.83	08/30/2028	Single Source Drug	105699412	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992304001	Envarsus XR 4mg 100 Tab	Brand	FDA	12/22/2023	52.54	2679.37	08/30/2028	Single Source Drug	47258	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	06/30/2023	68992304003	Envarsus XR 4mg 30 Tab	Brand	FDA	06/23/2023	26.65	788.05	08/30/2028	Single Source Drug	58188207	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000416	Veloxis Pharmaceuticals, Inc.	12/31/2023	68992304003	Envarsus XR 4mg 30 Tab	Brand	FDA	12/22/2023	15.76	803.81	08/30/2028	Single Source Drug	82394	None	the factors that influenced the increase were a direct result of measurable increasing operational costs including sales, marketing, and distribution	None	no change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000450	Vericel Corporation	09/30/2023	69866103005	MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 1 BAG in 1 BOX (69866-1030-5) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-4) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-3) Package Size 1 Quantity 1	Brand	FDA	07/01/2023	3919.00	56171.00	11/25/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-01. The product was relabeled and given a new NDC # 69866-1030-05 with a market entry date 05/10/2021.
Rx0000450	Vericel Corporation	09/30/2023	69866103008	MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6) Package Size 2 Package Quantity 1	Brand	FDA	07/01/2023	7838.00	112342.00	11/25/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021.
Rx0000502	Viatris Specialty LLC	03/31/2023	00069781030	Caduet Tabs 10mg/10mg 30s	Brand	FDA	01/03/2023	34.25	523.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069216030	Caduet Tabs 10mg/10mg 30s (DC)	Brand	Medispan	01/03/2023	34.25	523.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00069-2160-30 is a discontinued NDC effective 08/31/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069218030	Caduet Tabs 10mg/20mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 01/27/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069225030	Caduet Tabs 10mg/40mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 01/18/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069227030	Caduet Tabs 10mg/80mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 01/18/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069215030	Caduet Tabs 5mg/10mg 30s	Brand	Medispan	01/03/2023	34.25	523.50	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 02/03/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069217030	Caduet Tabs 5mg/20mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 02/03/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069219030	Caduet Tabs 5mg/40mg 30s	Brand	Medispan	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069226030	Caduet Tabs 5mg/80mg 30s	Brand	FDA	01/03/2023	46.85	716.14	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 01/27/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049241010	Cardura Tabs 1mg 100s	Brand	FDA	01/03/2023	37.63	575.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This NDC represents an NDC Change from the previous NDC: 00049-2750-66 (included within this report), and this NDC represents the new, updated NDC for the same product. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049275066	Cardura Tabs 1mg 100s (DC)	Brand	Medispan	01/03/2023	62.74	575.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2750-66 is a discontinued NDC effective 10/19/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049251210	Cardura Tabs 2mg 100s	Brand	FDA	01/03/2023	37.63	575.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049276066	Cardura Tabs 2mg 100s (DC)	Brand	Medispan	01/03/2023	62.74	575.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2760-66 is a discontinued NDC effective 10/19/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049261410	Cardura Tabs 4mg 100s	Brand	FDA	01/03/2023	39.49	603.66	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049277066	Cardura Tabs 4mg 100s (DC)	Brand	Medispan	01/03/2023	65.84	603.66	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2770-66 is a discontinued NDC effective 10/19/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049278066	Cardura Tabs 8mg 100s	Brand	Medispan	01/03/2023	41.47	633.90	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 02/15/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049204010	Cardura XL Tabs 4mg 30s	Brand	FDA	01/03/2023	12.98	198.35	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049271030	Cardura XL Tabs 4mg 30s (DC)	Brand	Medispan	01/03/2023	21.64	198.35	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2710-30 is a discontinued NDC effective 01/21/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049208010	Cardura XL Tabs 8mg 30s	Brand	FDA	01/03/2023	13.63	208.37	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049272030	Cardura XL Tabs 8mg 30s (DC)	Brand	Medispan	01/03/2023	13.63	208.37	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-2720-30 is a discontinued NDC effective 04/26/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152031	Celebrex Caps 100mg 100s	Brand	FDA	01/03/2023	62.36	953.25	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152051	Celebrex Caps 100mg 500s	Brand	FDA	01/03/2023	311.82	4766.36	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152034	Celebrex Caps 100mg UD100	Brand	FDA	01/03/2023	62.36	953.25	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152531	Celebrex Caps 200mg 100s	Brand	FDA	01/03/2023	102.29	1563.59	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152551	Celebrex Caps 200mg 500s	Brand	FDA	01/03/2023	511.45	7817.91	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025152534	Celebrex Caps 200mg UD100	Brand	FDA	01/03/2023	102.29	1563.59	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025153002	Celebrex Caps 400mg 60s	Brand	FDA	01/03/2023	92.07	1407.29	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025153001	Celebrex Caps 400mg UD100	Brand	FDA	01/03/2023	153.44	2345.44	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025151501	Celebrex Caps 50mg 60s	Brand	FDA	01/03/2023	17.49	267.29	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071036932	Dilantin ER Caps 100mg 1000s	Generic	FDA	01/03/2023	104.82	1602.31	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071036924	Dilantin ER Caps 100mg 100s	Generic	FDA	01/03/2023	10.48	160.24	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071036940	Dilantin ER Caps 100mg UD100	Generic	FDA	01/03/2023	11.57	176.82	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071374066	Dilantin ER Caps 30mg 100s	Generic	FDA	01/03/2023	9.04	138.16	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071000724	Dilantin Infatabs 50mg 100s	Generic	FDA	01/03/2023	9.82	150.14	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071000740	Dilantin Infatabs 50mg UD100	Generic	FDA	01/03/2023	13.93	212.95	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083621	Effexor XR Caps 150mg 30s	Brand	FDA	01/03/2023	39.02	596.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083622	Effexor XR Caps 150mg 90s	Brand	FDA	01/03/2023	117.05	1789.19	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083721	Effexor XR Caps 37.5mg 30s	Brand	FDA	01/03/2023	31.97	488.68	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083722	Effexor XR Caps 37.5mg 90s	Brand	FDA	01/03/2023	95.91	1466.00	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083321	Effexor XR Caps 75mg 30s	Brand	FDA	01/03/2023	35.82	547.54	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00008083322	Effexor XR Caps 75mg 90s	Brand	FDA	01/03/2023	107.47	1642.77	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049035260	Geodon Caps 20mg 60s	Brand	FDA	01/03/2023	93.25	1425.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049005260	Geodon Caps 20mg 60s (DC)	Brand	Medispan	01/03/2023	155.48	1425.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-0052-60 is a discontinued NDC effective 11/08/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049005460	Geodon Caps 40mg 60s	Brand	Medispan	01/03/2023	93.25	1425.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049035660	Geodon Caps 60mg 60s	Brand	FDA	01/03/2023	113.16	1729.78	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049035860	Geodon Caps 80mg 60s	Brand	FDA	01/03/2023	113.16	1729.78	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049392083	Geodon Injection 20mg/mL SDV 10PK	Brand	FDA	01/03/2023	40.14	613.61	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049120310	Geodon Injection 20mg/mL SDV 10PK (Premier Pro)	Brand	Medispan	01/03/2023	66.93	613.61	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00049-1203-10 is a discontinued NDC effective 11/09/2021 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025171001	Inspra Tabs 25mg 30s	Brand	FDA	01/03/2023	27.64	422.45	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025171002	Inspra Tabs 25mg 90s	Brand	FDA	01/03/2023	82.91	1267.35	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) This product was discontinued on 03/08/2023. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025172003	Inspra Tabs 50mg 30s	Brand	FDA	01/03/2023	27.64	422.45	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00025172001	Inspra Tabs 50mg 90s	Brand	FDA	01/03/2023	82.91	1267.35	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00025-1720-01 is a discontinued NDC effective 12/27/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071015892	Lipitor Tabs 80mg UD64	Brand	FDA	01/03/2023	77.38	1182.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00071-0158-92 is a discontinued NDC effective 12/27/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101568	Lyrica Caps 100mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101541	Lyrica Caps 100mg UD100	Brand	FDA	01/03/2023	69.35	1060.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101668	Lyrica Caps 150mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101641	Lyrica Caps 150mg UD100	Brand	FDA	01/03/2023	69.35	1060.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101768	Lyrica Caps 200mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101968	Lyrica Caps 225mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101268	Lyrica Caps 25mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101868	Lyrica Caps 300mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101368	Lyrica Caps 50mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101341	Lyrica Caps 50mg UD100	Brand	FDA	01/03/2023	69.35	1060.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101468	Lyrica Caps 75mg 90s	Brand	FDA	01/03/2023	56.75	867.41	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071101441	Lyrica Caps 75mg UD100	Brand	FDA	01/03/2023	69.35	1060.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071102701	Lyrica CR Tabs 165mg 30s	Brand	FDA	01/03/2023	32.50	496.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071102901	Lyrica CR Tabs 330mg 30s	Brand	FDA	01/03/2023	32.50	496.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071102601	Lyrica CR Tabs 82.5mg 30s	Brand	FDA	01/03/2023	32.50	496.84	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071102001	Lyrica Oral Solution 20mg/mL 473 mL	Brand	FDA	01/03/2023	79.45	1214.38	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071080324	Neurontin Caps 100mg 100s	Brand	FDA	01/03/2023	18.03	275.64	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071080524	Neurontin Caps 300mg 100s	Brand	FDA	01/03/2023	45.09	689.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071080624	Neurontin Caps 400mg 100s	Brand	FDA	01/03/2023	54.09	826.81	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071201247	Neurontin Oral Solution 250mg/5mL 470mL	Brand	FDA	01/03/2023	32.03	489.57	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071201244	Neurontin Oral Solution 250mg/5mL 470mL (DC)	Brand	FDA	01/03/2023	32.03	489.57	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	(1) 00071-2012-44 is a discontinued NDC effective 07/12/2022 and would typically not appear on Viatris’ analysis for NDCs to report because it was no longer sold by Viatris on the date of the price increase. Viatris is reporting this NDC on this report only because it was included on and in response to California’s “Notice of Potential Wholesale Acquisition Cost Increase Report” in an abundance of caution and in the interest of supporting California’s Drug Price Transparency Program. We do not believe that a price increase report is actually required for this NDC because Viatris no longer sold this NDC at the time of the price increase. Viatris reserves the right on future reports to reassess the reporting implications for discontinued NDCs. (2) This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071051324	Neurontin Tabs 600mg 100s	Brand	FDA	01/03/2023	85.65	1309.24	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071040124	Neurontin Tabs 800mg 100s	Brand	FDA	01/03/2023	102.77	1570.87	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071041724	Nitrostat Sublingual Tabs 0.3mg 100s	Brand	FDA	01/03/2023	4.62	70.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071041824	Nitrostat Sublingual Tabs 0.4mg 100s	Brand	FDA	01/03/2023	4.62	70.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071041813	Nitrostat Sublingual Tabs 0.4mg 100s (Convenience Pack)	Brand	FDA	01/03/2023	10.07	153.95	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00071041924	Nitrostat Sublingual Tabs 0.6mg 100s	Brand	FDA	01/03/2023	4.62	70.56	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069154068	Norvasc Tabs 10mg 90s	Brand	FDA	01/03/2023	65.13	995.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069154041	Norvasc Tabs 10mg UD100	Brand	FDA	01/03/2023	72.36	1106.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069152068	Norvasc Tabs 2.5mg 90s	Brand	FDA	01/03/2023	47.50	726.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069153072	Norvasc Tabs 5mg 300s	Brand	FDA	01/03/2023	158.35	2420.45	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069153068	Norvasc Tabs 5mg 90s	Brand	FDA	01/03/2023	47.50	726.13	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069153041	Norvasc Tabs 5mg UD100	Brand	FDA	01/03/2023	52.78	806.77	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049233045	Relpax Tabs 20mg 6s	Brand	FDA	01/03/2023	30.19	461.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049234005	Relpax Tabs 40mg 12s	Brand	FDA	01/03/2023	60.39	923.06	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049234045	Relpax Tabs 40mg 6s	Brand	FDA	01/03/2023	30.19	461.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069033801	Revatio Injection 0.8mg/mL 12.5mL	Brand	FDA	01/03/2023	16.92	258.60	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069033621	Revatio Oral Powder for Suspension 10mg/mL 112mL	Brand	FDA	01/03/2023	665.53	10173.06	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00069419068	Revatio Tabs 20mg 90s	Brand	FDA	01/03/2023	346.85	5301.85	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00013830304	Xalatan Ophthalmic Drops 0.005% 2.5mL	Brand	FDA	01/03/2023	16.47	251.70	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009002901	Xanax Tabs 0.25mg 100s	Brand	FDA	01/03/2023	33.94	518.84	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009002902	Xanax Tabs 0.25mg 500s	Brand	FDA	01/03/2023	169.71	2594.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009005501	Xanax Tabs 0.5mg 100s	Brand	FDA	01/03/2023	42.29	646.39	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009005503	Xanax Tabs 0.5mg 500s	Brand	FDA	01/03/2023	211.44	3231.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009009001	Xanax Tabs 1mg 100s	Brand	FDA	01/03/2023	56.43	862.51	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009009004	Xanax Tabs 1mg 500s	Brand	FDA	01/03/2023	282.13	4312.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009009401	Xanax Tabs 2mg 100s	Brand	FDA	01/03/2023	95.94	1466.49	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009005707	Xanax XR Tabs 0.5mg 60s	Brand	FDA	01/03/2023	39.25	599.94	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009005907	Xanax XR Tabs 1mg 60s	Brand	FDA	01/03/2023	48.84	746.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009006607	Xanax XR Tabs 2mg 60s	Brand	FDA	01/03/2023	64.82	990.82	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00009006807	Xanax XR Tabs 3mg 60s	Brand	FDA	01/03/2023	97.22	1486.10	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049005001	Zoloft Oral Solution 20mg/mL 60mL	Brand	FDA	01/03/2023	18.58	284.05	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049491030	Zoloft Tabs 100mg 30s	Brand	FDA	01/03/2023	27.03	413.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049491041	Zoloft Tabs 100mg UD100	Brand	FDA	01/03/2023	90.11	1377.44	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049496030	Zoloft Tabs 25mg 30s	Brand	FDA	01/03/2023	27.03	413.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049490030	Zoloft Tabs 50mg 30s	Brand	FDA	01/03/2023	27.03	413.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000502	Viatris Specialty LLC	03/31/2023	00049490041	Zoloft Tabs 50mg UD100	Brand	FDA	01/03/2023	90.11	1377.44	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizer’s Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn)
Rx0000066	ViiV Healthcare	03/31/2023	49702024613	DOVATO TAB 50-300MG - 30 tablets per bottle	Brand	FDA	01/01/2023	157.54	2809.73	01/24/2031	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702024213	JULUCA TAB 50-25MG - 30 tablets per bottle	Brand	FDA	01/01/2023	185.89	3315.31	01/24/2031	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702025537	TIVICAY PD TAB 5MG - 60 tablets per bottle	Brand	FDA	01/01/2023	23.90	426.19	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702022613	TIVICAY TAB 10MG - 30 tablets per bottle	Brand	FDA	01/01/2023	23.90	426.19	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702022713	TIVICAY TAB 25MG - 30 tablets per bottle	Brand	FDA	01/01/2023	59.74	1065.43	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702022813	TIVICAY TAB 50MG - 30 tablets per bottle	Brand	FDA	01/01/2023	119.48	2130.86	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	03/31/2023	49702023113	TRIUMEQ TAB - 30 tablets per bottle	Brand	FDA	01/01/2023	198.34	3537.40	12/08/2029	Single Source Drug	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000314	VistaPharm Inc	12/31/2023	66689077508	Phenytoin Oral Suspension 125 MG/5ML - 237mL Bottle	Generic	FDA	10/26/2023	50.97	75.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000314	VistaPharm Inc	12/31/2023	66689003650	Phenytoin Oral Suspension 125 MG/5ML - 4mL cup - 50ct	Generic	FDA	10/26/2023	122.42	367.26	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000314	VistaPharm Inc	12/31/2023	66689003601	Phenytoin Oral Suspension 125 MG/5ML - 4mL cup (unit dose)	Generic	FDA	10/26/2023	2.45	7.35	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000380	Xeris Pharmaceuticals, INC.	03/31/2023	71090000101	Keveyis Dichlorphenamide Oral Tablet 50 MG, 100 Each, Bottle	Brand	FDA	02/06/2023	2984.92	33135.59	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Keveyis was relabeled from 71090-0001-01 to 72065-0001-01 with an effective date of 12/15/2022. 72065-0001-01 is the NDC that will be used moving forward.
Rx0000380	Xeris Pharmaceuticals, INC.	03/31/2023	72065000101	Keveyis Oral Tablet 50 MG, 100 Each, Bottle	Brand	FDA	02/06/2023	2984.92	33135.59	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Keveyis was relabeled from 71090-0001-01 to 72065-0001-01 with an effective date of 12/15/2022. 72065-0001-01 is the NDC that will be used moving forward.
Rx0000380	Xeris Pharmaceuticals, INC.	09/30/2023	72065000301	Recorlev Oral Tablet 150 MG, 50 Each, Bottle	Brand	FDA	07/01/2023	1548.69	17854.00	03/02/2040	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000351	Zogenix, Inc.	06/30/2023	43376032230	Fintepla 2.2mg/mL Oral Solution; 30mL Bottle	Brand	FDA	04/03/2023	59.40	1540.80	12/29/2038	Single Source Drug	11245700	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Zogenix believes is in the public domain or otherwise publicly available.
Rx0000351	Zogenix, Inc.	06/30/2023	43376032236	Fintepla 2.2mg/mL Oral Solution; 360mL Bottle	Brand	FDA	04/03/2023	712.80	18489.60	12/29/2038	Single Source Drug	11245700	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Zogenix believes is in the public domain or otherwise publicly available.
Rx0000163	Zyla Life Sciences	03/31/2023	69344010101	Indocin (Indomethacin) Oral Suspension 25 mg per 5mL (237mL/Bottle)	Brand	FDA	01/01/2023	213.31	2367.98	None	Innovator Multiple Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	01/31/2019	Iroko Pharmaceuticals, Inc.	87000000	None	Purchase Price is an estimate of a portion of the purchase price of the product acquired from Iroko - multiple products were acquired via a single transaction.	891.98	891.98	1985	232.17	None	Some historical pricing data relates to product's previous NDC 42221-0101-01. Zyla did not own this product at time of market introduction. Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for market introduction data points. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013).
Rx0000163	Zyla Life Sciences	06/30/2023	69344010233	Indomethacin Suppository 50 mg per suppository (30 Suppository/Box)	Generic	FDA	04/15/2023	507.15	10857.15	None	Non-innovator Multiple Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. ?? (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.	None	No change.	None	01/31/2019	Iroko Pharmaceuticals	87000000	None	Purchase Price is an estimate of a portion of the purchase price of the product acquired from Iroko - multiple products were acquired via a single transaction.	2550.00	2550.00	1984	309.62	None	Some pricing data may relate to historical NDC codes for this porduct. Zyla did not own this product at time of market introduction. Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for market introduction data points. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013)
Rx0000163	Zyla Life Sciences	03/31/2023	69344011311	Oxaydo (oxycodone hydrochloride) 5 mg/1 Tablet (100 per Bottle)	Brand	FDA	01/01/2023	96.50	1071.25	03/16/2025	Single Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired in last 5 years.
Rx0000163	Zyla Life Sciences	03/31/2023	69344021311	Oxaydo (oxycodone hydrochloride) 7.5 mg/1 Tablet (100 per Bottle)	Brand	FDA	01/01/2023	144.59	1605.11	03/16/2025	Single Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired in last 5 years.
Rx0000163	Zyla Life Sciences	03/31/2023	69344014463	Sprix (ketorolac tromethamine) 15.75mg/1 Spray, 8 Sprays / Bottle (1 Bottle)	Brand	FDA	01/01/2023	44.48	493.66	None	Innovator Multiple Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired in last 5 years.
Rx0000163	Zyla Life Sciences	03/31/2023	69344014443	Sprix (ketorolac tromethamine) 15.75mg/1 Spray, 8 Sprays per Bottle (5 Bottles per Carton)	Brand	FDA	01/01/2023	222.36	2468.30	None	Innovator Multiple Source Drug	None	1	"Factors that contributed to the price increase: Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products.? "	None	No Change	None	None	None	None	None	None	None	None	None	None	None	Product not acquired in last 5 years.